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Abstract 
 
 
 
SYMPTOMS, CYTOKINES, AND QUALITY OF LIFE OF PATIENTS WITH CHRONIC 
GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM 
CELL TRANSPLANTATION  
 
By Debra Lynch Kelly, BS 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2014 
 
Director: Suzanne W. Ameringer, Associate Professor, Department of Family and Community 
Health Nursing 
 
 
 
Introduction: Chronic graft-versus-host disease (cGVHD) is a serious complication following 
allo-HSCT characterized by immune dysregulation, organ dysfunction, risk for infection, and 
distressing symptoms. Complications may include scleroderma, hepatic dysfunction and 
bronchiolitis obliterans.  Advances in allo-HSCT for many hematologic dyscrasias (e.g. acute 
and chronic leukemias, aplastic anemia, and myelodysplastic syndrome) have improved survival 
which has generated a renewed focus on survivorship issues.  Distressing symptoms are noted as 
negatively impacting quality of life (QoL).  The relationship between inflammation and 
behavioral responses may impact symptom characteristic thus examining patterns and levels of 
inflammation with symptoms is relevant.  Objective: The aims of this study were to examine 1) 
levels of symptoms (cGVHD specific, general symptoms, and cluster symptoms [pain, depression 
and fatigue]), inflammation (cytokines [Interleukin {IL}-1β, IL-6, IL-10, TNF, and INF-γ] and 
C-reactive protein [CRP]) and QoL in patients diagnosed with cGVHD and 2) relationships 
between and among symptoms, inflammation and QoL in individuals with cGVHD.   
Methods: A cross-sectional study design examined 24 individuals (ages 29-79) with cGVHD 
enrolled from an NCI-designated cancer center after obtaining informed consent. Data were 
collected using medical record and validated questionnaires.  Plasma cytokine levels were 
measured using BioRad® multiplex assay. C-reactive protein levels were measures using an 
enzyme-linked immunosorbant assay.  Statistical analyses included descriptive statistics and 
pairwise correlations.  Results: Participants (58.3% female) with cGVHD had multiple, 
concurrent symptoms. Several pro-inflammatory cytokines were higher in participants with 
symptoms versus those without symptoms. IL-6 correlated with lack of energy (r= .42; p= .04) 
and dry mouth (r= .42; p= .04).  IL-10 was correlated with difficulty sleeping (r= .43; p= .03).  
Sexual dysfunction correlated with social well-being (r= -.44; p=.03). Many symptoms 
negatively correlated with QoL.  Conclusion: Findings from this study, one of the first to 
examine levels of symptoms and inflammatory markers in individuals with cGVHD, demonstrate 
significant relationships among symptoms, inflammation, and quality of life.  The relationship of 
inflammatory biomarkers with symptoms and symptom severity emphasize the need for further 
interdisciplinary research.  Further understanding mechanisms associated with symptoms is 
necessary for the development of targeted interventions to improve QoL for individuals with 
cGVHD. 
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Chapter 1 
Introduction 
 
 
 
 The focus of inquiry for this dissertation study was prompted by observations made by an 
experienced oncology certified nurse and though an extensive literature review which revealed 
gaps in the literature about cGVHD.  Individuals with many hematologic dyscrasias such as 
acute and chronic leukemias, aplastic anemia, and myelodysplastic syndrome may receive 
hematopoietic stem cell transplantation (bone marrow transplantation) as a life-saving 
intervention.  Receiving stem cells that are not “self” cells is termed an allogeneic donor. A late 
effect complication that is serious and not uncommon after receiving allogeneic donor cells is 
cGVHD.  Though the etiology of cGVHD is poorly defined, it is marked by immune 
dysregulation and inflammatory proliferation.  Bone marrow transplants have increased greatly 
over the past ten years (Hahn, 2013). This increase is due, in part, to new treatments prior to 
transplant that allow patients who once would not be eligible for a transplant to obtain one 
(Hahn, 2013). As a consequence of both the increase in the number of transplants and 
conditioning regimens, the number of individuals diagnosed with cGVHD is increasing.  
Survivorship issues, such as quality of life (QoL), have been gaining attention as the focus of 
research in cGVHD.  Symptoms have been found to influence QoL in cGVHD; however, the 
literature is limited in its description of the number of symptoms, and various characteristics of 
symptoms such as frequency, severity and distress (Lynch-Kelly, 2014).  Symptoms were 
therefore chosen as the focus of this study as a way to gain preliminary insight into QoL of 
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individuals with cGVHD.  This researcher’s philosophical assumptions are consistent with the 
biobehavioral framework which holds that biology and behavior are inextricably linked and 
should be examined concurrently.  As cGVHD is a complication involving an over-exaggerated 
inflammatory response and there is evidence that cytokines (surrogate markers of inflammation) 
play a role in the development and presentation of symptoms, it was logical to examine cytokines 
in relation to symptoms of cGVHD (Ratanatharathorn, Ayash, Lazarus, & Uberti, 2001) .    
Prior to the establishment of the specific aims for this study, an extensive literature 
review was conducted to determine what was known about symptoms, cytokines, and quality of 
life of patients diagnosed with cGVHD.  Findings from the review provided evidence about the 
involvement of symptoms in cGVHD. Symptoms are more pronounced when cGVHD is more 
severe (Fall-Dickson, 2010).  A limitation of the research is that symptoms have been examined 
in relation to the organ affected by cGVHD and usually with a single measure (Lynch-Kelly, 
2014).  There was some consistency regarding which cytokines were examined in cGVHD 
(Lynch-Kelly, 2012).  Individuals with cGVHD were found to have lower QoL than other 
populations (McQuellon et al., 1997).  Also, QoL negatively correlated with cGVHD severity 
(Pidala et al., 2011).  What was not known from the literature was an extensive profile of 
symptoms, if cytokines were related to the symptoms, and how symptoms related to QoL. Thus 
the specific aims for this study were to: 1) examine the levels of symptoms (cGVHD specific, 
general symptoms, and cluster symptoms [pain, depression and fatigue]), inflammation 
(cytokines [Interleukin {IL}-1β, IL-6, IL-10, TNF, and INF-γ] and C-reactive protein [CRP]) 
and QoL in patients diagnosed with cGVHD and 2) examine the relationships between and 
among symptoms, inflammation and QoL in individuals with cGVHD.  Knowledge about 
symptoms and biological mechanisms (e.g. increased systemic inflammation expression) 
 3 
 
involved in symptom manifestation is important for the development and testing of novel 
interventions to successfully manage symptoms and improve QoL for patients with cGVHD.   
Findings from this study lend evidence about symptoms individuals diagnosed with 
cGVHD may be experiencing. It also provides information about median cytokine and CRP 
levels as well as some comparison cytokine levels between individuals with a certain symptom 
and individuals not experiencing that certain symptom.  A mean QoL score is also provided.  
This study also provides insight into relationships that may exist among and between symptoms, 
inflammation and QoL. In this study, many individuals were experiencing multiple symptoms 
concurrently and had varying levels of frequency, severity, and distress.  There were significant 
relationships among symptoms and cytokines and CRP as well as among symptoms and QoL. 
Information gained from this study serves as a starting point by providing preliminary 
information about symptoms, cytokines and QoL of cGVHD. This information may be used to 
move the science forward in this challenging population and may eventually lead to the 
development and testing of novel interventions to mitigate symptoms thereby increasing the QoL 
for individuals living with cGVHD. 
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Chapter 2 
 
Symptoms, Cytokines, and Quality of Life of Patients with Chronic Graft-Versus-Host Disease: 
An Integrative Review 
 
 
 
Hematopoietic stem cell transplantation has become the standard treatment for many 
hematologic cancers including acute leukemia, chronic myelogenous leukemia, and multiple 
myeloma.  There has been a 165% increase in the number of allogeneic hematopoietic stem cell 
transplants (alloHSCT) from 1994-2005 and survival rates post 100 days transplant have 
increased nearly 86% (Hahn et al., 2013).  Patients receiving an alloHSCT are at risk for 
developing a serious, potentially life-threatening complication known as chronic graft-versus-
host disease (cGVHD).  This is a complex, multisystem issue involving immune dysregulation 
and immunodeficiency, impaired organ function, and decreased survival (Baird and Pavletic, 
2006).  This phenomenon occurs in as many as 90% of all alloHSCT recipients who survive 
greater than 100 days post-transplant (Lee, Cook, Soiffer, & Antin, 2002; Lee, Vogelsang, & 
Flowers, 2003).  Any of the body systems can be affected by cGVHD.  Cutaneous and ocular 
cGVDH occur most often and pulmonary and hepatic cGVHD pose the greatest risk for 
mortality.  In addition to being the most serious complication of alloHSCT, cGVHD is also the 
most common (Pidala et al., 2011; Vogelsang, 2011).  Debilitating consequences of cGVHD 
include loss of sight, pulmonary disease, and joint contractures as well as death due to chronic 
immune suppression secondary to prolonged immunosuppressive therapy (Filipovich et al., 
2005).   
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Understandnig the frequency and severity of symptoms and the interplay between 
symptoms and inflammation, as indicated by levels of cytokines, may be major factors 
contributing to the quality of life of patients with cGVHD.  Patients with cGVHD may 
experience similar symptoms as other cancer survivors such as pain, depressive symptoms, and 
fatigue; however, due to the lack of literature aimed at helping patients with cGVHD manage 
their symptoms, adequate management of symptoms is a barrier to caring for these patients and 
is a major issue (Lee et al., 2002; Perez-Simon, Sanchez-Abarca, Diez-Campelo, Caballero, & 
San Miguel, 2006; Williams et al., 2007). Biological factors such as cytokines are speculated to 
influence the frequency and severity of symptoms that are common among cancer patients and 
are also associated with other autoimmune and chronic conditions similar to cGVHD (Baird & 
Montine, 2008; Bazzichi et al., 2007; Klimiuk et al., 2003; Seruga, Haibo, Bernstein, &Tannock, 
2008). Research in the past has focused on survivorship.  Advances such as earlier 
transplantation, better human leukocyte antigen matching between donor and recipient and 
improvements in transplant conditioning have increased survivorship (Perez-Simon, Sanchez-
Abarca, Diez-Campelo, Caballero, & San Miguel, 2006).   
Due to increased survivorship of patients with cGVHD, improving quality of life is of 
growing importance (Flowers et al., 2008; Lee et al., 2002; Lee et al., 2003).  Quality of life is 
altered due to many factors among which are symptoms (Monga et al., 2007). Among patients 
surviving hematopoietic stem cell transplantation, quality of life returned to pre transplant levels 
within one to two years except for patients experiencing cGVHD (Baker and Fraser, 2008).  The 
National Institutes of Health (NIH) Chronic Graft-Versus-Host Disease Consortium put forth a 
series of papers in which it was concluded the need for the development and validation of 
biomarkers includes examining both biological and behavioral (patient-reported) measures 
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objectively with quality of life as a possible endpoint to measure success of research testing 
novel interventions for supportive care (Filipovich et al., 2005;).  The aims of this integrative 
review are to determine what is known about the symptoms and cytokine patterns and levels of 
patients with cGVHD and to examine the impact of cGVHD on quality of life.  The goal is to 
identify areas for future research leading to the development and testing of interventions to 
mitigate distressing symptoms of patients with cGVHD thereby improving quality of life.   
Symptoms  
 Symptoms are a major source of distress and discomfort for patients with cancer and are 
a major barrier in caring for patients with cGVHD (Lee et al., 2002; Perez-Simon et al., 2006; 
Theobald, Kirsh, Holtsclaw, Donaghy, & Passik, 2003;).  The National Institutes of Health 
(2002) reported that the most commonly experienced symptoms among patients with cancer are 
pain, depression, and fatigue.  Insomnia is also frequently reported as a symptom associated with 
cancer (Fox & Lyon, 2007; Fox, Lyon, & Farce, 2007; Theobald et al., 2003).  In a study 
examining cancer, it was reported that as many as 90% of cancer patients experience pain, 91% 
fatigue, and up to 25% depression (Fox & Lyon, 2006; Fox & Lyon, 2007).  The symptoms 
experienced by patients with cancer may be due to the cancer itself and/or due to the treatments.  
Symptoms, particularly fatigue, may persist well into survivorship (Oh & Seo, 2011).  A major 
role of the oncology nurse is to decrease the burden of symptoms.   
Cytokines  
Biobehavioral science is based in the assumption that the biology of a phenomenon is 
inextricably linked with behavior thereby making it necessary to examine them as two 
dimensions of the same whole.  It is speculated that cytokines act neurologically to induce 
psychological and behavioral changes (Kelley, 2003).  It is also speculated that the production 
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and release of certain cytokines can be effected by the cancer itself and these cytokines may 
mediate symptoms (Seruga, Zhang, Bernstein, & Tannock, 2008).  A call by the National Cancer 
Institute (2006) to investigate strategies for the development and validation of biomarkers in 
cGVHD research could be beneficial in elucidating strategies to combat the devastating effects 
of cGVHD (Baird and Pavletic, 2006).  The establishment of the relationship between symptoms 
and cytokines in this population may serve to determine the interplay of certain inflammatory 
cytokines and symptom severity which may in turn lead to advanced interventions to relieve 
bothersome symptoms for patients with cGVHD.  
There is a growing body of evidence supporting the role of cytokines in symptom 
expression of patients with cancer and other chronic illnesses.  This was first noted as 
observations of a flu-like syndrome of patients treated with immunological agents such as TNF 
and some interleukins (Myers, 2008).  The cytokine interleukin 6 has been linked with the 
symptom of depression and cognitive impairment (Myers, 2008).  Fatigue is the most common 
symptom among cancer patients and may persist well into survivorship.  Interleukin 1 beta and 
Tumor Necrosis Factor have been associated with fatigue (Lee et al., 2004; Seurga et al., 2008). 
Other psychobehavioral symptoms of cancer such as pain and depression have been linked with 
cytokines interleukin 1, interleukin 6, Tumor Necrosis Factor, and interfeuron (Lee at al., 2004; 
Myers, 2008; Seruga et al., 2008).  To develop targeted interventions for symptoms management 
in individuals with cGVHD, it is important to understand the relationship between cytokines and 
symptoms.    
Quality of Life  
 Quality of life is a multi-dimensional concept encompassing several domains including 
physical, emotional, social, and functional (Pidala et al., 2011).  It also includes the subjective 
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measure of an individual’s evaluation of his well-being and functionality (Pidala et al., 2011).  
Quality of life in patients with cancer is altered due to many factors among which one is the 
symptoms that are experienced (Monga et al., 2007).  .  In patients surviving hematopoietic stem 
cell transplantation, quality of life returned to pre transplant levels within one to two years except 
for patients experiencing cGVHD (Baker and Fraser, 2008).  Previous focus on patients with 
hematologic cancers undergoing bone marrow transplant has been survivorship.  With the 
increase in survivorship, focus has turned toward managing the consequences of complications 
such as cGVHD.  Symptom management and quality of life improvement is moving to the 
forefront of cGVHD management (Flowers et al., 2008; Lee et al., 2002; Lee et al., 2003).   
Method 
Articles were retrieved utilizing PubMed, Cumulative Index of Nursing and Allied Health 
Literature (CINAHL), and Cochrane Database of Systematic Reviews databases.  Searches in 
PubMed and CINAHL were conducted to produce an exhaustive list of literature surrounding the 
concepts of symptoms, cytokines and quality of life in conjunction with cGVHD. The full 
description of the search terms used to capture the literature is presented in the appendix.  The 
Cochrane Review Database was searched using the search term “chronic graft-versus-host 
disease”.  Articles were restricted, using search filters, to those adults greater than 18 years of 
age, published in English, and human studies.  Inclusion criteria were: 1) the concept under 
investigation (symptoms, cytokines, or quality of life) must be described in relation to patients 
with cGVHD and must yield specific information about the concept, 2) any research method, and 
3) any research design. 
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Exclusion criteria for this review were: 1) articles that only use broad terms (such as 
“symptoms”) or do not provide any explicit information regarding the concepts under 
investigation (symptoms, cytokines, or quality of life). 
Results 
A total of 704 articles were returned.  The flow diagram (Figure 1) describes the process 
by which articles were selected for this review.  After excluding duplicate articles, applying 
inclusion and exclusion criteria, review of titles, review of abstracts, and finally full text 
screening, 35 articles were used for this literature review.    
Figure 1 
Chronic Graft-versus-Host Disease Articles Flow Diagram 
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Symptoms 
There were a total of 11 symptoms articles included in this analysis.  The literature 
regarding symptoms of patients with cGVDH is varied.  Sample sizes ranged considerably, with 
a sample population as few as n=3 to as many as n=427 (Allen, Greenberg, and Amato, 2009; 
Pidala et al., 2012). One study was conducted at multiple sites (Pidala et al., 2012).  Table 1 
provides a description of the symptom literature.   
Study design.  A variety of descriptive designs were used to examine symptoms in 
cGVHD.  There were no qualitative studies.  There were three case studies (Allen et al., 2009; 
Elad et al., 2003; Takahide et al., 2007), two retrospective studies (Andree et al., 2008; de la 
Parra-Colin et al., 2011) and six prospective, cross-sectional studies (Akpek et al., 2003; Fall-
Dickson et al., 2010; Mitchell et al., 2010; Pidala et al., 2012; Stratton et al., 2007; Treister et al., 
2008).      
Measurement approach.  Researchers relied on a variety of instruments to assess 
patients’ symptoms.  Most (n=6) included information about symptoms that came from provider 
observance or by patient verbal description of symptom presentation (Akpek et al., 2003; Allen 
et al., 2009; de la Parra-Colin et al., 2011; Elad et al., 2003; Stratton et al., 2007; Treister et al., 
2008).  Information provided by patients described the presence of symptoms only.  The visual 
analog scale, used to measure pain severity, was used in three studies (Elad et al., 2003; Fall-
Dickson et al., 2010; Treister et al., 2008).  In studies that examined ocular cGVHD, one used 
the ocular surface index and the other used the Schirmer test to measure symptoms (de la Parra-
Colin et al., 2011; Takahide et al., 2007).  The ocular surface index assesses the presence and 
interference of dry eyes and the Schirmer test assesses the presence of dry eyes.  Two studies did 
not examine site specific cGVHD and used the Lee cGVHD scale (Mitchell et al., 2010; Pidala et 
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al., 2012).  This is a scale that assesses the dimension of symptom bother.  One study did not 
report how symptoms were assessed (Allen et al., 2009).   
Context.  The context in which symptoms were assessed varied.  Some researchers 
assessed symptoms by specific site of disease and some assessed symptoms across sites of 
disease.  Site specific studies include oral (Elad et al., 2003; Fall-Dickson et al., 2010; Treister et 
al., 2008), ocular (de la Parra-Colin et al., 2011; Takahide et al., 2007), gastrointestinal (Akpek 
et al., 2003; Andree et al., 2008),  dermatomysitis (inflammation of the skin and muscles) (Allen 
et al., 2008), and genital, specifically vaginal cGVHD (Stratton et al., 2007). Two studies 
examined symptoms of patients with cGVHD of any site (Mitchell et al., 2010; Pidala et al., 
2012). 
The symptom most frequently examined was pain (Akpek et al., 2003; Elad et al., 2003; 
Fall-Dickson et al., 2010; Stratton et al., 2007; Takahide et al., 2007; Treister et al., 2008).  The 
study conducted by Elad et al. (2003) reported severe oral pain whereas the study conducted by 
Fall-Dickson et al. (2010) reported mild oral pain.  Other symptoms reported in the presence of 
oral cGVHD included odynophagia (pain when swallowing), avoiding certain foods and 
tightness in the mouth (Treister et al. 2008).  Ocular cGVHD studies examined dry eyes, 
photophobia, and foreign body perception (de la Parra-Colin et al., 2011; Takahide et al., 2007). 
The feeling of having a foreign body in the eyes has been described as a “gritty” feeling like sand 
constantly abrading the cornea (Choi, Levine and Ferrara, 2010; Joseph, Couriel, and 
Komanduri, 2008; Vogelsang, 1996).  Both studies that examining ocular cGVHD reported 
patients complained of photophobia (de la Parra-Colin et al., 2011; Takahide et al., 2007).  
Gastrointestinal cGVHD examined nausea, dysphagia, feeling full, heartburn, diarrhea and 
weight loss (Akpek et al., 2003; Andree et al., 2008). Abdominal pain was the most commonly 
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reported symptom in one study (Akpek et al., 2003) and nausea in another (Andree et al., 2008).  
The case study reported by Allen et al. (2009) found muscle weakness (fatigue) and myalgia to 
be the patients’ complaints.  Painful intercourse and pain due to strictures were present in all 
patients (n=33) with vaginal cGVHD (Stratton et al., 2007).  Symptom bother was assessed in 
the two studies that examined symptoms in any site (Mitchell et al., 2010; Pidala et al; 2012).  
The scores were 28.4 and 20.7 respectively, out of a possible 100, with a higher score indicating 
greater symptom bother (Mitchell et al., 2010; Pidala et al., 2012).     Specific symptoms were 
not reported in either of these studies.   
Cytokines 
Cytokines are small proteins that act to regulate the intensity and duration of immune 
response and mediate cell-to-cell communication. Elevated levels of cytokines are associated 
with autoimmune or chronic inflammatory diseases that are comparable to cGVHD (Baird & 
Montine, 2008; Bazzichi et al., 2007; Klimiuk et al., 2003).  A total of 14 cytokine articles were 
included in this analysis. Sample sized ranged from n=3 to n=229 and from a one group design 
to a three group design (Cullup et al., 2003; Kaminska, et al., 2007).  Table 2 provides a 
description of cytokine literature examined in the presence of cGVHD.   
Study design. All reviews articles selected used a descriptive design to examine levels of 
cytokines; however, there was variability in the number of groups and the temporality among 
studies.  Four studies used a single group (Craciun et al., 2002; D’Elios et al., 1997; Gorgun, 
Miller, & Foss, 2002; Poloni et al., 2011).  One study included a donor group (Cullup, Dickson, 
Cavet, Jackson, & Middleton, 2003).  All other studies used two groups (case group and control 
group) (Aractingi, Gluckman, Le Goue, Dubertret, & Carosella, 1996; Bladon & Taylor, 2006; 
Darvay, Salooja, & Russell, 2004; Fall-Dickson et al., 2010; Hettinga, Verdonck, Fijnheer, 
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Rijkers, & Rothova, 2007; Kaminska et al., 2010; Nakamura et al., 2005; Ricci et al., 2006; 
Tauchmanova et al., 2004).  There were two case studies used in this analysis (Hettinga et al., 
2007; Kaminska et al., 2010).  Eight studies were longitudinal (Bladon & Taylor, 2006; Craciun 
et al., 2002; Darvay et al., 2004; Gorgun et al., 2002; Nakamura et al., 2005; Poloni et al., 2011; 
Ricci et al., 2006; Tauchmanova et al., 2004).  Four studies were cross-sectional (Aractingi, et 
al., 1996; Cullup et al., 2003; D’Elios et al., 1997; Fall-Dickson et al., 2010).  .   
Measurement methodology.  Cytokines can be measured through many vectors and by a 
variety of instruments.  There was heterogeneity in methods used by the researchers across 
studies.  The most common (n=10) vector for assessing cytokines was blood (Bladon & Taylor, 
2006; Craciun et al., 2002; Cullup, 2003; D’Elios et al., 1997; Darvay et al., 2004; Gorgun et al., 
2002; Nakamura et al., 2005; Poloni et al., 2011; Ricci et al., 2006; Tauchmanova et al., 2004). 
Other vectors included tissue (n=4), saliva (n=1), and ocular fluid (n=1) (Aractingi et al., 1996; 
D’Elios et al., 1997; Fall-Dickson et al., 2010; Hettinga et al., 2007, Kaminska et al., 2010; 
Poloni et al., 2011).  The method for assessing the measurement of cytokines was inconsistent 
across studies.  The two most often used were flow cytometry and enzyme-linked 
immunosorbent assay.  Flow cytometry was used for cytokine analysis in six studies (Bladon & 
Taylor, 2006; Darvay et al., 2004; Gorgun et al., 2002; Hettinga et al., 2007; Ricci et al., 2006; 
Tauchmanova et al., 2004).  Enzyme-linked immunosorbent assay was used for cytokine analysis 
in three studies (D’Elios et al., 1997; Fall-Dickson et al., 2010; Nakamura et al., 2005).  
Context.  The circumstances in which cytokines were measured include inteventional and non-
interventional studies, site specific and non-site specific studies, and all families of cytokines.  
Interventional studies explored cytokine levels of patients before and after receiving 
extracorporeal photopheresis (Aractingi et al., 1996; Bladon & Taylor, 2006; Craciun et al., 
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2002; Darvay et al., 2004; Gorgun et al., 2002).  Pre-treatment levels of cytokines are reported to 
ascertain presence and levels of cytokines found in patients with cGVHD unmitigated by the 
effects of treatment.  Other studies did not include an intervention. There were both site specific 
and non-site specific articles reviewed.  Site specific articles included cutaneous (n=1), oral 
cGVHD (n=1), ocular (n=1) and renal (Aractingi et al., 1996; Fall-Dickson et al., 2010; Hettinga 
et al., 2007; Kaminska. et al, 2010). The remainder of the reviewed studies are not site specific. 
There are three families of cytokines, hematopoietins (interleukins), interfeurons, and 
tumor necrosis factors.  All studies measured levels of interleukines (IL).  The IL most often 
examined (n=7) was IL-10 (Craciun et al., 2002; Gorgun et al., 2002; Hettinga et al., 2007; 
Kaminska. et al, 2010; Nakamura et al., 2005; Ricci et al., 2006; Tauchmanova et al., 2004). 
Interfeuron gamma was the only interfeuron examined and was the cytokine most often 
measured (n=9) (D’Elios et al., 1997; Darvay et al., 2004; Gorgun et al., 2002; Hettinga et al., 
2007; Kaminska et al., 2010; Nakamura et al., 2005; Poloni et al., 2011; Ricci et al., 2006; 
Tauchmanova et al., 2004).  Tumor necrosis factor was examined in seven studies (Aractingi et 
al., 1996; Bladon & Taylor, 2006; Craciun et al., 2002; Kaminska. et al, 2010; Nakamura et al., 
2005; Ricci et al., 2006; Tauchmanova et al., 2004).  The least examined cytokine was IL-12 
(Poloni et al., 2011).    
Numerous cytokines were measured across studies.  There were consistencies across 
studies with regard to levels of some cytokines while levels of other cytokines across studies 
yielded varied results.  Six studies examined cytokines from the IL-1 family.  Three examined 
IL-1 alpha (α) (Bladon & Taylor, 2006; Cullup et al., 2003; Fall-Dickson et al, 2010) and three 
examined IL-1 beta (β) (Bladon & Taylor, 2006; Craciun et al., 2002; Poloni et al., 2011).  
Among patients with cGVHD, levels of IL-1α and IL-1β were higher in patients with cGVHD 
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across studies than in patients without cGVHD.  There were four studies that assessed cytokine 
IL-2 (Darvay et al., 2004; Kaminska et al., 2010; Ricci et al., 2006; Tauchmanova et al., 2004).  
Results were inconsistent across studies.  Two studies demonstrated elevated levels in patient 
with cGVHD, one demonstrated lower levels of IL-2 among patients with cGVHD and one 
demonstrated no difference between patients with and without cGVHD.  There was 
inconsistency among studies (n=6) that measured levels of IL-4.  Four found there to be no 
difference between patients with and without cGVHD and two found levels of IL-4 to be 
elevated among patients with cGVHD when compared to patients without cGVHD (D’Elios et 
al., 1997; Darvay et al., 2004; Gorgun et al., 2002; Nakamura et al., 2005; Ricci et al., 2006; 
Tauchmanova et al., 2004). Two articles examined IL-5.  One article described no difference in 
IL-5 levels between patients with and without cGVHD and one article described elevated levels 
of IL-5 in patients with cGVHD compared with patients that were not diagnosed with cGVHD 
(Ricci et al., 2006; Tauchmanova et al., 2004). Studies examining IL-6 (n=4) found patients with 
cGVHD to have higher levels of IL-6 than patients without cGVHD (Bladon and Taylor, 2006; 
Fall-Dickson et al., 2010; Hettinga et al., 2007; Kaminska et al., 2010).  In the study conducted 
by Aractingi et al. (1996), there was no difference in the expression of IL-8 between patients 
with cGVHD and patients without cGVHD.  Bladon and Taylor (2006) and Poloni et al. (2011) 
found elevated levels of IL-8 among patients with cGVHD when compared with patients 
withoug cGVHD.  Studies examining IL-10 yield varying results.  Five of the seven studies 
yielded elevated evels of IL-10 (Craciun et al., 2002; Gorgun et al., 2002; Hettinga et al., 2007; 
Kaminskaet al., 2010; Tauchmanova et al., 2004).  The remaining two found no difference in 
circulating levels of IL-10 between patients with and without cGVHD (Nakamura et al., 2005; 
Ricci et al., 2006).  
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Studies examining TNF-α (n=7) and IFN-ƴ (n=9 ) also yielded varying results. Three 
studies examining TNFα found elevated levels between patients with cGVHD and patients 
without cGVHD (Bladon & Taylor, 2006; Kaminska et al., 2010; Tauchmanova et al., 2004). 
Three found no difference in levels of TNFα between patients with cGVHD and patients without 
cGVHD.  Aractingi et al. (1996) reports TNF α is expressed in patients with cGVHD.   
The majority (n=6) of studies examining  IFNʎ in patients with cGVHD report elevated 
levels among patients with cGVHD (Darvay et al., 2004; Gorgun et al., 2002; Kaminska et al., 
2010; Poloni et al., 2011; Ricci et al., 2006; Tauchmanova et al., 2004). Hettinga et al. (2007) 
and Nakamura et al. (2005) report no difference between cGVHD cases and non cGVHD 
controls.  D’Elois et al. (1997) reports IFNʎ is expressed in patients with cGVHD.   
Quality of Life 
A total of 10 quality of life articles were included in this analysis.  Sample size ranged 
from n=37 to n=427 (Kim et al., 2010; Pidala et al., 2011).  Table 3 provides a description of 
quality of life literature examined in the presence of cGVHD.   
 Study design.  All quality of life research articles examined for this review used a 
descriptive study design. Aspects such as the use of a control group and sample size were varied.  
The majority of studies (n=6) used a cross-sectional study design to evaluate the effect of 
cGVHD on QoL (Fall-Dickson et al., 2010; Harris et al., 2010; Imanguli et al., 2010., Pallua et 
al., 2010; Pidala et al., 2011a; Pidala et al., 2011c).  The remainder of the studies used a 
longitudinal study design (Herzberg et al., 2010; Kim et al., 2010; Lee et al., 2006; Pidala et al., 
2011b).  Two studies included a control group (Herzberg et al., 2010; Pallua et al., 2010). The 
remainder of the literature reviewed had a one group design.  Eight studies used standardized 
scores to indicate level of quality of life and Two studies used “population norms” for 
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comparison of quality of life scores (Fall-Dickson et al., 2010; Pidalla et al., 2011b).  Five 
studies included a sample size over one hundred (Herzberg et al., 2010; Imanguli et al., 2010; 
Pidala et al.,2011; Pidala et al., 2011; Pidala et al., 2012).   
Measurement methodology.  The tools to capture quality of life of patients with 
cGVHD are well documented in the literature as being reliable and valid instruments.  The 
functional assessment of cancer therapy general was used in three studies (Fall-Dickson et al., 
2010; Harris et al., 2010; Imanguli et al., 2010).  The same measure with an the addition of a 
bone marrow transplant subscale was used in five studies (Herzberg et al., 2010; Lee et al., 2006; 
Pidala et al., 2011a; Pidala et al., 2011b; Pidala et al., 2011c).  Pidala et al. (2011a,b,c) and Kim 
et al. (2010)  used the short form- 36 to assess quality of life in addition to the functional 
assessment of cancer therapy.  The human activity profile scale was also used in the study by 
Pidala et al. (2011c).   
Context.  Quality of life in patients with cGVHD is explored in site specific populations 
and non-specific site populations and there are a variety of factors associated with quality of life. 
Eight of the ten studies included all patients with cGVHD and did not examine specific sites 
(Harris et al., 2010; Herzberg et al., 2010; Kim et al., 2010; Lee et al., 2006; Pallua et al., 2010; 
Pidala et al., 2011a; Pidala et al., 2011b; Pidala et al., 2011c). Two studies evaluated quality of 
life of patients with oral cGVHD (Fall-Dickson et al., 2010; Imanguli et al., 2010).  Factors 
associated with quality of life include severity of cGVHD (Fall-Dickson et al., 2010, Paulla et 
al., 2010), spirituality (Harris et al., 2010), physical functioning (Herzberg et al., 2010), and 
salivary gland dysfunction (Imanguli et al., 2010).  Having cGVHD showed to decrease quality 
of life across studies.  The study by Pidala et al. (2011c) did not find a difference in quality of 
life scoes for patients exhitbiting characteristics of both acute GVHD and cGVHD.   
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Discussion 
This review sought to examine the current literature to find out what is known about 
symptoms, cytokines and quality of life of patients with cGVHD.  The goal is to identify areas 
for future research leading to the development and testing of interventions to mitigate distressing 
symptoms of patients with cGVHD thereby improving quality of life. A total of 36 articles were 
extracted and reviewed.  Each variable was examinied for information regarding study design, 
measurement and methodology, and context.  All of the literature reviewed used a descriptive 
study design.  The methods for measuring the concepts are varied as are the results. Thus it is 
difficult to draw conclusions.  There is evidence that patients with cGVHD are experiencing 
distressing symptoms and cytokine dysregulation.  Quality of life appears to be affected by many 
factors associated with cGVHD.      
Symptoms  
Symptoms are a departure from normal function or feeling noticed by an individual and 
may be indicative of presence of disease or abnormality and are a major source of distress and 
discomfort for patients with cancer (Theobald, Kirsh, Holtsclaw, Donaghy, & Passik, 2003).  
The National Institutes of Health (2002) reported that the most commonly experienced 
symptoms among patients with cancer are pain, depression, and fatigue.  Insomnia is also 
frequently reported as a symptom associated with cancer (Fox & Lyon, 2007; Fox, Lyon, & 
Farce, 2007; Theobald et al., 2003).  In a study examining cancer, it was reported that as many as 
90% of cancer patients experience pain, 91% fatigue, and up to 25% depression (Fox & Lyon, 
2006; Fox & Lyon, 2007).  The symptoms experienced by patients with cancer may be due to the 
cancer itself and/or due to the treatments.  Symptoms, particularly fatigue, may persist well into 
survivorship (Oh & Seo, 2011).  A major role of the oncology nurse is to decrease the burden of 
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symptoms.  Patients with cGVHD may experience similar symptoms; however due to the lack of 
literature aimed at helping patients with cGVHD manage their symptoms, adequate management 
of symptoms is a major barrier to caring for these patients (Williams et al., 2007).  The literature 
is lacking in symptom management and little is known about which symptoms patients 
experience and to what extent. Distressing symptoms are the primary reason people seek medical 
attention, yet for patients with cGVHD, the symptoms experienced are not well elucidated.  Most 
articles examined for this review imply symptoms are a source of distress; however, few sought 
to present a symptom profile using a multi-symptom measure that quantifies symptom 
frequency, severity, and interference with daily life. The literature examined for this review 
regarding the symptom experience is limited.  Few studies examined symptoms of cGVHD using 
validated measures.   
Another gap in the literature regarding symptoms in the presence of cGVHD is there are 
many systems affected by cGVHD that were not identified.  There were no reviewed published 
studies that examined symptoms for pulmonary or hepatic involvement.  Other sites affected by 
cGVHD, such as the skin, which is the most commonly affected organ, were lacking in the 
literature. Implementing studies to include larger sample size with the use of validated measures 
would add to the existing body of knowledge about which symptoms patients with cGVHD are 
experiencing and the frequency, severity and distress of symptoms for better symptom 
management.  
Cytokines  
Biobehavioral science is based in the assumption that the biology of a phenomenon is 
inextricably linked with behavior thereby making it necessary to examine them as two 
dimensions of the same whole.  It is speculated that cytokines act neurologically to induce 
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psychological and behavioral changes (Kelley, 2003).  It is also speculated that the production 
and release of certain cytokines can be effected by the cancer itself and these cytokines may 
mediate symptoms (Seruga, Zhang, Bernstein, & Tannock, 2008).  A call by the National Cancer 
Institute (2006) to investigate strategies for the development and validation of biomarkers in 
cGVHD research could be beneficial in elucidating strategies to combat the devastating effects 
of cGVHD (Baird and Pavletic, 2006).  The establishment of the relationship between symptoms 
and cytokines in this population may serve to determine the interplay of certain inflammatory 
cytokines and symptom severity which may in turn lead to advanced interventions to relieve 
bothersome symptoms for patients with cGVHD.  
The complexity in the micro-environment of cGVHD is evident in the literature.  There 
are numerous speculations as to the role that cytokines play in the presentation of this 
complication of allogeneic hematopoietic stem cell transplantation.  Continued research is 
necessary to draw conclusion about the levels and patterns of cytokines present in patients with 
cGVHD and to establish relationship between cytokine levels and the occurrence and severity of 
cGVHD.  Future research examining cytokines is essential for better understanding the 
relationship of cytokine-mediated immune dysfunction and the development of cGVHD in 
patients receiving an allogeneic hematopoietic stem cell transplant.  Also, inflammatory markers 
associated with symptom presentation are necessary to gain understanding of the interplay of the 
biology and behavioral responses of patients with cGVHD.   
Quality of Life  
 Quality of life in patients with cancer is altered due to many factors among which one is 
the symptoms that are experienced (Monga et al., 2007).  Previous focus on patients with 
hematologic cancers undergoing bone marrow transplant has been survivorship.  With the 
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increase in survivorship, focus has turned toward managing the consequences of complications 
such as cGVHD.  Symptom management and quality of life improvement is moving to the 
forefront of cGVHD management (Flowers et al., 2008; Lee et al., 2002; Lee et al., 2003).   
Quality of life is a major concern for patients with cGVHD.  Symptoms that cause 
patients distress may be a contributing factor that impacts overall perception of quality of life; 
however, there is a gap in the literature to substantiate this hypothesis.  One study examined in 
this review sought to elucidate the impact  symptoms have on quality of life for patients with 
cGVHD and this study is site-specific.  The majority of articles examining quality of life for this 
review used a cross-sectional design and did not include  healthy controls.  Many of the patient 
samples in the quality of life literature are over 100 participants and  describe patient 
characteristics; however, there is a lack of description as to cGVHD classification in accordance 
with NIH guidelines.  There is a gap in the literature of sample homogeneity as to which 
characteristics of cGVHD were examined in relation to quality of life thus definitive associations 
between cGVHD and quality of life are not established. 
Conclusion 
It does appear from the literature reviewed that patients with cGVHD are experiencing a 
myriad of distressing symptoms.  The establishment of the impact that distressing symptoms 
have on patients’ quality of life has yet to be well characterized.  The literature also provides 
evidence that inflammatory markers may indicate the severity and possibly the persistence of 
cGVHD.  Correlative studies have demonstrated an association among symptoms, cytokines and 
quality of life and have also demonstrated length of time since diagnosis and the severity of 
cGVHD also effect patient perception of quality of life.    An initial step to the development and 
research of novel interventions to ameliorate distressing symptoms and increasing quality of life 
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for patients with cGVHD is to examine and describe, in depth and breadth, the symptoms 
patients are experiencing and how these symptoms are related to biological mechanisms such as 
inflammatory cytokines.  Also, how these factors together influence the quality of life for 
patients with cGVHD.  There is a need for further research examining these aspects of cGVHD 
using reliable and valid instruments as well as instruments that are comparable to draw 
conclusion across studies.  This would allow the science for the development of interventions to 
mitigate distressing symptoms of patients with cGVHD forward to improve quality of life. 
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Table 1.  
Studies Examining Symptoms of Chronic Graft-Versus-Host Disease 
Citation Design/n Purpose Patient 
Reported 
Symptom 
Measures/ 
Other 
Measures 
Result
Akpek, G., Chinratanalab, 
W., Lee, L., 
Torbenson, M., 
Hallick, J., Anders, 
V., & Vogelsang, G. 
(2003). 
Gastrointestinal 
involvement in 
chronic graft-versus-
host disease: A 
clinicopathologic 
study. Biology of 
Blood and Marrow 
Transplantation, 9, 
46-51. doi: 
10.1053/bbmt.2003.4
9999 
Prospective, 
descriptive, 
cross-
sectional/ n= 
40
To describe 
clinical findings 
in a group of 
patients with 
cGVHD whose 
gastrointestinal 
symptoms 
required 
endoscopic 
evaluation 
Patient self-
report and 
clinical 
assessment 
74% 
complained 
of diarrhea; 
45% 
complained 
of 
abdominal 
pain; 33% 
complained 
of nausea; 
19% 
complained 
of weight 
loss; 12% 
complained 
of GI 
bleeding; 
12% 
complained 
of 
dysphagia; 
12% 
complained 
of “feeling 
full”; 5% 
complained 
of 
heartburn.  
No 
information 
was 
reported on 
the 
frequency or 
severity for 
the 
33 
 
Citation Design/n Purpose Patient 
Reported 
Symptom 
Measures/ 
Other 
Measures 
Result
symptoms.  
No 
validated 
tools were 
used to 
measure the 
symptom 
experience 
and no 
definitions 
to quantify 
symptoms 
were 
described.
Allen, J.A., Greenberg, S.A, 
& Amato, A.A. 
(2009). 
Dermatomysitis-like 
muscle pathology in 
patients with chronic 
graft-versus-host 
disease. Muscle and 
Nerve, 40, 643-647. 
doi: 
10.1002/mus.21353 
Case Study/ 
n=3
To describe three 
patients with 
cGVHD who 
developed 
clinical and 
pathologic 
findings typically 
observed in 
dermatomysitis
Not reported Patients 
complained 
of muscle 
weakness 
(fatigue) 
and 
myalgia.  
How these 
symptoms 
were 
measured is 
not 
disclosed.  
No 
information 
was 
reported as 
to the 
frequency or 
severity of 
the 
symptoms.
Andree, H., Hilgendorf, I., 
Leithaeuser, M., 
Junghanss, C., 
Holzhueter, S., 
Retrospectiv
e, 
descriptive/ 
n=13
To 
retrospectively 
evaluate the 
efficacy of 
Not reported Thirteen 
patients 
were 
evaluated 
34 
 
Citation Design/n Purpose Patient 
Reported 
Symptom 
Measures/ 
Other 
Measures 
Result
Loddenkemper, C., . . 
. Wolff, D. (2008). 
Enteral budesonide in 
treatment for mild 
and moderate 
gastrointestinal 
chronic GVHD. Bone 
Marrow 
Transplantation, 42, 
541-546. doi: 
10.1038/bmt.2008.20
9 
budesonide for 
the treatment of 
mild to moderate 
gastrointestinal 
cGVHD 
and the 
description 
of 
symptoms 
was 
reported in a 
table 
describing 
each patient. 
Ten patients 
reported 
nausea; 
seven 
patients 
reported 
weight loss; 
six patients 
complained 
of mild to 
moderate 
diarrhea; 
eight 
patients had 
multi-organ 
involvement
.  No 
description 
of the 
frequency or 
interference 
and limited 
information 
about 
severity was 
reported.  
Measureme
nt tools 
were not 
described.  
de la Parra-Colin, P., Retrospectiv To describe the Patient 29% of 
35 
 
Citation Design/n Purpose Patient 
Reported 
Symptom 
Measures/ 
Other 
Measures 
Result
Agahan, A., Perez-
Simon, J., Lopez, A., 
Caballero, D., 
Hernandez, E., 
Barrientos-Gutierrez, 
T., & Calonge, M. 
(2011). Dry eye 
disease in chronic 
graft-versus-host 
disease: Results from 
a Spanish 
retrospective cohort 
study 
e, cohort, 
cross-
sectional, 
descriptive/ 
n= 57
incidence, risk 
factors and 
outcome of dry 
eye disease 
associated with 
cGVHD at a 
single center over 
a five year 
period.
reported 
symptom 
measure not 
reported.  Dry 
eye measured 
by Schirmer’s 
test for dry 
eye disease 
patients 
developed 
dry eye 
disease; 
59% 
complained 
of 
photophobia
; 23% 
complained 
of irritation; 
18% 
complained 
of feeling as 
though there 
was a 
foreign 
body in the 
eyes.  No 
evaluation 
of 
frequency, 
severity, or 
interference 
of 
symptoms 
was 
reported.
Elad, S., Or, R., Shapira, 
M.Y., Haviv, A., 
Galili, D., Garfunkel, 
A.A., Bitan, M., & 
Kaufman, E. (2003). 
CO2 laser in oral 
graft-versus-host 
disease: A pilot study 
Case Study/ 
n=4
To evaluate the 
efficacy of the 
CO2 laser to 
relieve severe 
pain caused by 
oral cGVHD
Visual analog 
scale and 
clinical 
evaluation 
Prior to 
laser 
treatments, 
2 patients 
rated their 
pain a 
10/10; one 
rated his 
pain an 
8/10; and 
one rated 
his pain a 
36 
 
Citation Design/n Purpose Patient 
Reported 
Symptom 
Measures/ 
Other 
Measures 
Result
7/10.  No 
evaluation 
of pain 
frequency or 
interference 
was 
reported.
Fall-Dickson, J.M., Mitchell, 
S.A., Marden, S., 
Ramsay, E. S., 
Guadagnini, J.P/. Wu, 
T., . . . Pavletic, S.Z. 
(2010). Oral symptom 
intensity, health-
related quality of life, 
and correlative 
salivary cytokines in 
adult survivors of 
hematopoietic stem 
cell transplantation 
with oral chronic 
graft-versus-host 
disease. Biology of 
Blood and Morrow 
Transplantation, 16, 
948-956. doi: 
10.1016.j.bbmt.2010.
01.017 
Prospective, 
cross-
sectional, 
descriptive/ 
n= 42
To examine the 
oral symptoms 
experience, 
health-related 
quality of life, 
and salivary 
proinflammatory 
cytokines in a 
sequentially 
accrued cohort of 
patients with oral 
cGVDH 
Visual Analog 
Scale (0-10) 
for pain 
intensity; a 
10cm 
Numeric 
rating Scale 
(0-10) for oral 
dryness; 
Functional 
Assessment of 
Cancer 
Therapy-
General; 
Enzyme-
linked 
Immunosorbe
nt Assay 
The mean 
oral pain 
score was 
0.13 with a 
median of 0 
and a range 
of 0-2; the 
mean oral 
dryness 
score was 
2.56 with a 
median of 0 
and a range 
of 0-10. 
More severe 
oral 
cGVHD 
was 
associated 
with a lower 
social/famil
y well-
being. 
Overall 
quality of 
life scores 
were lower 
in patients 
with 
cGVHD 
than the 
average 
score for the 
37 
 
Citation Design/n Purpose Patient 
Reported 
Symptom 
Measures/ 
Other 
Measures 
Result
US 
population 
norm. 
Inflammator
y cytokine 
Interleukin-
6 was 
associated 
with oral 
cGVHD 
severity and 
Interleukin 
1α was 
positively 
associated 
with oral 
dryness.
Mitchell, S.A., Leidy, N.K., 
Mooney, K.H., 
Dudkey, W.N., Beck, 
S.L., LaStayo, P.C., . 
. . Pavletic, S.Z. 
(2010). Determinants 
of functional 
performance in long-
term survivors of 
allogeneic 
hematopoietic stem 
cell transplantation 
with chronic graft-
versus-host disease 
(cGVHD). Bone 
Marrow 
Transplantation, 45, 
762-769. doi: 
10.1038/bmt.2009.23
8 
Prospective, 
cross-
sectional/ n= 
100
To determine the 
factors that 
account for 
variability in 
functional 
performance in 
long term 
allogeneic 
hematopoietic 
stem cell 
transplant 
survivors with 
cGVHD
Lee cGVHD 
symptom 
scale  
The mean 
symptom 
score was 
28.4 and the 
scores 
ranged from 
0.7-68.6. 
Symptom 
bother was a 
significant 
independent 
predictor of 
functional 
performance
. Depression 
was 
considered a 
co-morbid 
condition 
and was 
prevalent in 
43% of the 
participants.
38 
 
Citation Design/n Purpose Patient 
Reported 
Symptom 
Measures/ 
Other 
Measures 
Result
Pidala, J., Vogelsang, G., 
Martin, P., Chai, X., 
Storer, B., Pavletic, 
S., . . . Lee, S. (2012). 
Overlap subtype of 
chronic graft-versus-
host disease is 
associated with an 
adverse prognosis, 
functional 
impairment, and 
inferior patient-
reported outcomes: A 
Chronic Graft-versus-
Host Disease 
Consortium study. 
Haematologica, 97, 
451-458. doi: 
10.3324/haematol.201
1.055186 
Prospective, 
multi-site, 
cross-
sectional/ n= 
427
To examine 
whether the sub-
type of graft-
versus-host 
disease was 
associated with a 
different 
prognosis, 
functional 
limitations, or 
patient-reported 
outcomes 
compared to 
“classic” chronic 
graft-versus-host 
disease without 
any acute 
features
Lee cGVHD 
symptom 
scale; 
Functional 
assessment of 
cancer 
therapy- Bone 
marrow 
transplantatio
n; The human 
activity 
profile; The 
short form-36  
Patients 
with overlap 
sub-type 
cGVHD had 
a median of 
20.7 with a 
range of 0-
65.3 and 
patients 
with classic 
cGVDH had 
a median of 
18.1 with a 
range of 
4.1-56.6.  
There was 
not a 
significant 
difference 
between the 
groups for 
symptom 
summary 
scores; 
however 
patients 
with overlap 
sub-type 
cGVHD had 
significantly 
higher 
scores for 
skin and 
nutrition 
symptom 
bother.
Stratton, P., Turner, M.L., 
Childs, R., Barrett, J., 
Bishop, M., Wayne, 
A.S., & Pavletic, S. 
Prospective, 
observationa
l, cross-
sectional/ n= 
To describe the 
diagnosis and 
management of 
female genital 
Patient self-
report 
Vulvar pain, 
burning and 
dyspareunia. 
No 
39 
 
Citation Design/n Purpose Patient 
Reported 
Symptom 
Measures/ 
Other 
Measures 
Result
(2007). Vulvovaginal 
chronic graft-versus-
host disease with 
allogeneic 
hematopoietic stem 
cell transplantation. 
Obstetrics and 
Gynecology, 110, 
1041-1049.  
33 cGVHD symptom 
severity or 
frequency 
was 
reported.  21 
participants 
who were 
sexually 
active prior 
to 
enrollment 
were no 
longer due 
to pain 
completely 
interfering 
with sexual 
activity.
Takahide, K., Parker, P.M., 
Wu, M., Hwang, 
W.Y., Carpenter, 
P.A., Moravec, C., . . 
. Flowers, M.E. 
(2007). Use of fluid-
ventilated, gas 
permeable sclera lens 
for management of 
severe 
Keratoconjuntivitis 
Sicca secondary to 
chronic graft-versus-
host disease. Biology 
of Blood and Marrow 
Transplantation, 13, 
1016-1021. 
doi:10.1016/j.bbmt.20
07.05.006 
Case-Study/ 
n=9
To report 
outcomes of nine 
patients referred 
for sclera lens 
fitting as 
treatment for 
cGVHD related 
Keratoconjuntivit
is Sicca 
refractory to 
standard 
therapies 
Ocular surface 
disease index 
questionnaire  
The mean 
score for the 
Ocular 
surface 
disease 
index was 
81; 
symptoms 
reported 
were 
photophobia 
and pain. 
Treister, N.S., Cook, E.F., 
Antin, F., Lee, S.J., 
Soiffer, R., & Woo, 
Prospective, 
descriptive/ 
n=27
To characterize 
the distribution, 
type and extent 
Patient 
questionnaire 
answering 
Participants 
reported 
mouth pain 
40 
 
Citation Design/n Purpose Patient 
Reported 
Symptom 
Measures/ 
Other 
Measures 
Result
S.B. (2008). Clinical 
evaluation of oral 
chronic graft-versus-
host disease. Biology 
of Blood and Marrow 
Transplantation, 14, 
110-115. doi: 
10.1016/j.bbmt.2007.
06.017 
of lesions and 
their correlation 
with patient-
reported 
symptoms such 
as pain and 
discomfort
“yes” or “no”; 
Visual analog 
scale 
(41% of the 
visits), 
avoiding 
certain 
foods (79% 
of the 
visits), 
mouth 
tightness 
(23% of the 
visits), and 
odynophagi
a (20% of 
the visits); 
95% of the 
pain scores 
were < 5 out 
of 10 (0=no 
pain and 
10=worst 
pain);  there 
were no 
pain scores 
> 7.  
Key: cGVHD= chronic graft-versu- host disease, GI= gastrointestinal 
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Table 2. 
Studies Examining Cytokines of Chronic Graft-Versus-Host Disease 
Citation Design/n Purpose Cytokine Vector Tool Result
Aractingi, S., 
Gluckman, E., 
Le Goue, C., 
Dubertret, L., 
& Carosella, 
E.D. (1996). 
Lymphocytes, 
cytokines and 
adhesion 
molecules in 
chronic graft-
versus-host 
disease. 
Journal of 
Clinical and 
Molecular 
Pathology, 49, 
225-231.  
 
 
 
 
 
 
 
 
 
 
Descriptive, 
Case-
Control/18 
case, 8 
control 
To determine 
inflammatory 
and immune 
pathways 
responsible for 
the development 
and presentation 
of cGVHD
IL-1, IL-8, 
TNFα
Tissue Immuno 
histo-
chemical 
IL-1 and TNFα 
were expressed 
in “diseased” 
epidermis 
versus 
“normal” 
epidermis of 
patients with 
cGVHD.  IL-8 
was expressed 
in all 
keratinocytes 
in all samples.  
IL-1 was 
significantly 
expressed in 
“normal” skin 
in patients with 
lichen planus-
like cGVHD. 
 Bladon, J., & Taylor, 
P.C. (2006). 
The down-
regulation of 
IL-1α and IL-6, 
in monocytes 
exposed to 
extracorporeal 
photopheresis 
(ECP)- treated 
lymphocytes, is 
not dependent 
on lymphocyte 
Descriptive, 
Longitudinal/ 
n=12, n=9 
cGVHD  
To determine if 
monocyte 
immune-
suppression 
related to ECP is 
related to 
phosphate-
dylserine
TNFα, IL-
1α, IL-1β, 
IL-6, IL-8
Blood Flow 
cytometr
y 
All cytokine 
levels were 
elevated in 
patients with 
cGVHD prior 
to ECP.
42 
 
Citation Design/n Purpose Cytokine Vector Tool Result
phosphatidylser
ine 
externalization. 
Transplant 
International, 
19, 319-324. 
doi: 
10.1111/j.1432
-
2277.2006.002
78.x 
Craciun, L. I., 
Stordeur, P., 
Schandene, L., 
Duvillier, H., 
Bron, D., 
Lambermont, 
M., . . . 
Dupont, E. 
(2002). 
Increased 
production of 
interleukin-10 
and interleukin-
1 receptor 
antagonist after 
extracorporeal 
photochemothe
rapy in chronic 
graft-versus-
host disease. 
Transplantatio
n, 74, 995-
1000. doi: 
10.1097/01.TP.
0000031933.82
269.AC 
 
Descriptive, 
Longitudinal/
n=6 
To examine 
production of IL-
10 and IL-1RA 
after ECP 
treatment for 
cGVHD
IL-10, IL-
1RA, 
TNFα, IL-
1β, IL-
12p40
Blood Flow 
cytometr
y 
No significant 
changes in 
TNFα, IL-1β, 
or IL-12p40; 
ECP enhanced 
the production 
of IL-10 and 
IL-1RA.
43 
 
Citation Design/n Purpose Cytokine Vector Tool Result
Cullup, H., Dickson, 
A.M., Cavet, J., 
Jackson, G.H., 
Middleton, 
P.G. (2003). 
Polymorphisms 
of interleukin-
1α constitute 
independent 
risk factors for 
chronic graft-
versus-host 
disease after 
allogeneic bone 
marrow 
transplant. 
British Journal 
of 
Haematology, 
122, 778-787.  
Descriptive, 
Case-
Control/ 
n=98 
patients, 
n=94 donors 
(case), n=229 
control 
To compare 
clinical 
outcomes 
(GVHD and 
survival) of allo-
HSCT recipients 
with their 
genotype for two  
poly-morphisms 
present in the IL-
1α gene 
IL-1 α 
(two poly-
morphism
s: IL-1α-
889 and 
IL-1α 
VNTR
Blood Polymera
se Chain 
Reaction 
Allele 2 in the 
IL-1α-889 was 
significantly 
more prevalent 
in patients with 
cGVHD than 
in those 
without 
cGVHD; allele 
2 in the IL-1α 
VNTR was not 
significantly 
different 
between the 
cGVHD group 
and the control 
group.
D’Elios, M.M., 
Romagnani, P., 
Scaletti, C., 
Annunziato, F., 
Manghetti, M., 
Mavilia, C., . . . 
Romagnani, S. 
(1997). In vivo 
CD30 
expression in 
human diseases 
with 
predominant 
activation of 
Th2-like T 
cells 
Descriptive/ 
152 total 
participants; 
n= 22 with  
cGVHD 
To provide 
evidence that 
CD30 expression 
is associated 
with Th2 
dominated 
disorders
IFNγ, IL-4 Tissue 
and 
Blood 
Immunoh
isto-
chemical; 
ELISA 
IFNγ 
expression 
noted in 
cGVHD tissue; 
IL-4 was not; 
IL-4 
expression was 
noted in 
cGVHD blood 
samples. 
Serum CD30 
levels were 
increased in all 
cGVHD 
samples
Darvay, A., Salooja, 
N., & Russell-
Jones, R. 
(2004). The 
effect of 
extracorporeal 
photopheresis 
on intracellular 
cytokine 
Descriptive, 
Longitudinal, 
Case-
Control/n=9 
case, n=x 
To assess the 
effects of ECP 
on cytokine 
profiles of 
peripheral blood 
lymphocytes 
from patients 
with cGVHD
IL-2, 
IFNγ, IL-4
Blood Flow 
cytometr
y 
IL-2 was lower 
in patients with 
cGVHD than 
normal 
controls in 
both CD4 and 
CD8 T-cells; 
IFNγ was 
greater in 
44 
 
Citation Design/n Purpose Cytokine Vector Tool Result
expression in 
chronic 
cutaneous 
graft-versus-
host disease. 
European 
Journal of 
Dermatology 
and 
Venerology, 18, 
279-284. doi: 
10.111/j.1468-
3083.2004.008
14.x 
patients with 
cGVHD than 
normal 
controls in 
both CD4 and 
CD8 T-cells at 
baseline; IL-4 
greater in 
patients with 
cGVHD than 
normal 
controls at 
baseline in 
CD4 T-cells.  
Fall-Dickson, J.M., 
Mitchell, S.A., 
Marden, S., 
Ramsay, E.S., 
Guaddgnini, 
J.P., Wu, T., . . 
. Pavletic, S.Z. 
(2010). Oral 
symptom 
intensity, 
health related 
quality of life, 
and correlative 
salivary 
cytokines in 
adult survivors 
of 
hematopoietic 
stem cell 
transplantation 
with oral 
chronic graft-
versus-host 
disease. 
Biology of 
Blood Marrow 
Transplant, 16, 
948-956. doi: 
10.1016/jbbmt.
2010.01.017 
Cross-
sectional, 
Descriptive, 
Case-
Control/n=42 
case, 23 
control 
To describe 
relationships 
among clinical 
characteristic of 
oral cGVHD and 
related pain, 
dryness, selected 
salivary pro-
inflammatory 
cytokines and 
health related 
quality of life
IL-6, IL1α Saliva ELISA 31 subjects for 
analysis; there 
was a 
significant 
difference 
between the 
patient group 
and the control 
group for both 
IL-6 and IL-
1α.
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Gorgun, G., Miller, K., 
& Foss, F., 
(2002). 
Immunologic 
mechanisms of 
extracorporeal 
photochemothe
rapy in chronic 
graft-versus-
host disease. 
Blood, 100, 
941-947. doi: 
10.1182/blood-
2002-01-0068 
Descriptive, 
Longitudinal/ 
10 
To examine the 
functional effects 
of ECP on 
alloantigen 
presentation and 
cytokine 
production
IFNγ, IL-
4, IL-10
Blood Flow 
cytometr
y 
Patients 
receiving ECP 
had a decrease 
in IFNγ and an 
increase in IL-
4 and IL-10.
Hettinga, Y.M., 
Verdonck, L.F., 
Fijnheer, R., 
Rijkers, G.T., 
& Rothova, A. 
(2007). 
Anterior 
uveitis: A 
manifestation 
of graft-versus-
host disease. 
Journal of 
Ophthalmology
, 114, 794-797. 
 
 
 
 
 
 
Retrospectiv
e small case 
study/  3 
case, 4 
control 
To describe the 
occurrence of 
anterior uveitis 
after allo-HSCT
IL-6, IL-
10, TNF-
α, IFN-ƴ, 
sVCAM-
1, 
RANTES
Ocular 
Fluid 
Multiplex 
Immunoa
ssay 
IL-6, IL-10, 
RANTES, and 
sVCAM highly 
elevated in two 
cGVHD 
patients as 
compared with 
control 
patients.
Kaminska, D., Bernat, 
B., Vakulenko, 
O., Kuzniar, J., 
Tyran, B., 
Suchnicki, K., . 
. . Klinger, M. 
(2010). 
Glomerular 
lesion and 
increased 
cytokine gene 
Case Study/ 
2 cases, 1 
control 
To describe 
cytokine 
expression in 
two patients with 
glomerulopathies 
following allo-
HSCT with 
chronic graft 
versus host 
disease
TNFα, 
TGFβ, 
IFNγ, IL-
2, IL-6, 
IL-10
Renal 
Tissue 
Digoxige
nin 
mixture 
Levels of 
TNFα, TGFβ, 
IFNγ, IL-2, IL-
6 and IL-10 
were at least 
five times 
greater in cases 
than levels in 
the control 
sample.
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expression in 
renal tissue in 
patients with 
decompensated 
nephritic 
syndrome due 
to chronic graft 
versus host 
disease. Renal 
Failure, 32, 
510-514. doi: 
10.3109/08860
221003664256 
Nakamura, K., 
Amakawa, R., 
Takebayashi, 
M., Son, Y., 
Miyaji, M., 
Tajima, K., . . . 
Fukuhara, S. 
(2005). IL-4 
producing 
CD8+ T cells 
may be an 
immunological 
hallmark of 
chronic 
GVHD. Bone 
Marrow 
Transplantatio
n, 36, 639-647. 
48 
Prospective, 
Longitudinal, 
Descriptive, 
n=19case, 10 
controls; of 
the case 
group, 10 
developed 
cGVHD 
To examine 
cytokine 
expression in 
patients who 
underwent allo-
HSCT with and 
without cGVHD
IL-4, IL-
10, IFNƴ
Blood ELISA IL-4 producing 
CD 8+ cells 
were 
significantly 
increased in 
the cGVHD 
group; IFN ƴ 
producing CD 
8+ cells were 
significantly 
increased in 
the cGVHD 
group; there 
was no 
significant 
difference 
between 
groups for IL-4 
or IFN ƴ 
producing CD 
4+ cells; IL-10 
was not 
significantly 
different 
between 
groups.
Poloni, A., Sartini, D., 
Emanuelli, M., 
Trappolini, S., 
Mancini, S., 
Pozzi, V., . . . 
Prospective, 
Longitudinal, 
Descriptive 
study/14 
To examine the 
role of 
inflammatory 
cytokines in 
recipients of 
IL-8, IL-
1β, IL-
12A, 
IFNγ, 
TNFSF2, 
Blood, 
Tissue 
samples 
Microray 
analysis 
 CD4+ cells, 
TNFSF12 and 
PDGFβ were 
significantly 
elevated in 
47 
 
Citation Design/n Purpose Cytokine Vector Tool Result
Leoni, P. 
(2011). Gene 
expression 
profile of 
cytokines in 
patients with 
chronic graft-
versus-host 
disease after 
allogeneic 
hematopoietic 
stem cell 
transplantation 
with reduced 
conditioning. 
Cytokine, 53, 
376-383. doi: 
10.1016/j.cyto.
2010.12.008 
allo-HSCT with 
reduced intensity 
conditioning on 
cGVHD
TNFSF3, 
TNFSF10, 
TNFSF12, 
TNFSF13
B, PDGFβ
patients with 
cGVDG; 
CD8+ cells, 
IFNγ was 
significantly 
decreased and 
TNFSF10 was 
significantly 
increased; CD 
14+ cells, 
TNFSF3 and 
TNFSF10 were 
significantly 
decreased. 
Ricci, P., 
Tauchmanova, 
L., Ristano, A., 
Carella, C., 
Mazziotti, G., 
Lombardi, G., . 
. . Serelli, C. 
(2006). 
Imbalance of 
the 
osteoprotegerin
/RANKL ratio 
in bone marrow 
microenvironm
ent after 
allogeneic 
hematopoietic 
stem cell 
transplantation. 
Transplantatio
n, 82, 1449-
1456. doi: 
10.1097/01.tp.0
000244588.425
19.72 
Longitudinal, 
Descriptive, 
Case-
Control/ 36 
case, 36 
control; n= 
36 cGVHD 
To investigate 
OPG and 
RANKL in 
plasma of 
transplanted 
patients
IL-2, IL-4, 
IL-5, IL-
10, IFNγ, 
TNFα
Blood Multiplex There was no 
significant 
difference 
found in any of 
the IL 
cytokines or 
TNFα between 
groups; 
patients who 
had received 
an allogeneic 
hematopoietic 
stem cell 
transplant had 
significantly 
higher levels of 
IFN ƴ than 
normal 
controls. 
Tauchmanova, L., Longitudinal To better IL-2, IL-4, Blood Multiplex All evaluated 
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Matarese, G., 
Carella, C., 
DeRosa, G., 
Serio, B., 
Ricci, P., . . . 
Serelli, C. 
(2004). High 
serum leptin in 
patients with 
chronic graft-
versus-host 
disease after 
hematopoietic 
stem cell 
transplantation. 
Transplantatio
n, 78, 1376-
1383. doi: 
10.1097/01.TP.
0000140485.20
848.B7 
Case-
Control/60 
cases, 60 
controls; 
n=36 allo 
transplant, 21 
with cGVHD 
understand leptin 
production in 
patients with 
stem cell 
transplant
IL-5, IL-
10, TNFα, 
IFNγ
cytokine levels 
were greater in 
the group of 
patients with 
cGVHD.
Key: alloHSCT= allogeneic hematopoietic stem cell transplantation, cGVHD= chronic graft-
versus-host disease, ECP= extracorporeal photopheresis. ELISA = enzyme linked 
immunosorbent assay, IFN= interfeuron, IL = interleukin, PDGF= platelet- derived growth 
factor, SF= superfamily, sVCAM= soluble vascular cell adhesion molecule, TGF= transforming 
growth factor, TNF= tumor necrosis factor, OM= oral mucositis, OPG= Osteoprotegerin, RA= 
receptor agonist, RANKL= receptor activator of nuclear factor-kappaB ligand, RANTES= 
regulated on activation, normal t cell expressed and secreted, VNTR= variable number tandem 
repeat, 
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Table 3. 
Studies Examining Quality of Life of Patients with Chronic Graft-Versus-Host Disease 
Citation Design/n Purpose Tool Result
Fall-Dickson, J.M., Mitchell, 
S.A., Marden, S., 
Ramsay, E.S., 
Guadagnini, J.P., 
Wu, T., . . .  Pavletic, 
S.Z. (2010). Oral 
symptom intensity, 
health related quality 
of life, and 
correlative salivary 
cytokines in adult 
survivors of 
hematopoietic stem 
cell transplantation 
with oral chronic 
graft-versus-host 
disease. Journal of 
Biology of Blood and 
Marrow 
Transplantation, 16, 
948-956. 
doi:10.1016/jbbmt.2
010.01.017 
Descriptive, Cross-
sectional
n=42 
To elucidate 
the 
relationships 
among 
clinical 
characteristic
s of oral 
cGVHD and 
related oral 
complication
s, 
proinflammat
ory salivary 
cytokines and 
health related 
quality of life
Functional 
assessment 
of cancer 
therapy-
general/ 
Oral 
mucositis 
rating scale, 
ELISA 
There was 
a 
significant 
negative 
relationshi
p between 
oral 
cGVHD 
severity 
and the 
social 
well- being 
subscale of 
quality of 
life; there 
was a 
significant 
negative 
relationshi
p between 
oral 
dryness 
and quality 
of life; 
total 
quality of 
life scores 
were lower 
in patients 
with 
cGVHD 
than U.S. 
population 
normative 
scores.
Harris, B., Berger, A.M., 
Mitchell, S.A., 
Steinberg, S. M., 
Baker, K. L., Handel, 
D.L., . . . Pavletic, 
S.Z. (2010). Spiritual 
Prospective, Cross-
sectional, 
Observational
n= 52 patients with 
cGVHD
To describe 
the spiritual 
well-being of 
patients with 
cGVHD; to 
explore 
Functional 
assessment 
of cancer 
therapy-
general/ 
Functional 
Spiritual 
well-being 
was 
significantl
y, 
positively 
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well-being in long-
term survivors with 
chronic graft-versus-
host disease after 
hematopoietic stem 
cell transplantation. 
Journal of 
Supportive 
Oncology, 8, 119-
125.  
clinical and 
demographic 
factors 
associated 
with spiritual 
well-being of 
patients with 
cGVHD; to 
examine the 
association 
between 
spiritual 
well-being 
and cGVHD 
of patients 
with cGVHD
assessment 
of chronic 
illness 
Therapy-
Spiritual;  
correlated 
with all 
domains of 
quality of 
life 
(physical, 
social, 
emotional 
and 
functional)
Herzberg, P.Y., Heussner, 
P., Mumm, F.H.A., 
Horak, M., 
Hilgendorf, I., 
vonHarsdorf, S., . . . 
Wolff, D. (2010). 
Validation of the 
Human Activity 
Profile Questionnaire 
in patients after 
allogeneic 
hematopoietic stem 
cell transplant. 
Journal of Biology of 
Blood and Marrow 
Transplantation, 16, 
1707-1717. 
doi:10.1016/jbbmt.2
010.05.018 
Prospective, 
Longitudinal, 
Cohort, 
Correlational
n=176 (117 patients 
with cGVDH; 59 
patients without 
cGVHD)
Validation of 
the Human 
Activity 
Profile in 
recipients of 
alloHSCT 
with and 
without 
cGVHD
Functional 
assessment 
of cancer 
therapy-
Bone 
marrow 
transplantati
on/ Human 
activity 
profile, Lee 
cGVDH 
symptom 
scale, Short 
form-36, 
Berlin social 
support 
scale, 
Hospital 
anxiety and 
depression 
scale, 
NCCN-
distress 
thermomete
r 
117 
patients 
had classic 
cGVHD 
(mild=33; 
moderate=
50; 
severe=34)
; 24 
patients 
had 
progressiv
e onset 
cGVHD. 
Physical 
functionin
g has an 
overall 
effect on 
quality of 
life for 
patient 
with 
cGVHD; 
decreased 
physical 
function 
was 
associated 
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with a 
decreased 
quality of 
life and 
was noted 
with an 
increase in 
the 
severity of 
cGVHD.  
Imanguli, M.M., Atkinson, 
J.C., Mitchell, S.A., 
Avila, D.N., Bishop, 
R.J., Cowen, E.W., . 
. . Pavletic, S.Z. 
(2010). Salivary 
gland involvement in 
chronic graft-versus-
host disease: 
Prevalence, clinical 
significance, and 
recommendations for 
evaluation. Journal 
of Biology of Blood 
and Marrow 
Transplantation, 16, 
1362-1369. 
doi:10.1016/j.bbmt.2
010.03.023 
Cross-sectional
n=101
To 
systematicall
y examine 
the 
characteristic
s and 
correlates of 
salivary 
gland 
function in 
cGVHD
Oral health 
impact 
profile; 
Functional 
assessment 
of cancer 
therapy-
general 
Oral 
quality of 
life scores 
were 
significantl
y higher 
(indicating 
greater 
impairmen
t) in 
patients 
with 
salivary 
gland 
dysfunctio
n; quality 
of life was 
significantl
y 
positively 
correlated 
with the 
degree of 
patient 
perceived 
oral 
discomfort
; there was 
not a 
significant 
correlation 
between 
actual 
clinical 
oral 
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severity 
scores and 
patient 
perceived 
quality of 
life; there 
was no 
significant 
correlation 
between 
salivary 
dysfunctio
n and 
quality of 
life.
Kim, S.J., Lee, J.W., Jung, 
C.W., Min, C.K., 
Cho, B., Shin, H. J., . 
. . Won, J.H. (2010). 
Weekly rituximab 
followed by monthly 
rituximab treatment 
for steroid refractory 
chronic graft-versus-
host disease: Results 
from a prospective, 
multicenter, phase II 
study. 
Haematologica, 95, 
1935-1942. 
doi:10.3324/haemato
l.2010.026104   
Open-label, 
Multicenter, 
Prospective, Phase II 
study
n= 37
To evaluate 
treatment 
response to 
rituximab, to 
evaluate 
changes in 
patient 
reported 
quality of 
life, to 
evaluate 
effectiveness 
to treatment 
for 
discontinuati
on of steroid 
use
Short from-
36 
All 
baseline 
scores for 
all quality 
of life 
domains 
below 
normal in 
patients 
diagnosed 
with 
cGVHD.
Lee, S.J., Kim, H.T., Ho, 
V.T., Cutler, C., 
Alyea, E.P., Soiffer, 
R.J., 7 Antin, J.H. 
(2006). Quality of 
life associated with 
acute and chronic 
graft-versus-host 
disease. Bone 
Marrow 
Transplantation, 38, 
305-310. 
doi:10.1038/sjbmt.17
Prospective, 
Longitudinal
n= 96 (group 1: no 
acute GVHD and no 
cGVHD; group 2: no 
acute GVHD and yes 
cGVHD; group 3: 
yes acute GVHD and 
yes cGVHD)
To measure 
the impact of 
acute and 
chronic graft-
versus-host 
disease on 
quality of life 
and 
functional 
status prior to 
transplant, at 
six months 
and twelve 
Functional 
assessment 
of cancer 
therapy- 
Bone 
marrow 
transplant/ 
Medical 
outcomes 
study-Short 
form 12  
Baseline 
quality of 
life scores 
were not 
different 
among 
among 
patients; 
scores did 
not differ 
for mental 
functionin
g or 
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05434 months post-
transplant
physical 
functionin
g overtime 
for any 
group; the 
trial 
outcome 
index 
score for 
quality of 
life was 
significantl
y lower at 
6 months 
for patients 
in group 3 
and at 12 
months for 
patients in 
group 2. 
Pallua, S., Giesinger, J., 
Oberguggenberger, 
A., Kemmler, G., 
Nachbaur, D., 
Clausen, J., . . . 
Holzner, B. (2010). 
Impact of GvHD on 
quality of life in 
long-term survivors 
of haematopoietic 
transplantation. Bone 
Marrow 
Transplantation, 45, 
1534-1539. 
Case-Control Cross-
sectional 
n= 100
 
Retrospective/Prospe
ctive Longitudinal
n= 33
To 
investigate 
the impact of 
GvHD on the 
quality of life 
in survivors 
of bone 
marrow 
transplantatio
n and 
peripheral 
blood stem 
cell 
transplantatio
n; to 
investigate 
change in 
quality of life 
over time; 
Compare 
quality of life 
outcomes in 
hematopoieti
c stem cell 
transplant 
European 
Organizatio
n for 
Research 
and 
Treatment 
of Cancer 
Quality of 
Life 
Questionnai
re 
There were 
significant 
impairmen
ts in 
quality of 
life for 
patients 
with 
cGVHD 
when 
compared 
to patients 
without 
cGVHD or 
previous 
cGVHD in 
areas of 
role 
functionin
g and 
global 
quality of 
life.
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survivors to 
healthy 
controls
Pidala, J., Kurland, B., Chai, 
X., Majhail, N., 
Weisdorf, D.J., 
Pavletic, S., . . . Lee, 
S.J. (2011). Patient-
reported quality of 
life is associated with 
severity of chronic 
graft-versus-host 
disease as measured 
by NIH criteria: 
Report on baseline 
data from the 
Chronic GVHD 
Consortium. Blood, 
117, 4651-4657. 
doi:10.1182/blood-
2010-11-319509 
Prospective, 
Observational, 
Cross-sectional, 
Cohort enrolled 
across five centers
n=298
To describe 
the 
relationship 
between 
cGVHD 
severity and 
quality of 
life; to 
compare 
quality of life 
in patients 
with cGVHD 
to norm 
population 
data; to 
compare 
quality of life 
in patients 
with cGVHD 
to patients 
with other 
chronic 
health 
conditions; to 
determine the 
ability of 
quality of life 
measures to 
discriminate 
cGVHD 
severity
Short form- 
36; 
functional 
assessment 
of cancer 
therapy- 
bone 
marrow 
transplant 
Only 10% 
of patients 
had mild 
severity of 
cGVHD; 
All 
domains of 
both 
quality of 
life 
measures 
were 
significantl
y different 
between 
patients 
with mild 
cGVHD 
and severe 
cGVHD; 
All 
domains of 
both 
quality of 
life 
measures 
except the 
mental 
component 
score from 
the short 
form-36 
were 
significantl
y different 
between 
patients 
with 
moderate 
cGVHD 
and severe 
cGVHD.
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Pidala, J., Kurland, B.F., 
Chai, X., Vogelsang, 
G., Weisdorf, D.J., 
Pavletic, S., . . . Lee, 
S.J. (2011). 
Sensitivity of 
changes in chronic 
graft-versus-host 
disease activity to 
changes in patient 
reported quality of 
life: Results from the 
Chronic Graft-
Versus-Host Disease 
Consortium. 
Haematologica, 96, 
1528-1535. 
doi:10.3324/haemato
l.2011.046367 
Prospective, 
Longitudinal 
Observational, 
Cohort enrolled 
across six centers
n= 336
To assess the 
association 
between 
changes in 
quality of life 
and cGVHD 
severity
functional 
assessment 
of cancer 
therapy- 
Bone 
marrow 
transplant 
and Short 
form-36 
Most 
common 
cGVHD 
sites were 
skin, 
mouth, 
eye, and 
lung; At 
baseline, 
patients 
with 
cGVHD 
had lower 
than 
average 
(50) scores 
on the 
short form 
36 with the 
lowest 
score 
reported 
for 
physical 
role; The 
patient’s 
perception 
of severity 
negatively 
impacted 
quality of 
life scores.
Pidala, J., Vogelsang, G., 
Martin, P., Chai, X., 
Storer, B., Pavletic, 
S., . . . Lee, S.J. 
(2011). Overlap 
subtype of chronic 
graft-versus-host 
disease is associated 
with an adverse 
prognosis, functional 
impairment, and 
inferior patient 
reported outcomes: 
Prospective, 
Observational, 
Cross-sectional, 
Cohort enrolled 
across nine centers
n= 427
To identify 
differences in 
overlap 
subtype of 
cGVHD in 
an effort to 
distinguish it 
from late 
acute graft-
versus-host 
disease and 
classic 
cGVHD
Functional 
assessment 
of cancer 
therapy-
Bone 
marrow 
transplant/ 
Lee cGVHD 
symptom 
scale; 
Human 
activity 
profile; 
352 of the 
patients 
had 
overlap 
syndrome 
and only 
75 had 
classic 
cGVHD.  
Neither the 
cGVHD 
severity 
scores nor 
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A Chronic Graft-
Versus-Host Disease 
Consortium study. 
Haematologica, 97, 
451-458.  
Short form-
36;  
the quality 
of life 
scores 
differed 
significantl
y between 
the two 
groups.
Key: cGVHD= chronic graft-versus-host disease, ELISA= enzyme linked immunosorbent assay, 
NCCN= National Comprehensive Cancer Network 
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Chapter 3 
 
IRB Proposal: Research Plan 
 
 
 
VCU RESEARCH PLAN TEMPLATE 
 
Use of this template is required to provide your VCU Research Plan to the IRB.  Your responses should be written in terms for 
the non-scientist to understand.  If a detailed research protocol (e.g., sponsor’s protocol) exists, you may reference specific 
sections of that protocol.  NOTE: If that protocol does not address all of the issues outlined in each Section Heading, you 
must address the remaining issues in this Plan.  It is NOT acceptable to reference a research funding proposal.       
 
ALL Sections of the Human Subjects Instructions must be completed with the exception of the Section entitled “Special 
Consent Provisions.”  Complete that Section if applicable.  When other Sections are not applicable, list the Section Heading 
and indicate “N/A.” 
 
NOTE: The Research Plan is required with ALL Expedited and Full review submissions and MUST follow the 
template, and include version number or date, and page numbers.   
 
DO NOT DELETE SECTION HEADINGS OR THE INSTRUCTIONS.
 
I. TITLE    
 
Symptoms,	Cytokines,	and	Quality	of	Life	Profiles	of	Patients	with	Chronic	Graft‐Versus‐Host	Disease	
Following	Allogeneic	Hematopoietic	Stem	Cell	Transplantation	
 
 
II. RESEARCH PERSONNEL 
A. PRINCIPAL INVESTIGATOR 
List the name of the VCU Principal Investigator 
DEBRA E. LYON 
 
 
B.  STUDY PERSONNEL 
NOTE:   
1. Information pertaining to each project personnel, including their role, responsibilities, and qualifications, is to 
be submitted utilizing a VCU IRB Study Personnel Information and Changes Form. This form is available at 
http://www.research.vcu.edu/forms/vcuirb.htm. 
2. A roster containing a list of project personnel is to be maintained as a separate study document which is 
retained with the Research Plan, and is to be updated as applicable. The roster is to include all VCU project 
personnel (including the principal investigator) who are engaged in this research protocol, as well as non-VCU 
personnel who are also engaged but do not have local IRB approval for this protocol from their own 
institution,. This template document, entitled VCU IRB Study Personnel Roster, is available at 
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http://www.research.vcu.edu/forms/vcuirb.htm.  
 
C.  Describe the process that you will use to ensure that all persons assisting with the research are adequately informed 
about the protocol and their research-related duties and functions. 
 
Dr.	Lyon	will	work	closely	with	the	doctoral	student,	Debra	Lynch	Kelly,	finalizing	the	procedures	for	participant	
screening,	recruitment,	data	collecting,	documentation,	and	manuscript	preparation.		The	physicians	and	nurses	of	
the	Bone	Marrow	Transplant	Center	at	the	Massey	Cancer	Center	will	provide	a	clinical	link	for	the	recruitment	of	
participants	for	this	study.		In	the	first	month	of	the	study,	Debra	Lynch	Kelly	will	conduct	a	training	session	for	
staff	in	the	Bone	Marrow	Transplantation	Clinic.		All	personnel	will	be	familiar	with	the	proposal	and	measurement	
tools.		A	resource	manual	will	be	maintained	on	site	from	where	participants	will	be	recruited.		The	manual	will	
contain	the	mission	of	the	project,	detail	of	operations,	including	the	protocol,	forms,	IRB	materials,	the	monthly	
enrollment	form,	elevated	HAD‐S	scores	and	proper	questionnaire	completion.		The	principal	investigator	and	the	
doctoral	student	have	been	trained	extensively	in	research	procedures	and	in	issues	regarding	the	protection	of	
research	subjects’	rights	and	privacy.		All	study	personnel	have	completed	HIPAA	training.		Follow‐up	meetings	by	
telephone	calls,	faxes,	e‐mail	and	face‐to	–face	will	be	used	for	ongoing	communication	among	the	research	team	
and	the	clinic.	 
 
 
III. CONFLICT OF INTEREST 
Describe how the principal investigator and sub/co-investigators might benefit from the subject’s participation in this 
project or completion of the project in general. Do not describe (1) academic recognition such as publications or (2) 
grant or contract based support of VCU salary commensurate with the professional effort required for the conduct of 
the project 
 
No	member	of	the	research	team,	or	of	their	immediate	families,	has	a	financial	interest	in	any	external	entity	
related	to	the	work	to	be	conducted	under	the	project	or	interested	in	the	results	of	the	project.		To	the	best	of	our	
knowledge,	no	VCU	employee	has	a	financial	interest,	ownership,	or	equity	interest	in	the	funding	source	of	this	
project. 
 
 
IV. RESOURCES 
Briefly describe the resources committed to this project including: (1) time available to conduct and complete the 
research, (2) facilities where you will conduct the research, (3) availability of medical or psychological resources that 
participants might require as a consequence of the research (if applicable), and (4) financial support. 
 
1) The	doctoral	student,	Debra	Lynch	Kelly,	under	the	supervision	of	her	advisor,	Dr.	Debra	E.	Lyon,	will	focus	
full‐time	on	the	completion	of	the	study.		The	projected	completion	date	is	November,	2013.		The	doctoral	
student	will	attend	bi‐weekly	multi‐disciplinary	meetings	in	the	Bone	Marrow	Transplant	Center.	Data	
collection	will	commence	in	month	two	of	the	study	and	will	continue	through	month	seven.		Final	data	
analysis	will	be	conducted	throughout	month	ten	of	the	year.	Debra	Kelly	will	work	with	the	Clinical	
Coordinator,	Valerie	Charron,	to	arrange	study	visits.	
2) The	facility	to	be	used	for	recruitment	will	be	the	Bone	Marrow	Transplant	Clinic	of	the	Massey	Cancer	
Center	at	Virginia	Commonwealth	University	Health	System	
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3) Dr.	McCarty,	medical	director	of	the	bone	marrow	transplant	program,	will	serve	as	medical	resource	for	
the	study.		Participants	with	elevated	levels	of	depression	(a	score	of		>16	on	the	depressive	sub‐scale	of	the	
HAD‐S	(HADS‐D),	indicating	severe	depressive	symptoms,	will	be	referred	to	the	clinical	social	worker	in	
accord	with	the	current	system	in	place	in	the	bone	marrow	transplant	clinic	for	evaluation	of	acute	
psychiatric	symptoms.			
4) There	is	no	financial	support	for	this	project.		Gift	cards	will	be	provided	to	the	study	from	the	doctoral	
advisor’s	indirect	account	fund. 
 
 
V. HYPOTHESIS 
Briefly state the problem, background, importance of the research, and goals of the proposed project. 
 
Chronic	graft‐versus‐host	disease	is	the	perhaps	the	most	detrimental	and	the	most	common	late	term	complication	
following	allogeneic	hematopoietic	stem	cell	transplant.		Up	to	90%	of	patients	undergoing	allogeneic	
hematopoietic	stem	cell	transplantation	will	be	diagnosed	with	this	complication (Lee,	Cook,	Soiffer,	&	Antin,	2002;	
Lee,	Vogelsang,	&	Flowers,	2003).		Manifestations	of	chronic	graft‐versus	host‐disease	can	be	mild	to	severe	and	can	
occur	in	any	of	the	body	systems	with	the	integumentary	system	being	the	most	common	site.		The	literature	
regarding	this	phenomenon	is	predominantly	that	of	a	biomedical	focus.		Few	studies	have	focused	on	distressing	
features	of	chronic	graft	versus	host	disease	such	as	symptom	frequency	and	severity	and	decreased	quality	of	life.		
With	increased	survivorship	of	patients	with	cGVHD,	improvement	in	the	quality	of	life	for	patients	with	cGVHD	is	
of	growing	importance	(Flowers	et	al.,	2011;	Lee	et	al.,	2002;	Lee	et	al,	2003).			
										Symptom	management	is	a	major	issue	for	patients	experiencing	cGVHD	(Lee	et	al,	2002;	Perez‐Simon,	
Sanchez‐Abarca,	Diez‐Campelo,	Caballero,	&	San	Miguel,	2006).	There	is	a	gap	in	the	literature	establishing	the	
relationship	between	symptoms	experienced	in	this	vulnerable	population	and	quality	of	life.		The	relationship	
between	biological	markers	and	behavioral	responses	may	also	impact	the	frequency	and	severity	of	symptoms	
experienced	in	patients	with	chronic	graft‐versus‐host	disease.		As	chronic	graft‐versus‐host	disease	is	speculated	
to	be	an	allo‐reactive	complication,	examining	patterns	and	levels	of	inflammatory	markers	are	of	importance.	
									These	features	of	chronic	graft‐versus‐host	disease	make	examining	this	phenomenon	from	a	biobehavioral	
nursing	perspective	critical	for	caring	for	these	patients.		This	study	will	elucidate	features	associated	with	chronic	
graft‐versus‐host	disease	from	a	biobehavioral	nursing	perspective.		By	understanding	which	symptoms	are	
present	and	how	inflammation	presents	for	these	patients,	interventions	to	ameliorate	symptom	severity	and	
frequency	using	multiple	modalities	may	be	tested	and	may	be	implemented	to	positively	impact	patients’	quality	of	
life.	 
 
  
VI. SPECIFIC AIMS   
 
Therefore,	the	specific	aims	of	this	study	are:
1)	To	describe	symptoms,	inflammatory	markers,	and	quality	of	life	of	patients	with	cGVHD	
2)	To	examine	the	associations	among	selected	symptoms	(pain,	depression,	and	fatigue)	of	patients	with	cGVHD	
3)	To	examine	the	associations	among	selected	cytokines	(IL‐1β,	IL‐6,	IL‐10,	TNF‐α,	and	IFN‐ƴ)	of	patients	with	
cGVHD	
4)		To	examine	the	associations	among	selected	symptoms	(pain,	depression,	and	fatigue),	cytokines	(IL‐1β,	IL‐6,	IL‐
10,	TNF‐α,	and	IFN‐ƴ)	and	quality	of	life	of	patients	with	cGVHD	
5)	To	examine	the	associations	among	the	top	three	severe	and	bothersome	symptoms	determined	from	the	
Memorial	Symptoms	Assessment	Scale,	selected	cytokines,	and	quality	of	life. 
 
  
VII. BACKGROUND AND SIGNIFICANCE 
Include information regarding pre-clinical and early human studies.  Attach appropriate citations. 
 
Hematopoietic	stem	cell	transplantation	has	become	the	standard	treatment	for	many	hematologic	cancers	
including	acute	leukemia,	chronic	myelogenous	leukemia,	and	multiple	myeloma.		Patients	receiving	an	allogeneic	
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hematopoietic	stem	cell	transplant	(alloHSCT)	are	at	risk	for	developing	a	serious,	potentially	life‐threatening	
complication	known	as	chronic	graft‐versus‐host	disease	(cGVHD).		This	is	a	complex,	multisystem	issue	involving	
immune	dysregulation	and	immunodeficiency,	impaired	organ	function,	and	decreased	survival	(Baird	and	Pavletic,	
2006).			
This	phenomenon	occurs	in	as	many	as	90%	of	all	alloHSCT	recipients	who	survive	greater	than	100	days	
post‐transplant	(Lee,	Cook,	Soiffer,	&	Antin,	2002;	Lee,	Vogelsang,	&	Flowers,	2003).Any	of	the	body	systems	can	be	
affected	by	cGVHD.		Cutaneous	and	ocular	cGVDH	are	the	most	commonly	affected	sites	while	pulmonary	and	
hepatic	cGVHD	have	the	highest	mortality.		In	addition	to	being	the	most	serious	complication	of	alloHSCT,	cGVHD	
is	also	the	most	common	(Pidala	et	al.,	2011;	Vogelsang,	2011).		Debilitating	consequences	of	cGVHD	include	loss	of	
sight,	pulmonary	disease,	and	joint	contractures	as	well	as	death	resulting	from	chronic	immune	suppression	
(Filipovich	et	al.,	2005).	
	The	development	of	cGVHD	is	thought	to	be	linked	to	alloreactivity	and	the	processes	are	delayed	or	their	
effects	are	exerted	slowly	(Lee,	2005).	The	pathophysiology,	however,	is	still	poorly	understood	(Lee,	2005;	
Vogelsang,	2001).	As	cGVHD	is	speculated	to	be	an	inflammatory	process,	several	cytokines	such	as	interleukin‐6	
(IL‐6),	interferon‐gamma	(IFN‐γ),	interleukin‐10	(IL‐10),	interleukin‐10	(IL‐10)	as	well	as	tumor	necrosis	factor‐
alpha	(TNF‐α)	and	interleukin‐1	(IL‐1)	from	damaged	cells	may	contribute	to	cGVHD	development	(Aracting,	
Gluckman,	LeGoue,	Dubertret,	&	Carosella,	1996;	Craciun,	2002;	Lee,	2005;).			
Until	recently,	patients	experiencing	graft	versus	host	disease	were	diagnosed	with	acute	graft‐versus‐host	
disease	(aGVHD)	if	presentations	occurred	prior	to	100	days	post‐transplant	and	cGVHD	was	diagnosed	if	
presentations	occurred	100	days	or	more	post	transplant.		In	2005,	a	series	of	papers	produced	by	the	National	
Institutes	of	Health	consortium	on	cGVHD,	established	guidelines	for	new	diagnostic	and	classification	criteria	for	
cGVHD	(Filipovich	et	al.,	2005).		The	recommendations	for	diagnosing	and	scoring	cGVDH	are	as	follows	1)	
distinguishing	aGVHD	from	cGVHD,	2)	presence	of	at	least	one	diagnostic	clinical	sign	of	cGVHD	or	at	least	one	
distinctive	manifestation	confirmed	by	biopsy	or	other	testing,	and	3)	exclusion	of	other	diagnoses	(Filipovich	et	al.,	
2005).		In	addition	to	diagnosing	cGVHD,	scoring	cGVHD	allows	identification	of	disease	severity.		A	0‐3	scoring	
system	is	recommended	for	evaluation	of	organ	involvement	and	number	of	sites	involved.		A	global	assessment	
score	(mild,	moderate	or	severe)	is	ascertained	by	combining	the	organ	and	site	specific	scores	(Filipovich	et	al.,	
2005).		Classic	and	overlap	syndrome	are	the	two	main	designations	for	cGVHD	type.		Clasic	cGVHD	is	absent	of	any	
aGVHD	features	and	overlap	cGVHD	in	which	diagnostic	or	distinctive	features	of	both	aGVHD	and	cGVHD	are	
present	concurrently	(Filipovich	et	al.,	2005).		The	sequence	of	the	development	of	cGVHD	can	be	categorized	as:	1)	
de	novo	(onset	of	cGVHD	without	prior	diagnosis	of	aGVHD),	2)	progressive	(onset	of	cGVHD	is	an	extension	of	
aGVHD)	and	3)	quiescent	(onset	of	cGVHD	after	resolution	of	aGVHD).		Progressive	cGVHD	onset	is	the	most	
common	and	is	associated	with	the	worst	prognosis	(Galbizo	&	Williams,	2006;	Lee,	Vogelsang,	&	Flowers,	2003).	
	Due	to	increased	survivorship	of	patients	with	cGVHD,	improving	quality	of	life	is	of	growing	importance	
(Flowers	et	al.,	2011;	Lee	et	al.,	2002;	Lee	et	al.,	2003).		Symptom	management	is	also	a	major	issue	for	patients	
experiencing	cGVHD	(Lee	et	al.,	2002;	Perez‐Simon,	Sanchez‐Abarca,	Diez‐Campelo,	Caballero,	&	San	Miguel,	2006).		
From	December,	2005	through	May,	2006,	the	National	Cancer	Institute	published	a	series	of	papers	in	the	areas	of	
diagnosing	and	staging,	histopathology,	strategies	for	the	development	and	validation	of	biomarkers,	response	
criteria,	ancillary	therapy	and	supportive	care,	and	the	design	of	clinical	trials	for	cGVDH	(Baird	and	Pavletic,	2006).		
The	development	and	validation	of	biomarkers	includes	examining	both	biological	and	behavioral	(patient‐
reported)	measures	objectively	with	quality	of	life	as	a	possible	endpoint	to	measure	success	of	research	testing	
novel	interventions	for	supportive	care	(Filipovich	et	al.,	2005).			
Theory	
												The	proposed	study	adopts	the	Theory	of	Unpleasant	Symptoms	(Figure	1)	to	provide	the	theoretical	
perspective	for	this	research	to	explore	the	relationships	among	symptoms	commonly	associated	with	cancer	(pain,	
depression,	and	fatigue)	and	quality	of	life	in	patients	diagnosed	with	cGVHD.		The	theory	will	be	modified	to	
include	the	biological	markers	(cytokines)	and	the	relationships	between	and	among	symptoms,	cytokines,	and	
quality	of	life.					
The	Theory	of	Unpleasant	Symptoms	(TOUS)	was	developed	by	nurses	who	were	researching	symptoms	in	various	
clinical	settings	and	realized	that	there	were	certain	commonalities	among	symptoms	while	simultaneously	
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exhibiting	uniqueness	(Lenz,	Suppe,	Gift,	Pugh,	&	Milligan,	1995).		Further	research	led	them	to	conclude	that	
symptoms	rarely	occur	in	isolation	but	usually	more	than	one	at	a	time	and	that	the	relationships	among	the	
influencing	factors	(physiologic,	psychological,	and	situational),	the	symptoms	experienced	and	the	outcome	
(performance)	were	not	linear	but	interactive	(Lenz,	Pugh,	Mulligan,	Gift,	&	Suppe,	1997).		The	TOUS	has	been	used	
as	the	framework	for	many	studies	in	the	examination	of	symptom	clusters	across	many	patient	populations	and	
has	been	used	in	many	cancer	related	studies	as	well	(Chen	&	Tseng,	2005;	Farrell	&	Savage,	2010;	Fox	&	Lyon,	
2007;	Fox,	Lyon,	&	Farace,	2007;	Jurgens	et	al.,	2009).		However,	in	the	literature	reviewed,	the	TOUS	has	not	been	
tested	in	the	cGVHD	population.			
	 	Figure	1.	Updated	version	of	the	middle‐range	theory	of	unpleasant	symptoms	
	
Symptoms	
	 Symptoms	are	a	major	source	of	distress	and	discomfort	for	patients	with	cancer	(Theobald,	2006).		The	
National	Institutes	of	Health	(2002)	reported	that	the	most	commonly	experienced	symptoms	among	patients	with	
cancer	are	pain,	depression,	and	fatigue.		Insomnia	is	also	frequently	reported	as	a	symptom	associated	with	cancer	
(Fox	&	Lyon,	2007;	Fox,	Lyon,	&	Farce,	2007;	Theobald,	2006).		In	a	study	examining	cancer,	it	was	reported	that	as	
many	as	90%	of	cancer	patients	experience	pain,	91%	fatigue,	and	up	to	25%	depression	(Fox	&	Lyon,	2007).		The	
symptoms	experienced	by	patients	with	cancer	may	be	due	to	the	cancer	itself	and/or	due	to	the	treatments.		
Symptoms,	particularly	fatigue,	may	persist	well	into	survivorship	(Oh	&	Seo,	2011).		A	major	role	of	the	oncology	
nurse	is	to	decrease	the	burden	of	symptoms.		Patients	with	cGVHD	may	experience	similar	symptoms;	however	
due	to	the	lack	of	literature	aimed	at	helping	patients	with	cGVHD	manage	their	symptoms,	adequate	management	
of	symptoms	is	a	major	barrier	to	caring	for	these	patients	(Williams	et	al.,	2007).		The	literature	is	lacking	in	
symptom	management	and	little	is	known	about	which	symptoms	patients	experience	and	to	what	extent.		
Pain	
												Pain	is	defined	as	an	unpleasant	sensory	or	emotional	sensation	causing	distress	and	is	the	number	one	
reason	why	people	seek	medical	attention	(Cheng,	Foster,	&	Huang,	2003).		Patients	with	cancer	may	not	only	be	
experiencing	pain	directly	related	to	the	cancer	process	but	may	experience	pain	caused	by	the	treatments	for	
cancer	(Miaskowski	et	al.,	2006).		Pain	results	from	diagnostic	procedures,	treatment,	and	psychological	suffering	
(Kreitler	&	Merimski,	2007).		Interventions	to	ameliorate	pain	in	this	population,	is	a	challenge	for	health	care	
providers,	family,	care‐givers	and	the	patient	(Caraceni,	2001).		The	percentage	of	uncontrolled	chronic	cancer	pain	
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has	been	shown	to	be	as	high	as	96%	and	is	reported	by	patients	with	cancer	to	be	a	major	cause	of	distress	
(Caraceni,	2001;	Stenseth,	2007).		Patients	with	cGVHD	experience	many	different	types	of	pain;	however,	it	is	the	
severity	of	the	pain	that	is	found	to	be	most	distressing	followed	by	the	impact	on	quality	of	life	(Perez‐Simon,	et	al.,	
2006).		In	order	to	develop	interventions	to	adequately	manage	pain	in	this	patient	population,	there	must	be	an	
adequate	assessment	of	the	pain	(Theobald,	2004).	
Depression	
												Depression	is	feeling	“sad”	or	“blue”	for	an	extended	period	of	time	and	these	feeling	interfere	with	normal	
activities	(National	Institute	of	Mental	Health	[NIMH],	2010).		Symptoms	may	include	feeling	sad	or	empty,	
hopeless,	helpless.		One	may	have	a	gloomy	outlook	on	life	and	the	inability	to	feel	happiness	towards	to	things	
which	used	to	be	enjoyable	(NIMH,	2010).		Depression	and	illness	are	often	co‐existing	and	one	may	be	the	cause,	
consequence	or	predisposition	of	the	other	(NIMH).		Depression	is	present	in	up	to	30%	of	all	cancer	patients	and	is	
a	predictor	of	mortality	(Kroenke	et	al.,	2010).		In	a	study	with	215	randomly	assigned	patients	with	cancer,	68%	
had	adjustment	disorders	with	a	depressed	or	anxious	mood	(Massie,	2004).		Depression	is	reported	as	one	of	the	
symptoms	most	common	in	all	types	of	cancer	and	negatively	impacts	quality	of	life	(Fox	et	al.,	2007;	Miaskowski	et	
al.,	2004;	Roeland,	et	al.,	2010).			
Fatigue	
													Fatigue	is	defined	as	weariness	or	tiredness	or	lack	of	energy	(Mendoza	et	al.,	1999).		Fatigue	experienced	by	
the	general	population	serves	as	a	protective	response	to	physical	and	psychological	stress	and	is	often	relieved	by	
rest;	however,	for	patients	with	cancer	fatigue	is	described	as	unrelieved	by	rest,	chronic,	unpleasant,	distressing,	
and	life	altering	(Servaes,	Verhagen,	&	Bleijenberg,	2002).		Fatigue	is	the	most	commonly	reported	symptom	in	
patients	with	cancer	and	one	of	the	main	causes	of	emotional	and	physical	distress.		It	is	the	symptom	among	
cancer	patients	reported	to	cause	the	most	interference	with	daily	life	(Lawrence	et	al.,	2004;	Lyon	&	Fox,	2007;	
Fox,	Lyon,	&	Farace,	2007;	Ross	&	Alexander,	2001).		Cancer	related	fatigue	can	have	devastating	effects	on	the	
social	and	personal	lives	of	patients	experiencing	such	fatigue.		Furthermore,	this	fatigue	may	last	long	after	the	
completion	of	treatment	(Prue,	Rankin,	Allen,	Gracey,	&	Cramp,	2006).		Fatigue	is	thought	to	be	a	side	effect	of	
treatment	modalities	and	a	consequence	of	the	biologic	effects	of	the	cancer	(Lawrence	et	al.,	2004).		A	major	
disease	and	treatment	burden	for	patients	with	cancer	is	fatigue	(Mendoza	et	al.,	1999).		Patients	experiencing	
cancer	at	different	stages,	throughout	treatment	and	into	survivorship	experience	fatigue	(Seyidova‐Khoshknabi,	
Davis,	&	Walsh,	2011).			
													Occurrence	of	reported	fatigue	has	been	shown	to	be	as	high	as	99%	in	patients	with	cancer	and	91%	in	
patients	with	hematologic	cancers	requiring	bone	marrow	transplantation	(Lawrence	et	al.,	2004;	Seyidova‐
Khoshknabi	et	al.,	2011).				Management	of	symptoms	associated	with	distress	requires	an	assessment	of	the	
severity	of	the	symptom	and	is	essential	for	effective	intervention	and	improved	quality	of	life	(Ross	&	Alexander,	
2001).		
Cytokines		
													Biobehavioral	science	is	based	in	the	assumption	that	the	biology	of	a	phenomenon	is	inextricably	linked	
with	behavior	thereby	making	it	necessary	to	examine	them	as	two	dimensions	of	the	same	whole.		It	is	speculated	
that	cytokines	act	neurologically	to	induce	psychological	and	behavioral	changes	(Kelley,	2003).		It	is	also	
speculated	that	the	production	and	release	of	certain	cytokines	can	be	effected	by	the	cancer	itself	and	these	
cytokines	may	mediate	symptoms	(Seruga,	Zhang,	Bernstein,	&	Tannock,	2008).		A	call	by	the	National	Cancer	
Institute	(2006)	to	investigate	strategies	for	the	development	and	validation	of	biomarkers	in	cGVHD	research	
could	be	beneficial	in	elucidating	strategies	to	combat	the	devastating	effects	of	cGVHD	(Baird	and	Pavletic,	2006).		
The	establishment	of	the	relationship	between	symptoms	and	cytokines	in	this	population	may	serve	to	determine	
the	interplay	of	certain	inflammatory	cytokines	and	symptom	severity	which	may	in	turn	lead	to	advanced	
interventions	to	relieve	bothersome	symptoms	for	patients	with	cGVHD.	C‐reactive	protein	(CRP)	is an inflammatory 
marker regulated by pro-inflammatory cytokines.  It is non-specific and is an acute phase marker.  Several studies have 
shown a positive correlation between elevated CRP levels and increased depressive symptoms.  Fewer studies have 
examined this phenomenon in patients with cancer.  	
Quality	of	Life	
	 Quality	of	life	in	patients	with	cancer	is	altered	due	to	many	factors	among	which	one	is	the	symptoms	that	
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are	experienced	(Monga	et	al.,	2007).		Previous	focus	on	patients	with	hematologic	cancers	undergoing	bone	
marrow	transplant	has	been	survivorship.		With	the	increase	in	survivorship,	focus	has	turned	toward	managing	
the	consequences	of	complications	such	as	cGVHD.		Symptom	management	and	quality	of	life	improvement	is	
moving	to	the	forefront	of	cGVHD	management	(Flowers	et	al.,	2011;	Lee	et	al.,	2002;	Lee	et	al.,	2003).			
	
 
 
 
 
 
VIII. PRELIMINARY PROGRESS/DATA REPORT 
If available. 
 
N/A 
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IX. RESEARCH METHOD AND DESIGN 
Include a brief description of the project design including the setting in which the research will be conducted and 
procedures.  If applicable, include a description of procedures being performed already for diagnostic or treatment 
purposes. 
 
This	study	will	use	a	cross‐sectional,	correlative,	descriptive	design	to	address	the	following	specific	aims	on	
patients	with	alloHSCT:	
1)	To	describe	symptoms,	inflammatory	markers,	and	quality	of	life	of	patients	with	cGVHD	
2)	To	examine	the	associations	among	selected	symptoms	(pain,	depression,	and	fatigue)	
3)	To	examine	the	associations	among	selected	cytokines	(IL‐1β,	IL‐6,	IL‐10,	TNF‐α,	and	IFN‐ƴ)	
4)	To	examine	the	association	of	selected	symptoms	and	cytokines	among	each	other	and	quality	of	life		
5)	To	examine	the	associations	among	the	top	three	severe	and	bothersome	symptoms	determined	from	the	
Memorial	Symptoms	Assessment	Scale,	selected	cytokines,	and	quality	of	life.	
Setting	
Massey	Cancer	Center’s	Bone	Marrow	Transplant	Center:		
										The	Massey	Cancer	Center	(MCC),	which	serves	to	coordinate	clinical	research	on	cancer	at	VCU,	is	among	the	
nation's	leading	research	and	clinical	institutions.	One	of	only	60	National	Cancer	Institute	(NCI)	designated	Centers	
in	the	United	States	and	one	of	only	two	in	Virginia,	MCC	is	central	Virginia's	most	important	resource	for	cancer	
research,	clinical	trials,	and	treatment	with	an	annual	census	of	more	than	1,400	patients.	MCC	is	the	focal	point	for	
basic	and	clinical	research,	education,	and	cancer	health	delivery	activities.	Located	on	the	Medical	Center	Campus	
of	VCU,	MCC	was	designated	as	a	clinical	cancer	center	by	the	NCI	in	1975	with	the	award	of	its	first	core	grant;	MCC	
has	had	continuous	NCI	center	funding	since	that	time.		
										There	are	160	MCC	member	scientists	(including	Dr.	Lyon)	from	25	academic	departments,	of	whom	more	
than	90	are	involved	in	collaborative	research	activities	within	the	context	of	MCC	programs.	Research	programs	
include	developmental	therapeutics,	radiation	biology	and	oncology,	cancer	cell	biology,	immune	mechanisms,	and	
cancer	control.	Post‐doctoral	training	at	MCC	is	supported	by	an	NCI	funded	training	grant.	The	Bone	Marrow	
Transplant	(BMT)	Center	has	been	continuously	operating	since	1988	and	is	the	largest	comprehensive	BMT	
provider	in	the	state.		It	is	also	an	Anthem	Blue	Cross	and	Blue	Shield	Blue	Distinction	Center	—	one	of	just	70	
nationwide.	
Subject	Recruitment,	Enrollment,	Tracking,	and	Retention	
										Participants	will	be	recruited	from	Massey	Cancer	Center	Bone	Marrow	Transplant	Unit.		The	doctoral	student	
will	contact	the	potential	participant	after	discussion	with	the	transplant	team.		After	obtaining	informed	consent,	
participants	will	complete	questionnaires,	and	have	a	blood	sample	taken.		A	blood	sample	will	be	collected	(less	
than	one	tablespoon)	from	an	appropriate	vein	or	venous	access	device.			
										The	study	visit,	including	the	consent	process,	questionnaires	and	specimen	collection,	will	take	
approximately	one	hour	to	complete.		The	study	visit	will	be	conducted	during	a	routine	clinic	visit	or	another	
convenient	time.		After	the	participant	has	had	all	questions	answered	adequately	and	has	signed	the	IRB	approved	
Informed	Consent	Form,	he	will	be	assigned	a	patient	identification	number	unique	to	the	study	to	protect	his	
identity.		A	tracking	system,	similar	to	that	which	is	being	used	in	Dr.	Lyon’s	current	studies	will	be	used	to	enhance	
participant	retention	over	the	study	period.				
Prior	to	Initial	Visit	
									Before	the	study	visit,	there	will	be	demographic	data	collected	on	the	patient	such	as	age,	sex,	disease	profile	
(type	of	cancer,	HLA	match,	related	versus	unrelated	donor),	marital	status,	support	system,	past	medical	history,	
and	socio‐economic	factors.	
At	Study	Visit	
										At	the	study	visit	the	patient	will	be	asked	to	fill	out	symptom	questionnaires	(Pain‐using	the	Brief	Pain	
Inventory,	Depressive	Symptoms‐using	the	Hospital	Anxiety	and	Depression	Scale,	Fatigue‐using	the	Brief	Fatigue	
Inventory,	Other	Symptoms‐using	the	Memorial	Symptoms	Assessment	Scale	and	the	Lee	cGVHD	Symptom	Scale)	
and	the	Functional	Assessment	of	Cancer	Treatment‐	Bone	Marrow	Transplant	quality	of	life	questionnaire.	
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Participants	will	also	fill	out	a	questionnaire	regarding	lifestyle	habits	using	the	Lifestyle	Profile.		The	Perceived	
Stress	Scale	will	also	be	completed.		Patients	will	have	a	blood	specimen	collected	(less	than	a	tablespoon).		Blood	
samples	will	be	collected	in	appropriate	container	and	transported	to	the	CBCR	laboratory	in	the	School	of	Nursing.		
Blood	will	be	centrifuged	in	the	CBCR.		Samples	will	be	stored	at	‐200	C	until	further	processing.			
How	Variables	will	be	Measured		
										Variables	examined	in	this	study	will	be	measured	using	the	following	instruments.		All	concepts	and	
measures	for	domains	of	interest	are	presented	in	Table	1.		The	conceptual	model	(Figure	2)	explains	the	concepts	
under	investigation	and	their	relationships.	
Demographic,	Individual,	Disease,	and	Treatment	Related	Variables.	
										The	medical	record	will	be	reviewed	for	information	regarding	transplant	data	such	as	patient	and	donor	race,	
age,	and	gender;	HLA	and	related	versus	unrelated	donor;	performance	status,	and	type	of	cGVHD.		It	is	important	
to	collect	information	regarding	patient	related,	disease	related,	and	treatment	related	variables	that	may	relate	to	
the	major	study	variables	and	are	therefore	possible	significant	covariates.		The	demographic	and	disease	profile	
questionnaire	will	be	completed	by	the	doctoral	student	to	ascertain	the	prescribed	treatment	plan	and	to	capture	
specific	details	of	the	pre	and	post‐transplant	sequelae.		In	addition,	participants	will	complete	a	lifestyle	profile	
questionnaire	(Walker,	Fleschler,	&	Heaman,	1998)	and	a	perceived	stress	scale	(Cohen,	1988).	
General	Symptoms	
Lee	cGVHD	Symptoms	Scale	
										The	Lee	Symptom	Bother	Scale	is	a	multi‐symptom	scale	that	measures	the	severity	of	symptoms	as	described	
as	how	much	a	symptom	bothers	the	patient	(Lee,	Cook,	Soiffer,	&	Antin,	2006).		There	are	seven	domains	assessed:	
1)	skin,	2)	eye,	3)	mouth,	4)	lung	function,	5)	nutrition,	6)	psychosocial	status,	and	7)	energy.		All	areas	are	rated	
using	a	5	point	Likert	type	scale	where	0	indicates	“Not	at	all”	and	4	indicates	“Extremely”	bothered.		A	summary	
score	is	created	by	taking	the	mean	of	all	items	and	linearly	transforming	that	value	to	a	0‐100	scale.		The	
Chronbach’s	α	is	between	.79	and	.90.		The	test‐retest	reliability	for	all	subscales	is	.74‐.93	except	psychosocial	is	
.55	and	lung	is	.28.		The	scale	has	good	convergent	validity	(Lee	et	al.,	2006).	
Memorial	Symptom	Assessment	Scale	
          To	comprehensively	explore	which	symptoms	patients	with	cGVHD	are	experiencing,	the	Memorial	Symptom	
Assessment	Scale	(MSAS‐SF)	will	be	used	to	obtain	frequency,	severity	and	distress	of	symptoms	commonly	
reported	by	patients	with	cancer	(Portney	et	al.,	1994).		This	scale	is	a	validated	multidimensional	symptom	
assessment	instrument	that	assesses	severity,	frequency	and	distress	of	32	prevalent	symptoms	(Chang,	Hwang,	
Feuerman,	Kasimis,	&	Thaler,	2000).		This	measure	includes	a	physical	symptom	subscale,	a	psychologic	subscale,	
and	a	global	distress	index.		Tested	with	a	sample	of	299	cancer	patients,	the	Cronbach	alpha	for	the	MSAS‐SF	
subscales	ranged	from	.76‐.86	and	the	test‐retest	correlation	coefficients	ranged	from	.86‐.94	at	one	day	and	one	
week	respectively	(Chang	et	al.,	2000).		Portenoy	et	al.	(1994)	tested	the	MSAS‐SF	with	a	group	of	246	cancer	
patients	and	found	a	Cronbach’s	alpha	of	.88	for	the	physical	subscale	and	.83	for	the	psychologic	subscale.		The	
total	time	to	complete	this	form	is	approximately	10	minutes.		In	addition	to	the	32	prevalent	symptoms,	this	form	
allows	for	patients	to	identify	and	quantify	“other”	symptoms.		This	scale	has	been	validated	in	patients	with	cancer,	
congestive	heart	failure,	auto‐immune	deficiency	syndrome	and	in	both	in‐patient	and	out‐patient	settings	(Chang	
et	al.,	2000;	Portenoy	et	al.,	1994;	Tranmer	et	al.,	2003).	
	
Selected	Symptoms	
Pain	
												Pain	will	be	assessed	using	the	Brief	Pain	Inventory	(BPI).		This	instrument	was	chosen	for	its	use	in	the	
oncology	population,	its	validity	and	it	feasibility	(Cleeland,	2009).		The	BPI	was	originally	created	in	1989	by	the	
Pain	Research	Group	under	the	leadership	of	Dr.	Charles	S.	Cleeland	at	the	University	of	Wisconsin’s	School	of	
Medicine	in	response	to	a	need	for	patients	with	cancer	to	have	adequate	pain	management	(Cleeland,	2009).		The	
utilization	of	the	BPI	for	the	measurement	of	pain	is	well	established	(Borden	et	al.,	2006;	Callstrom	et	al.,	2002;	
Garbez,	Chan,	Neighbor,	&	Puntillo,	2006;	Hadi	et	al.,	2008;	McMillan,	Tofthagen,	Tittle,	&	Laughlin,	2008).		The	BPI	
has	been	psychometrically	validated	in	many	languages	including	English,	Arabic,	Chinese,	Filipino,	French,	
German,	Spanish,	and	Thai	(Cleeland,	2009).		The	BPI	was	created	to	evaluate	two	dimensions	of	pain:	1)	the	
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severity	and	2)	the	interference.	
												Validity	for	this	tool	was	established	through	a	two‐factor	structure,	internal	stability,	and	test‐retest	
reliability.		Through	factor	analyses,	pain	severity	and	pain	interference	each	had	an	eigenvalue	greater	than	one	
(Cleeland,	2009).		According	to	Kaiser	(1960),	there	are	as	many	reliable	factors	as	there	are	eigenvalues	greater	
than	one.		In	a	national	study	conducted	by	the	Eastern	Cooperative	Oncology	Group	involving	1,261	participants	
with	recurrent	or	metastatic	cancer	diagnoses	from	80	centers	this	two‐factor	structure	was	confirmed	(Cleeland,	
2009).		Internal	stability	was	also	assessed	and	the	Cronbach’s	alpha	was	.80‐.87	pain	severity	and	.89‐.92	for	the	
interference	items	(Mendoza,	Mayne,	Rublee,	&	Cleeland,	2006).		The	test‐retest	reliability	was	established	for	one	
day	to	one	week	and	was	.93	for	“worst”	pain,	and	.78	for	“usual”	pain.		The	test‐retest	was	lower	(.59)	for	pain	
“now”	(Cleeland,	2009).		A	German	study	involving	109	patients	with	cancer	found	similar	results	(Cleeland,	2009).		
												The	BPI	consists	of	a	body	diagram	to	indicate	location	of	pain	and	a	general	question	asking	if	pain	is	
present.		Four	items	assess	pain	intensity	or	severity	using	an	eleven	point	scale	where	0	indicates	no	pain	and	10	
indicates	the	worst	pain	imaginable.		There	is	also	a	question	regarding	medications	taken	for	pain	relief	and	the	
efficacy	of	the	medication	taken.		There	are	seven	interference	questions.		The	eleven	point	scale	is	used	to	assess	
how	much	pain	interferes	with	daily	living	where	0	indicates	that	pain	does	not	interfere	at	all	with	the	activity,	and	
10	indicates	pain	completely	interferes	with	that	activity.		The	activities	are	further	divided	into	affective	
dimensions	(relations	with	others,	enjoyment	of	life,	and	mood)	and	general	dimensions	(walking,	general	activity	
and	work).		The	categorization	of	sleep	was	unclear	(Cleeland,	2009).		The	developers	of	the	BPI	recommend	
calculating	the	severity	score	by	adding	the	four	items	and	dividing	the	score	by	four	to	find	the	mean	severity	
score	(Cleeland,	2009).		The	interference	score	is	calculated	the	same	way	and	can	only	be	used	if	four	or	more	of	
the	seven	items	is	completed	(Cleeland,	2009).		The	developers	of	the	instrument	do	not	indicate	scoring	of	the	
categorical	question	regarding	the	presence	or	absence	of	pain	and	as	such	was	used	as	a	characteristic	description.		
There	is	also	no	recommendation	for	scoring	the	use	of	analgesics	and	the	efficacy	of	the	medications	taken.		This	
instrument	takes	less	than	ten	minutes	to	complete.		The	questionnaire	can	be	completed	by	the	participant	or	by	
the	investigator	and	is	easy	to	translate	for	patients	whose	primary	language	is	not	English	(Mendoza	et	al.,	2006).	
Depressive	Symptoms	
												Depressive	symptoms	will	be	assessed	using	the	subscale	for	depression	from	the	Hospital	Anxiety	and	
Depression	Scale	(HADS).		This	scale	was	chosen	for	its	use	in	the	oncology	population,	its	validity	and	it	
feasibility	(Zigmond	&	Snaith,	1983).		The	measurement	has	been	widely	used	in	cancer	settings	as	well	as	general	
medical	settings	and	is	reported	to	be	the	most	often	used	scale	to	assess	depressive	symptoms	in	the	palliative	
care	setting	(Mitchell,	Meader,	and	Symonds,	2010).		In	a	systematic	review	of	the	literature	to	evaluate	the	validity	
of	the	HADS,	twenty	four	out	of	the	fifty	studies	used	the	HADS	in	an	oncology	or	palliative	population	(Mitchell	et	
al.,	2010).			
												The	HADS	was	developed	in	1983	by	Zigmond	and	Snaith	to	provide	clinicians	with	a	reliable	screening	tool	
for	psychiatric	disorders.		This	tool	was	a	modification	from	the	General	Health	Questionnaire	in	an	effort	to	make	
the	questionnaire	less	time	consuming	and	provide	information	regarding	the	“nature”	of	the	condition	(Zigmond	&	
Snaith,	1983).		It	was	the	intention	of	the	developers	of	this	instrument	to	have	separate	scores	for	anxiety	and	
depression	(Zigmond	&	Snaith,	1983).		For	the	purposes	of	this	study,	only	the	subscale	of	depression	was	analyzed.		
												This	instrument	is	used	to	assess	the	presence	and	severity	of	anxiety	and	depressive	symptoms	over	a	seven	
day	period.		The	depression	subscale	is	comprised	of	seven	items	using	a	four	point	scale	ranging	from	0	(least	
severe)	to	3	(most	severe).		These	items	were	based	on	the	anhedonic	state	(Zigmond	&	Snaith,	1983).		A	higher	
score	indicates	more	depression	and	a	score	of	greater	than	16	is	considered	severe	and	may	indicate	a	need	for	
intervention.	
												Cronbach’s	alpha	has	been	found	to	be	high	(.82‐.90)	for	the	HADS	depression	subscale	(Mykletun,	Stordal,	&	
Dahl,	2001).		In	principal	component	analysis	(of	depression),	a	two‐factor	analysis	yielded	an	eigenvalue	of	3.6	
(Mykletun	et	al.,	2001).		The	depressive	symptom	questions	loaded	with	depression	(Mykletun	et	al.,	2001).		It	is	a	
brief	self‐report	tool	that	takes	less	than	five	minutes	to	complete	(Zigmond	&	Snaith,	1983).	
Fatigue	
												Fatigue	will	be	assessed	using	the	Brief	Fatigue	Inventory	(BFI).		This	instrument	was	chosen	for	its	use	in	
the	oncology	population,	its	validity	and	its	feasibility	(Mendoza	et	al.,	1999).		The	BFI	is	a	nine	item,	eleven	point	
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scale	that	assesses	physical,	affective,	cognitive	and	social	domains	in	a	two	dimensions,	pain	intensity	or	severity	
(sensory)	and	interference	(reactive)	that	can	be	described	as	the	subjective	report	of	fatigue	severity	(Mendoza	et	
al.,	1999;	Seyidova‐Khoshknabi,	Davis,	&	Walsh,	2011).		It	can	be	administered	as	a	self‐report,	interview	with	a	
research	staff,	or	interactive	voice	response	system	(Mendoza	et	al.,	1999).		Severity	scores	are	as	follows:	1)	mild	
(1‐3),	2)	moderate	(4‐6)	and	3)	severe	(7‐10).		The	wording	of	the	tool	was	designed	to	be	understandable	by	
patients	who	are	educationally	disadvantaged	and	for	ease	of	translation	for	non‐English	speaking	patients.		It	is	
also	able	to	be	translated	into	many	languages	(Mendoza	et	al.,	1999).		
												The	BFI	was	developed	by	researchers	from	the	M.	D.	Anderson	Cancer	Center	in	Houston,	Texas	for	the	
purpose	of	assessing	fatigue	in	patients	with	cancer	or	fatigue	related	to	cancer	treatment	(including	patients	who	
have	undergone	bone	marrow	transplantation)	(Mendoza	et	al.,	1999).		It	was	also	developed	to	assess	the	severity	
of	fatigue	experienced	and	the	impact	of	fatigue	on	daily	functioning	(Mendoza,	et	al.,	1999).		The	BFI	has	been	
psychometrically	validated	in	many	languages	including	English,	Chinese,	Filipino,	German,	Greek,	Japanese,	Korean	
and	Russian	(Mendoza	et	al.,	1999).			
												Validation	for	this	instrument	was	established	in	through	construct	validity,	concurrent	validity,	and	
discriminant	validity.		Construct	validity	was	established	through	factor	analysis	which	demonstrated	high	validity	
with	a	score	of	.81	for	usual	fatigue	and	.92	for	activity	related	fatigue	(Mendoza,	et	al.,	1999).		Concurrent	validity	
was	established	through	correlation	of	the	BFI	with	The	Profile	of	Mood	States	and	the	fatigue	subscale	of	the	
Functional	Assessment	of	Cancer	Therapy.		The	BFI	was	significantly	correlated	to	the	fatigue	subscales	of	both	the	
Profile	of	Mood	States	(r	=	.84,	p	<	0.001)	and	the	Functional	Assessment	of	Cancer	Therapy	(r	=	‐.88,	p	<	0.001)	
(Mendoza,	et	al.,	1999).		The	Profile	of	Mood	States	and	the	Functional	Assessment	of	Cancer	Therapy	are	also	
significantly	correlated	(r	=	‐.92,	p	<	0.001)	(Mendoza	et	al.,	1999).	Discriminant	validity	was	established	through	
comparing	BFI	scores	of	patients	expected	to	have	fatigue	based	on	performance	status	(Mendoza	et	al.,	1999).		The	
scores	were	significantly	different	(p	<	0.001)	(Mendoza	et	al.,	1999).		Also,	a	Cronbach’s	coefficient	alpha	was	
calculated	for	BFI.		The	Coefficient	ranges	from	0	to	1.		Ascending	values	indicate	less	measurement	error.		The	
Cronbach's	alpha	ranged	from	.95‐.96	for	individual	items	and	an	internal	consistency	of	.96	overall	(Mendoza	et	al.,	
1999).		The	questionnaire	takes	approximately	five	minutes	to	complete	and	a	global	score	can	be	ascertained	by	
averaging	the	total	score	(Mendoza	et	al.,	1999).	
Cytokines		
Cytokines	will	be	analyzed	using	the	Bio‐Plex®	(Bio‐Rad)	multiplex	assay.		Compared	to	the	traditional	
enzyme‐linked	immunosorbant	assays	(ELISA),	the	Bio‐Plex	is	comparable	and	more	sensitive	to	lower	
concentration	levels	of	cytokines	than	the	ELISA.	One	laser	identifies	a	specific	bead	and	another	laser	identifies	the	
reported	antibody	associated	with	the	bead‐bound	cytokine.		One	hundred	beads	for	each	of	the	17	cytokines	in	
every	sample	are	assayed	and	a	mean	cytokine	binding	for	the	sample	is	determined.		The	manufacturer	reports	
that	the	assay	accurately	measures	cytokine	values	in	a	range	of	1‐2500pg/ml.		This	is	acceptable	for	this	study.		
Also	the	measure	is	precise	showing	less	than	1%	cross	reactivity	among	other	cytokines	or	with	other	molecules.		
All	samples	will	be	retained	for	the	data	set	by	log	transforming	below‐detection	levels	of	cytokines	by	assigning	a	
value	below	the	previously	detected	value	from	previous	measure.  Serum	CRP	will	be	measured	using	the	ALPCO’s	
(American	Laboratory	Products	Company)	high‐sensitivity	CRP	assay	which	uses	latex	particle	enhanced	
immunoturbidimetry	for	quantitative	CRP	determination.	
Quality	of	Life	
												Quality	of	life	will	be	assessed	using	the	Functional	Assessment	of	Cancer	Treatment‐	Bone	Marrow	
Transplantation	(FACT‐BMT).		This	instrument	was	chosen	for	its	use	in	the	bone	marrow	transplant	population,	
its	validity	and	its	feasibility	(McQuellon	et	al.,	1997).	This	instrument	was	developed	in	1997	by	a	group	of	
oncology	experts.		The	items	chosen	for	this	measure	were	generated	from	a	list	produced	by	oncology	experts	and	
patients	to	assess	issues	specific	to	the	bone	marrow	transplant	population.		The	FACT‐BMT	incorporates	items	
from	the	Functional	Assessment	of	Cancer	Therapy	General	(FACT‐G)	scale	with	a	bone	marrow	transplant	
subscale.		The	use	of	this	instrument	is	well	established	(Kropp	et	al.,	2000;	Lau	et	al.,	2002;	Lee	et	al.,	2006;	Pidala	
et	al.,	2011).			
					The	validity	of	the	FACT‐BMT	is	established	through	internal	consistency	and	construct	validity.		Internal	
nsistency	was	reported	using	the	Cronbach’s	alpha.		The	Cronbach’s	alpha	coefficients	were	.84	for	physical	well‐
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ng,	.69	for	social/family	well‐being,	.67	for	emotional	well‐being,	and	.78	for	functional	well‐being.		The	Cronbach’s	
ha	was	.88	for	the	FACT‐G	total	and	.89	for	the	FACT‐BMT	(Lau	et	al.,	2002).		When	compared	with	the	quality	of	life	
dy	group	of	the	European	Organization	for	Research	and	Treatment	of	Cancer	(EORTC	QLQ‐30),	all	like	domains	has	
gnificant	positive	relationship	ranging	from	.30	to	.77	(Kropp	et	al.,	2000).			
												The	FACT‐BMT	is	a	self‐administered	questionnaire	developed	to	measure	multiple	dimensions	of	quality	of	
life	in	the	bone	marrow	transplant	population.		It	consists	of	the	27‐item	FACT	–G	and	a	23‐item	bone	marrow	
transplant	subscale.		The	FACT‐G	assesses	physical	well‐being	(7‐items),	social/family	well‐being	(6‐items),	
emotional	well‐being	(6‐items),	and	functional	well‐being	(7‐items)	and	uses	a	five	point	Likert‐type	scale	to	score	
the	responses.		A	value	of	0	represents	the	statement	has	been	“not	at	all”	true	for	the	individual	at	all	over	the	last	
seven	days	and	a	4	represents	the	statement	has	been	“very	much”	true	for	the	individual	over	the	last	seven	days	
(Lau	et	al.,	2002).		This	quality	of	life	measurement	has	been	translated	and	validated	into	over	20	languages	(Lau	
et	al.,	2002).	
	
Table	1.	Data	Collection	and	Major	Variables
Domain	 Concept Operational	Measure
Physiologic	
Demographic	
	
Medical	Record	Data
Demographic	Profile	Questionnaire	
	
Lifestyle
	
Lifestyle	Profile	Questionnaire
	
Performance	Status
	 Eastern	Cooperative	Oncology	Group	
Donor/Situational	 Disease/	Treatment		
Medical	Record
Disease	Profile	Questionnaire	
	
Psychologic	 Perceived	Stress	 Perceived	Stress	Scale	
Behavioral	Manifestations	
Pain	 Brief	Pain	Inventory
Depression		 Hospital	Anxiety	and	Depression‐Scale	
Fatigue Brief	Fatigue	Inventory,
General	Symptoms	
Memorial	Symptom	Assessment	
Scale	
Lee	Chronic	Graft‐versus‐Host	
Disease	Scale	
Biological	Factors	 Immunology/Inflammation	 Cytokines	(IL‐1β,	IL‐6,	IL‐10,	TNF‐α,	and	IFN‐ƴ)	CRP	
Outcome	
	
Quality	of	Life	
	
Functional	Assessment	of	Cancer	
Treatment‐Bone	Marrow	Transplant	
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Figure 2. Conceptual Model 
 
 
X.  PLAN FOR CONTROL OF INVESTIGATIONAL DRUGS,  BIOLOGICS, AND DEVICES.  
Investigational drugs and biologics:  IF Investigational Drug Pharmacy Service (IDS) is not being used, attach the IDS 
confirmation of receipt of the management plan.   
 
Investigational and humanitarian use devices (HUDs): Describe your plans for the control of investigational devices 
and HUDs including:  
(1) how you will maintain records of the product’s delivery to the trial site, the inventory at the site, the use by each 
subject, and the return to the sponsor or alternative disposition of unused product(s);  
(2) plan for storing the investigational product(s)/ HUD as specified by the sponsor (if any) and in accordance with 
applicable regulatory requirements;  
(3) plan for ensuring that the investigational product(s)/HUDs are used only in accordance with the approved protocol; 
and  
(4) how you will ensure that each subject understands the correct use of the investigational product(s)/HUDs (if 
applicable) and check that each subject is following the instructions properly (on an ongoing basis). 
 
N/A 
 
 
 
XI. DATA ANALYSIS PLAN 
For investigator–initiated studies. 
 
Descriptive	statistics	will	be	used	to	characterize	the	sample	in	terms	of	demographic	variables	(gender,	
race/ethnicity,	stage	of	disease,	and	treatment	modalities).	Estimated	correlations	for	all	pairwise	combinations	
among	selected	symptoms,	cytokines	and	quality	of	life	will	be	calculated.		All	statistical	analyses	will	be	done	
utilizing	JMP	software.		Dr.	Ronald	K	Elswick	in	the	School	of	Nursing	holds	a	PhD	in	Biostatistics	and	is	a	faculty	
member	in	the	School	of	Nursing.		Dr.	Elswick	serves	on	the	doctoral	student’s	dissertation	committee.				 
 
  
XII. DATA AND SAFETY MONITORING 
 If the research involves greater than minimal risk and there is no provision made for data and safety monitoring by 
any sponsor, include a data and safety-monitoring plan that is suitable for the level of risk to be faced by subjects 
and the nature of the research involved.   
 70 
 
 If the research involves greater than minimal risk, and there is a provision made for data and safety monitoring by 
any sponsor, describe the sponsor’s plan. 
 If you are serving as a Sponsor-Investigator, identify the Contract Research Organization (CRO) that you will be 
using and describe the provisions made for data and safety monitoring by the CRO.  Guidance on additional 
requirements for Sponsor-Investigators is available at http://www.research.vcu.edu/irb/wpp/flash/X-2.htm 
 
This	study	is	a	descriptive	study	with	minimal	risks	and	therefore	no	adverse	events	(AE)	are	expected.		However,	if	
any	event	occurs	and	is	possibly	related	to	the	study,	the	doctoral	student,	with	PI	supervision,	will	assume	
responsibility	for	reporting	the	even	to	the	health	care	provider	and	any	referral	for	recommended	treatment.		She	
will	also	notify	the	Virginia	Commonwealth	University	Institutional	Review	Board	(VCU	IRB).		AE	reporting	forms	
are	available	online	at	the	VCU	website.		
          The	data	from	the	proposed	study	will	come	from	three	sources:	questionnaires	collected	by	the	doctoral	
student	in	a	secure	location	to	maintain	privacy,	cytokine	data,	from	the	School	of	Nursing	lab,	and	patient	
information	from	medical	records	data	to	be	collected	by	the	doctoral	student.		All	information	will	be	maintained	
in	locked	filing	cabinets	within	a	locked	office	in	a	secured	building.	Only	the	PI	and	the	doctoral	student	will	have	
access	to	the	information.	 
 
  
XIII. MULTI-CENTER STUDIES 
If VCU is the lead site in a multi-center project or the VCU PI is the lead investigator in a multi-center project, 
describe the plan for management of information that may be relevant to the protection of subjects, such as reporting 
of unexpected problems, project modifications, and interim results. 
 
71 
 
 
 
Chapter 4 
 
Symptoms, Cytokines and Quality of Life of Patients with Chronic Graft-versus-Host Disease 
following Allogeneic Hematopoietic Stem Cell Transplantation:  
A Cross-sectional, Correlational Study 
 
 
Chronic graft-versus-host disease (cGVHD) is a serious complication following 
allogeneic hematopoietic stem cell transplantation (HSCT) marked by immune dysregulation and 
debilitating clinical sequelae (Perez-Simon, Sanchez-Abarca, Diez-Campelo, Caballero, & San 
Miguel, 2006).  Allogeneic transplant refers to HSCT using donor stem cells versus autologous 
HSCT which is the use of previously harvested stem cells from the patient who then receives his 
own cells back during the transplant.  Donor cells for allogeneic HSCT are matched according to 
human leukocyte antigens (HLA), proteins that make up a person’s tissue type and play an 
important role in immune response (National Cancer Institute).  As cGVHD is a complication of 
donor immune cells’ ability to assimilate in the host environment, donor cells mount an over-
exaggerated immune response (Bishop & Pavletic, 2008; Choi, Levine, & Ferrara, 2010). This is 
called an allo-reaction and is characterized by inflammatory responses that may have deleterious 
effects; therefore examining patterns and levels of inflammation are of importance (Vose, 2011). 
Manifestations of cGVHD usually appear several months after transplantation and the 
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pathophysiology of cGVHD remains vexing (Ratanatharathorn, Ayash, Lazarus, Fu, & Uberti, 
2001).   
Reports have demonstrated that as many as 80% of patients undergoing allogeneic HSCT 
develop cGVHD (Lee, Cook, Soiffer, & Antin, 2002; Lee, Vogelsang, & Flowers, 2003).  
Complications include scleroderma, destruction of saliva and tear ducts, and liver and pulmonary 
dysfunction (Filipovich et al., 2005).  With an increase in number of allogeneic transplants and a 
decrease in mortality due to earlier transplantation, better HLA matching between donor and 
recipient and improvements in transplant conditioning, there is a resultant shift of focus to 
survivorship issues (Flowers et al., 2008). Important survivorship issues include symptom 
management, enhancing quality of life (QoL) and improving functional status for survivors of 
allogeneic HSCT (Flowers et al., 2008; Lee et al., 2002; Lee et al., 2003; Schlomchik, Lee, 
Couriel, & Pavletic, 2007).  Progress toward achieving these outcomes includes adequate 
assessment and targeted therapeutic interventions to mitigate distressing symptoms and long-
term complications (Perez-Simon et al., 2006).   
Symptom management is a major issue for patients experiencing cGVHD (Lee et al, 
2002; Perez-Simon et al., 2006).  Yet, there remains a gap in the literature establishing the 
relationship between symptoms in this population and QoL (Lynch-Kelly, 2014).  Further, there 
has been little study of the relationship of symptoms and biological markers of cGVHD although 
the interplay between biological markers and symptoms may impact the frequency and severity 
of symptoms experienced by patients with cGVHD (Lynch-Kelly, 2014).   
Understanding symptoms of cGVHD, inclusive of the biological underpinnings of 
symptoms, is a fundamental step toward managing symptoms effectively.  Knowing the 
relationships among symptoms and QoL gives insight into the impact symptoms may have on 
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QoL for patients with cGVHD.  Thus, the aims of this study were to 1) examine the levels of 
symptoms (cGVHD specific, general symptoms, and cluster symptoms [pain, depression and 
fatigue]), inflammation (cytokines [Interleukin {IL}-1β, IL-6, IL-10, TNF, and INF-γ] and C-
reactive protein [CRP]) and QoL in patients diagnosed with cGVHD and 2) examine the 
relationships between and among symptoms, inflammation and QoL in individuals with cGVHD.  
Knowledge about symptoms and biological mechanisms (e.g. increased systemic inflammation 
expression) involved in symptom manifestation is important for the development and testing of 
novel interventions to successfully manage symptoms and improve QoL for patients with 
cGVHD.   
Background and Significance 
HSCT has become the standard treatment for many hematologic cancers including acute 
leukemias, chronic leukemias, multiple myeloma, and myelodysplastic syndrome (Pidala, 2011).  
Before HSCT, patients receive conditioning therapy of chemotherapy, radiation, or both to 
destroy the cancer cells after which donor cells are infused through a central venous catheter 
similarly to a blood transfusion (Alyea et al., 2006; Gupta, Lazarus, & Keating, 2003; Toze et al., 
2005).  There has been a 165% increase in the number of allogeneic HSCT from 1994-2005 and 
survival rates post 100 days HSCT increased nearly 86% (Hahn et al., 2013).  This increase in 
HSCT is partially due to advances in conditioning known as a mini transplant involving lower 
doses of chemotherapy and radiation thus allowing HSCT for individuals who may have once 
been ineligible (Hahn et al., 2013). 
One of the complications of HSCT is GVHD.  There are two types of GVHD, acute and 
chronic.  Acute GVHD usually appears within the first 100 days post-transplant and involves 
different immune cell subsets and different cytokine profiles than cGVHD (Ratanatharathorn et 
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al., 2001).  Acute GVHD is speculated to involve alloreactive memory T cells existent in donor 
cells.  Usually, cGVHD presents post 100 days and the pathobiology cGVHD is not well 
elucidated (Pidala, 2011).  The focus of this study is on cGVHD. 
The exact cause of cGVHD is unknown; but is speculated to involve mechanisms 
associated with proliferation and exaggeration of inflammation as with other autoimmune 
disorders (Baird & Montaine, 2008; Bazzichi et al., 2008; Klimiuk, Sierakowski, Domyslawska, 
& Chweicko, 2011).  Diagnosis and staging of cGVHD is relatively recent.  In 2005, the 
National Institutes of Health (NIH) cGVHD consortium developed criteria for distinguishing 
cGVHD by type of onset, severity of presentation, and number of organs involved (Filipovich et 
al., 2005).  Acute GVHD is a primary risk factor for the development of cGVHD.  Other factors 
such as gender match, transplant conditioning, and diagnosis have been identified as risk factors 
of cGVHD as well (Flowers et al., 2011; Remberger et al., 2002).  Any of the body systems can 
be affected by cGVHD.  Skin (cutaneous) and eye (ocular) cGVDH are the most frequently 
occurring while those with lung (pulmonary) and/or liver (hepatic) cGVHD have the highest 
mortality (Pidala et al., 2012; Vogelsang, 2001).  In addition to being perhaps the most serious 
complication following allogeneic HSCT, cGVHD is also the most common (Pidala et al., 2011; 
Vogelsang, 2001).   
Due to increased survivorship of patients with cGVHD, improving QoL is of growing 
importance (Flowers et al., 2011; Lee et al., 2002; Lee et al., 2003).  From December, 2005 
through May, 2006, the National Cancer Institute (NCI) published a series of papers in the areas 
of diagnosing and staging, histopathology, strategies for the development and validation of 
biomarkers, response criteria, ancillary therapy and supportive care, and the design of clinical 
trials for cGVDH (Baird & Pavletic, 2006).  The validation of biomarkers includes examining 
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both biological and behavioral (patient-reported) measures with QoL as a possible endpoint to 
measure success of research testing novel interventions for supportive care (Filipovich et al., 
2005).   
Theory 
            This study adapted the Theory of Unpleasant Symptoms (TOUS) (Lenz, Suppe, Gift, 
Pugh, & Milligan, 1995) to provide the theoretical perspective to explore the relationships 
among symptoms commonly associated with cancer (pain, depression, and fatigue) and QoL in 
patients diagnosed with cGVHD.  The TOUS was developed after observation of symptoms in 
various clinical settings demonstrated there were certain commonalities among symptoms while 
simultaneously exhibiting uniqueness (Lenz et al., 1995).  Symptoms are a multidimensional 
concept including: 1)temporality, 2) quality, 3) intensity, and 4) distress (Lenz et al., 1995). 
Further research led to the conclusion that symptoms rarely occur in isolation but usually more 
than one at a time and that the relationships among the influencing factors, the symptoms 
experienced and the outcome are not linear but interactive (Lenz, Pugh, Milligan, Gift, & Suppe, 
1997).  The TOUS has been used as the framework for many studies in the examination of 
symptoms across many patient populations including cancer symptom research (Chen & Tseng, 
2007; Farrell & Savage, 2010; Fox & Lyon, 2007; Fox, Lyon, & Farace, 2007; Jurgens et al., 
2009).   
The TOUS was modified (Figure 1) to portray the biobehavioral perspective used to 
examine the specific aims of this study.  Biobehavioral research assumes that biology and 
behavior are inextricably linked, thus necessitates examining biological correlates with 
behavioral manifestations.  The model depicts the relationships among concepts examined in this 
study.  It assumes: 1) multiple symptoms occur simultaneously, 2) relationships exist between 
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and among symptoms, 3) inflammation is present and is related to symptoms, and 4) relationship 
exist among symptoms, inflammation, and QoL.  
Symptoms  
Symptoms are a major source of distress and discomfort for patients with cancer (Lee et 
al., 2002; Perez-Simon et al., 2006; Theobald, Kirsh, Holtsclaw, Donaghy, & Passik, 2006).  
Patients with cGVHD may experience multiple symptoms but little is known about which 
symptoms and to what extent, as such adequate management of symptoms is a major barrier to 
caring for these patients (Williams et al., 2007).   
cGVHD specific symptoms.  Symptoms of cGVHD have been predominantly explored 
in studies focusing on a single organ system affected by cGVHD such as skin, mouth, or eyes 
with symptom description related to the specific body system (Lynch-Kelly, 2014). For example, 
studies examining oral cGVHD have focused on dry mouth and oral pain (de la Parra-Colin, et 
al., 2011; Fall-Dickson, 2010; Hettinga, Verdonck, Fijnheer, Rijkers, & Rothova, 2007).  Studies 
examining gastro-intestinal cGVHD, have focused on distressing symptoms of bloating and 
nausea (Akpek et al., 2003).  As cGVHD can affect multiple body systems concurrently, having 
a detailed description of symptoms by body system is important for supportive treatment.  
Findings from cGVHD studies have noted symptoms similar to those of other cancers and 
include pain, nausea, bloating, weight loss, depressive symptoms, and sexual dysfunction (Akpek 
et al., 2003; Andree, 2008; Mitchell et al., 2010; Stratton et al., 2007; Wong et al., 2013). 
General symptoms.  Patients with cancer report the presence of many symptoms such as 
pain, numbness in hands and feet, bowel disturbances, and vomiting (American Cancer Societym 
n.d.).  Insomnia is also frequently reported as a symptom associated with cancer (Fox & Lyon, 
2007; Fox et al., 2007; Theobald et al., 2006). These symptoms may be due to the cancer itself or 
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treatments and have been shown to persist after treatment cessation.  The percentage of 
uncontrolled chronic cancer pain has been shown to exceed 75% in some instances and is 
reported to be a major cause of distress (Caraceni et al., 2001; Stenseth, Bjornnes, Kaasa, & 
Klepstad, 2007).  Approximately 30% of cancer patients report depression (Oh & Seo, 2011).  
Depression may persist well into survivorship and is a predictor of both fatigue and mortality 
(Kroenke et al., 2010; Oh & Seo, 2011).   
Cluster symptoms.  Common symptoms across cancer populations reported by the 
National Institute of Nursing Research (NINR) (2011) are pain, depression, and fatigue.  In a 
studies examining lung, breast and ovarian cancer, it was reported that as many as 90% of cancer 
patients experience pain, 91% fatigue, and up to 25% depression (Chen & Tseng, 2007; Fox & 
Lyon, 2007).  The symptom triad of pain, depression and fatigue often co-occur in patients with 
cancer and are also described in the cGVHD literature but not as concurrent, correlating 
symptoms examined with in-depth measures of pain, depression and fatigue.  Management of 
symptoms requires adequate symptom assessment and is essential for improving QoL (Ross & 
Alexander, 2001).  
Pain.  Pain is the unpleasant sensory or emotional sensation causing distress and is the 
number one reason why people seek medical attention (Cheng, Foster, & Huang, 2003).  Patients 
with cancer may not only be experiencing pain directly related to the cancer process but may 
experience pain caused by treatments.  Pain can cause both physical and psychological suffering 
(Kreitler & Merimski, 2007; Miaskowski et al., 2006).  It has been estimated that 40% to 80% of 
cancer patients experience pain (Porteny & Lesage, 1999).  In order to develop interventions to 
adequately manage pain in this patient population, there must be an adequate assessment of the 
pain (Theobald et al., 2006). 
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Depression. Depression is feeling “sad” or “blue” for an extended period of time and 
these feelings interfere with normal activities (National Institute of Mental Health [NIMH], 
2010).  Symptoms may include feeling sad or empty, hopeless, helpless.  One may have a 
gloomy outlook on life and the inability to feel happiness towards things which used to be 
enjoyable (NIMH, 2010).  Depression and illness often co-exist; one may be the cause, 
consequence or predisposition of the other (NIMH, 2010).  In a study with 215 randomly 
assigned patients with cancer, 68% had a depressed or anxious mood (Massie, 2004).  
Depression is reported as one of the most common symptoms in all types of cancer and 
negatively impacts QoL (Fox et al., 2007; Miaskowski et al., 2004).   
Fatigue. Fatigue is weariness or tiredness or lack of energy (Mendoza et al., 1999).  
Fatigue experienced by the general population serves as a protective response to physical and 
psychological stress and is often relieved by rest. However, for patients with cancer, fatigue is 
described as distressing, life altering, unrelieved by rest, and chronic (Servaes, Verhagen, & 
Bleijenberg, 2002).  Fatigue is the most commonly reported symptom in patients with cancer. It 
is also highly reported by patients after bone marrow transplantation.  Fatigue is thought to be a 
side effect of treatment modalities and a consequence of biologic effects (Lawrence, Kupelnick, 
Miller, Devine, & Lau, 2004; Seyidova-Khoshknabi, Davis, & Walsh, 2011).   Fatigue has been 
described as the symptom that most interferes with daily life.  It has been reported by patients as 
a symptom that begins before diagnosis and persists after treatment completion (Lawrence et al., 
2004; Lyon & Fox, 2007; Fox et al., 2007; Mendoza et al., 1999; Prue, Rankin, Allen, Gracey, & 
Cramp, 2006; Ross & Alexander, 2001; Seyidova-Khoshknabi et al., 2011).    
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Inflammation 
Cytokines and CRP.  Cytokines are non-antibody proteins that act as mediators among 
cells to induce or prohibit inflammatory responses in the body.  It is speculated that cytokines act 
neurologically to induce psychological and behavioral changes (Kelley, 2003).  It is also 
speculated that the production and release of certain cytokines can be effected by the cancer 
itself and these cytokines may mediate symptoms (Seruga, Zhang, Bernstein, & Tannock, 2008).  
A call by the NCI (2006) to investigate strategies for the development and validation of 
biomarkers in cGVHD research could be beneficial in elucidating strategies to combat the 
devastating effects of cGVHD (Baird & Pavletic, 2006).  The establishment of the relationship 
between symptoms and cytokines may serve to determine the interplay of certain inflammatory 
cytokines and symptom severity which may in turn lead to advanced interventions to relieve 
bothersome symptoms for patients with cGVHD.  
An acute phase reactant, CRP, was once thought to be produced only by hepatic cells 
(Yeh, 2005).  Studies have now demonstrated both epithelial cells and respiratory cells produce 
CRP.  Furthermore, CRP has a direct effect on epithelial cells to stimulate production of 
cytokines (Gould & Wiser, 2001; Jabs et al., 2004).   Levels of CRP rise in response to 
inflammation and are used in current practice to monitor progression or remission of certain 
conditions and treatment efficacy for some auto-immune conditions such as rheumatoid arthritis 
and systemic lupus erythematous.  These conditions appear to have similar clinical presentations 
as cGVHD (Baird & Montine, 2008; Bazzichi et al., 2007; Klimiuk et al., 2003; Seruga, Zhang, 
Bernstein, &Tannock, 2008).  
 
 
80 
 
QoL 
The World Health Organization (WHO) broadly defines QoL as the perception an 
individual has of their life situation with regards to goals, expectations, standards and concerns 
(1997).  QoL is affected by many aspects of an individual’s health and encompasses many 
domains such as physical, social, emotional and functional well-being (Cella et al., 1997).  The 
presence of distressing symptoms is one factor that contributes to decreased QoL among cancer 
survivors (Monga et al., 2007).  The evaluation of treatment efficacy once focused on survival 
time (quantity) with little regard for QoL. Currently, one of the considerations for treatment 
efficacy is the impact treatment will have on QoL.  Preservation of as high a QoL as possible is 
now evaluated as a part of treatment decisions.   
Materials and Methods 
Design, Sample, and Setting 
 This study used a prospective, descriptive, cross-sectional design.  Participants were 
recruited from a convenience sample of patients diagnosed with cGVHD receiving post 
allogeneic HSCT care at an urban health care facility. Patients were eligible for participation if 
they were at least 18 years of age, had a diagnosis of cGVHD, and could speak English.  Patients 
were ineligible for participation if they had begun taking antidepressants within a month, were 
pregnant, or incarcerated.  Prior to the conduct of the study, a power analysis calculated using 
nQueary Advisor ® v.7.0 determined that a 0.05 two-sided Fisher’s z test of the null hypothesis 
that the Pearson correlation coefficient p=0, has 80% power to detect a ρ as small as 0.43 when 
the sample size is 40.  However due to recruitment issues, a sample of N=24 was recruited for 
this study.  
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Procedure 
 This study was approved by the Massey Cancer Center’s Protocol Review Monitoring 
Committee and the health care system’s Institutional Review Board.  Patients were referred to 
the study by the transplant center’s medical director in consultation with the attending physician 
and the clinical coordinators.  Written consent was obtained from all participants.  Individual and 
disease factors were collected from both the medical record and self-report by participants.  
Severity of cGVHD was obtained using standard criteria based on evaluation of organ systems in 
accordance with the NIH global rating scale (Filipovich et al., 2005).  Symptom and QOL data 
were collected by patient self-report.  A blood draw for measures of inflammatory cytokines and 
CRP was collected by the clinic nurse via venipuncture or a venous access device at a regularly 
scheduled clinic visit. Study visits took approximately one hour to complete.  Participants 
received a $25.00 visa card after completing the study. 
Measures 
Individual and disease factors.  All individual factors and disease factors were collected 
by either chart review or patient report.  Information collected included demographic information 
on age, race, ethnicity, and marital status.  Other individual factors collected included type of 
cancer, donor characteristics and functional status were also collected.  Disease factors were 
related to cGVHD onset, NIH global rating, blood platelet count and immunosuppressive 
therapy. 
Symptoms. 
cGVHD Specific Symptoms. 
 Lee cGVHD Symptom Scale.  The Lee cGVHD Symptom Scale was used to assess 
symptom bother by body system (Lee et al., 2006).  There are seven subscales, each based on the 
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body system that may be affected by cGVHD: 1) skin, 2) eye and mouth, 3) breathing, 4) eating 
and digestion, 5) muscles and joints, 6) energy, and 7) mental and emotional.  Items are rated 
using a 5-point Likert-type scale where 0 indicates “Not at all” and 4 indicates “Extremely” 
bothered over the past month.  A summary score is created by linearly transforming the mean of 
all items to a 0-100 scale. This measures has demonstrated adequate internal consistency 
reliability with Cronbach’s alphas ranging from .79 to .90 and good convergent validity (Lee et 
al, 2006). The Cronbach’s alpha for this study was .79. 
 General Symptoms. 
Memorial Symptom Assessment Scale.  The Memorial Symptom Assessment Scale 
(MSAS) was used to assess dimensions of 32 prevalent cancer symptoms (Portenoy et al., 1994).  
The MSAS consists of three subscales: 1) physical, 2) psychological, and 3) global distress. Each 
item is assessed for the presence or absence of a particular symptom.  If the symptom is present, 
most items (24) are rated on a 4-point or 5-point Likert-type scale for: 1) frequency (where 1 
indicates “rarely” and 4 indicates “almost constant”), 2) severity (where 1 indicates “slight” and 
4 indicates “very severe”) and 3) distress (where 0 indicates “not at all” and 4 indicates “very 
much”) over the past week.  The distress of a symptom is broadly defined as the extent to which 
a symptom impedes the ability to cope and how much the symptom is a bother (Cleeland, 2000; 
Lenz et al., 1995).  Distress negatively impacts daily living and decreases QoL in patients with 
cancer (Cleeland, 2000). The remaining 8 items are rated on severity and distress only, not on 
frequency.  A mean score is calculated for each item, each subscale, and the total measure. This 
instrument has been tested and validated in many patient populations (Chang, Hwang, Feuerman, 
Kasimis, & Thaler, 2000; Portenoy et al., 1994; Tranmer et al., 2003).  This measure has 
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demonstrated adequate internal consistency reliability with Cronbach’s alphas ranging from .76 
to .88 (Chang et al., 2000; Portenoy et al., 1994). The Cronbach’s alpha for this study was .89. 
Cluster symptoms. 
Pain.  The Brief Pain Inventory (BPI) was used to assess dimensions of pain (Cleeland, 
2009).  The BPI consists of two subscales: 1) severity and 2) interference (Cleeland, 2009). Four 
items assess pain severity and seven items assess interference.  Each item is rated on an 11-point 
Likert-type scale where 0 indicates “no pain” or “no interference” and 10 indicates “the worst 
pain imaginable” or “complete interference” over the past twenty-four hours.  A mean score is 
calculated for each subscale and the total measure.  Fifty percent of the questions must be 
answered to calculate a score. The measure has demonstrated adequate internal consistency 
reliability with Cronbach’s alphas ranging from .80 to .87 for pain severity items and from .89 to 
0.92 for interference items (Cleeland, 2009).  The Cronbach’s alpha for this study was .95. 
Depression.  The depression subscale of the Hospital Anxiety and Depression Scale 
(HADS) was used to assess symptoms of depression (Zigmond & Snaith, 1983). This instrument 
has been used widely in cancer settings as well as general medical settings (Mitchell, Meader, & 
Symonds, 2010).  The depression subscale is comprised of seven items.  Each item is rated on a 
4-point Likert-type scale where 0 indicates “least severe” and 3 indicates “most severe” for how 
the participant is currently feeling.  The score is the sum of all items for the subscale.  The 
measure has demonstrated adequate internal consistency reliability with Cronbach’s alphas 
ranging from .82 to .90 (Mykletun, Stordal, & Dahl, 2001).  The Cronbach’s alpha for this study 
was .77. 
Fatigue.  The Brief Fatigue Inventory (BFI) was used to assess dimensions of fatigue 
(Mendoza et al., 1999). The BFI consists of two subscales: 1) severity and 2) interference.  Three 
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items assess fatigue severity and six items assess fatigue interference.  Each item is rated on an 
11-point Likert-type scale where 0 indicates “no fatigue” or “no interference” and 10 indicates 
“worst fatigue imaginable” or “complete interference” over the past twenty-four hours.  A mean 
score is calculated for each subscale and the total measure (Mendoza et al., 1999; Seyidova-
Khoshknabi et al., 2011).  The measure has demonstrated adequate internal consistence 
reliability with Cronbach's alphas ranging from .95 to .96 (Mendoza et al., 1999, Mendoza, 
Mayne, Rublee, & Cleeland, 2006). The Cronbach’s alpha for this study was .93. 
 Inflammation.   Blood was collected in a 3ml Ethylenediamineteraacidic tube and 
transported (on ice) to the research lab.  The blood was centrifuged at 1030 rpm for 10 minutes at 
4°c.  Plasma was aliquotted to 3 microfuge tubes (500µl each).  Samples were stored in a -80°c 
freezer until processed for analysis.   
 Cytokines.  Serum cytokine levels were analyzed using the BioPlex®(Bio-Rad) 
multiplex assay.  Bioplex allows the simultaneous measurement of multiple cytokines in a single 
biological sample.  Dual laser technology allows for the detection of multiple analytes across 
numerous fluorescent spectra; this provides accurate quantification of cytokines.   
CRP.  Serum CRP levels were measured using the ALPCO’s (American Laboratory 
Products Company) high-sensitivity CRP enzyme-linked immunosorbant assay per 
manufacturer’s protocol.   
QoL.  QoL was assessed using the Functional Assessment of Cancer Treatment- Bone 
Marrow Transplantation (FACT-BMT) (McQuellon et al., 1997).  The FACT-BMT measures 
multiple dimensions of QoL.  It consists of the 27-item FACT –General (G) and a 12-item BMT 
subscale.  The FACT-G assesses physical well-being (PWB) (7-items), social/family well-being 
(SWB) (6-items), emotional well-being (EWB) (6-items), and functional well-being (FWB) (7-
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items).  The trial outcome index (TOI) is the sum of the PWB, FWB, and BMT subscales.  Each 
item is rated on a 5-point Likert-type scale where 0 represents the statement has been “not at all” 
true for the individual and a 4 represents the statement has been “very much” true for the 
individual over the past week (Lau et al., 2002).  To produce the subscale score, the sum of the 
item scores are multiplied by the number of items in the subscale then divided by the number of 
items answered.  At least 50% of the items must be answered to score this measure.  The total 
FACT-BMT score is the sum of all subscores.  The measure has demonstrated adequate internal 
consistency reliability with Cronbach’s alphas of .84 for physical well-being, .69 for 
social/family well-being, .67 for emotional well-being, and .78 for functional well-being.  The 
Cronbach’s alpha was .88 for the FACT-G total and .89 for the FACT-BMT (Kopp et al., 2000; 
Lau et al., 2002).  The Cronbach’s alpha for this study was .91. 
Data Analysis 
 Descriptive statistics were used to characterize the individual and disease factors of the 
sample and to profile symptoms, cytokines and QoL.  Frequencies and percentages were used to 
describe categorical variables.  Means and standard deviations or median and ranges were used 
to describe continuous variables.  Student’s t-tests were performed to compare cytokine and CRP 
levels for each item on the MSAS between individuals who reported having the symptom and 
individuals who did not report having the symptom.  Biologic variables were log transformed to 
meet the statistical assumption of normality.  Specificity was evaluated by visually inspecting the 
dot plot for spectral overlap of biological data.  To test associations among symptoms, cytokines, 
CRP, and QoL, Pearson product-moment correlation coefficient was used for all pairwise 
combinations of variables displaying normal distribution.  Spearman’s rank correlation 
coefficient was used to test associations for skewed data.  All statistics were calculated using 
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statistical software package JMP 10.0.  This was an exploratory analysis thus alpha was set at 
.05.   
Results 
Profiles of Symptoms, Cytokines and QoL 
 The first aim of this study was to examine the levels of symptoms (cGVHD specific, 
general symptoms, and cluster symptoms [pain, depression and fatigue]), inflammation  
(cytokines [Interleukin {IL}-1β, IL-6, IL-10, TNF, and INF-γ] and C-reactive protein [CRP]) 
and QoL in patients diagnosed with cGVHD.  Individual and disease factors are profiled in 
Tables 1 and 2.  In this sample (N=24), the majority of participants were female (58.3%), 
Caucasian (87.5%), and married (79.2%). Half of the participants were not employed. The 
median age of participants was 54 years and ranged from 28 to 73 years.  The median time from 
transplant to cGVHD diagnosis was 191 days with a range of 123 to 702 days.  The mean 
hemoglobin level was 12.5 (2.2).  Most participants (29.2%) had a diagnosis of acute 
myelogenous leukemia.  Most received stem cells from a relative (79.2%) and were gender 
matched (58.8%).  Functional impairment was noted in 91.7% of participants. 
Symptoms. 
 cGVHD specific symptoms.  The Lee scale assessed the bother of a symptom for the past 
week.  For the skin, the most frequently reported symptom was changes in skin color (50%).  On 
the eyes and mouth subscale, dry eyes was the most reported symptom (83%).  Nearly half of 
participants (49%) were either “quite a bit” or “extremely bothered” by dry eyes and 75% were 
bothered by having to use eye drops frequently.  On the breathing subscale, shortness of breath 
was reported by 50% of participants.  Two participants reported being “extremely” bothered by 
the need to use supplemental oxygen.  On the eating and digestion subscale, all participants were 
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able to receive nutrition without any intravenous or feeding tube supplementation. On the 
muscles and joints subscale, being bothered by limited joint movement and “aches” was reported 
by 50% of participants.  On the energy subscale, loss of energy was reported by 79% of 
participants and the need to sleep more was bothersome for 66.7% of participants.  On the mental 
and emotional subscale, difficulty sleeping was the most reported symptoms (58.4%).  The 
symptoms for the Lee cGVHD Scales are reported in Table 3 and Table 4.     
General symptoms.  The MSAS assessed the frequency, severity, and distress of 
symptoms for the past week.  The most frequently reported symptom was lack of energy (83.3%) 
followed by dry mouth (66.7%). Among those experiencing the symptom, the most often 
reported symptoms were dry mouth, and lack of appetite.  The most severe symptoms were pain 
and sexual dysfunction and the most distressing symptoms were sexual dysfunction and lack of 
energy.  The mean scores for each subscale and overall score and description individual 
symptom items of the MSAS are reported in Table 4 and Table 5. 
Cluster symptoms.  Pain, depressive symptoms, and fatigue were examined using in-
depth measures for each symptom.  The majority of participants (54%) reported having pain and 
nearly half (46%) reported interference with activity because of pain.  Pain severity scores for 
worst pain ranged from 1.0 to 10.0, for least pain 0.0 to 4.0, for average from 0.0 to 5.0.  The 
overall median pain severity scores ranged from 0.0 to 5.8.  Pain interference scores ranged from 
0.0 to 8.8.  The overall total pain scores ranged from 0.0 to 6.4.  Nearly all (96%) participants 
reported having some depressive symptoms.  Median scores for depressive symptoms ranged 
from 0.0 to 11.0.  Fatigue severity scores for worst fatigue ranged from 0.0 to 10.0 and for usual 
fatigue ranged from 0.0 to 8.0.  Fatigue interference scores ranged from 0.0 to 9.0. The overall 
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total fatigue scores ranged from 0.0 to 8.0 (see Table 6 for description of cluster symptom 
scores).     
Inflammation.  Blood samples were collected on all participants and the specificity was 
confirmed by visually inspecting the dot plot for spectral overlap of biological data.  In a 
comparison between the serum levels of cytokines, CRP, and general symptoms, there were 
significant differences noted between cytokines and symptoms. Participants reporting lack of 
energy had significantly elevated (difference of 2.23, SE= .98, 95% CI = .19-4.27) serum levels 
of IL-6 compared to individuals who did not report lack of energy (df= 22, t= 2.07, p= .03).  
Participants reporting problems with urination had significantly higher (difference of 1.81, SE= 
.73, 95% CI= .30-3.31) serum levels of IL-1β compared to individuals who did not report 
problems with urination (df= 22, t= 2.07, p= .02).  Participants reporting swelling of arms and 
legs had significantly lower (difference of 1.18, SE= .54, 95% CI= .06-2.3) of serum IL-10 
compared to individuals who did not report swelling of arms and legs (df=22, t= 2.07, p=.04).  
Figures 4a-f present levels of inflammatory markers of patients with and without symptoms 
reported on the MSAS.  Levels of serum cytokines and CRP are reported in Table 7. 
QoL.  The FACT-BMT scores (see Table 8) demonstrate impaired QoL for many 
participants.  The FWB subscale had the lowest mean of all scales measured by the FACT-BMT 
followed by the PWB subscale.  The TOI subscale score was about 72% of the total physical and 
functional well-being.  The ranges for all scales were varied with some participants experiencing 
decreased QoL on all scales.   
Associations among Symptoms, Cytokines and QoL 
 The second aim of this study was to examine the relationships between and among 
symptoms (top three general symptoms and cluster symptoms), inflammation and QoL in 
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individuals with cGVHD.  There were six symptoms identified by the MSAS that were present in 
over 30% of participants with a total mean score greater than 2 out of 4:1) pain, 2) lack of 
energy, 3) dry mouth, 4) difficulty sleeping, 5) shortness of breath, and 6) sexual dysfunction.  
Significant correlations were noted among MSAS items pain, lack of energy, dry mouth and 
sexual dysfunction. The MSAS pain item significantly correlated with the BPI total pain score 
(r= .78; p< .01).  The MSAS lack of energy item significantly correlated with other MSAS items 
dry mouth (r= .48; p= .02) and sexual dysfunction (r= .53; p< .01). The MSAS lack of energy 
item also showed significant correlations with cluster symptoms HADS-D (r= .65; p< .01), and 
the BFI total fatigue score (r= .78; p< .01).  The MSAS sexual dysfunction item significantly 
correlated with the BFI severity subscale (r=.43, p=.03). 
 Dimensions of cluster symptoms demonstrated some significant correlations among each 
other. The BPI total score did not show significant correlations with the BFI total score.  Figure 2 
displays the correlations between the BPI and the BFI. The HADS_D demonstrated significant 
positive correlations with the BPI Interference subscale and all scales of the BFI shown in Figure 
3. 
 Inflammation.  Cytokines and CPR were found to have several significant correlations 
among each other, symptoms, and QoL.  Cytokine IL-1β had significant positive correlations 
with TNF (r= .78; p< .01), IFN-ƴ (r= .97; p< .001), IL-6 (r= .44; p= .031), and IL-10 (r= .79; p< 
.001).  Cytokine IL-6 showed significant correlations with IFN-ƴ (r= .58; p< .01), MSAS item 
lack of energy (r= .42; p= .04), MSAS item dry mouth (r= .42; p= .04), and near significance 
with the EWB subscale (r= -.40; p=.05).  Cytokine IL-10 showed significant positive correlations 
with IFN-ƴ (r= .78; p< .01), TNF (r= .82; p= <.01), and MSAS item difficulty sleeping (r= .43; 
p= .03). TNF was significantly correlated with IFN-ƴ (r= .73; p=< .01).  CRP was significantly 
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correlated with the SWB subscale (r= -.56; p< .01), and was nearing significance with MSAS 
item sexual dysfunction (r= .41; p= .05).  
QoL.  Many significant correlations were found among QoL and pain, depression and 
fatigue.  The MSAS pain item significantly correlated with the PWB subscale (r= -.57, p< .01).  
The MSAS item lack of energy showed significant correlations with the PWB subscale (r= -.70, 
p< .01), the FWB subscale (r= -.53; p< .01), the BMT subscale (r= -.71; p< .01), the FACT-G 
subscale (r= -.64; p< .01), and the FACT_BMT (r= -.68, P< .01).  The MSAS dry mouth item 
correlated to the BMT subscale (r= -.55, p< .01), the TOI subscale (r= -.41; p=.04), and the 
FACT-BMT (r= -.42, p= .04). The MSAS sexual dysfunction item correlated with the SWB 
subscale (r= -.44; p=.03) and the BMT subscale (r= -.44; p= .03).  Cluster symptoms pain, 
depression, and fatigue showed significant correlations with the FACT-BMT and the subscales 
of the FACT-G, TOI, and BMTS.  Correlations among cluster symptoms and QoL are noted in 
Table 9. 
Discussion 
This study described symptoms, inflammation, and QoL and examined associations 
among these variables in a sample of patients diagnosed with cGVHD following allogeneic 
HSCT.  Markers of inflammation (cytokines IL-1β, IL-6, IL-10, TNF, and IFN-ƴ and CRP) have 
been noted in cGVHD literature and were selected to examine as biological correlates of cGVHD 
symptoms (Lynch-Kelly, 2012).  
Reported symptoms and findings of existent relationships from this study highlight the 
symptom complexity of patients with cGVHD.  Among the most pronounced symptoms captured 
by the MSAS were dry mouth, difficulty sleeping, shortness of breath, and sexual dysfunction.   
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Dry mouth was reported among participants with and without oral cGVHD.  Certain 
medications and treatments can cause dry mouth.  Dry mouth can cause serious health issues 
such as an increased number of dental carries and creates an environment for invasion of 
opportunistic microorganisms (Visvanathon & Nix, 2010).  There was a positive association 
between dry mouth and inflammatory marker IL-6 which has been associated with Sjogren’s 
syndrome, a complication of inflammatory cell infiltration of the lacrimal and salivary ducts 
manifesting as dryness of the eyes and mouth (Ratanatharathorn et al., 2001).  Secondary 
Sjogren’s syndrome may be a clinical sequela of cGVHD (Kawanami et al., 2012).  This 
association supports findings by Fall-Dickson et al. (2010) as the potential for IL-6 as a 
candidate biomarker for oral cGVHD.  The significant correlation between dry mouth and lack 
of energy as well as a negative trend between dry mouth and QoL warrant further exploration of 
these findings.     
Sleeping difficulties have been cited as being among the most commonly experienced 
symptoms of patients with cancer and other chronic diseases and has a negative impact on 
physical functioning and poorer QoL (Basta, Chrousos, Velo-Bueno, & Vgontzas, 2007).  A 
positive association between difficulty sleeping and IL-10 is consistent with literature which 
suggestive of dysregulation in the circadian release of IL-10 (Basta et al., 2007; Roque, Correia-
Neves, Mesquita, Palha, & Sousa, 2009).  
 Shortness of breath was reported among all participants with pulmonary cGVHD 
regardless of cGVHD severity. Pulmonary cGVHD carries a higher rate of mortality than 
cGVHD of other body systems (Gazourian et al., 2014).  Careful attention to the respiratory 
status, including assessment of shortness of breath, of patients is essential for early detection of 
pulmonary complications.  Shortness of breath (dyspnea) occurring at rest is a late sign of 
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pulmonary complications so assessment of early signs of dyspnea is important.  Dyspnea is 
subjective and is based on the individual’s perception of feeling short of breath with varying 
degrees of activity.  The Borg dyspnea scale is a widely used scale to assess perception of 
dyspnea (Borg, 1970).  There are objective measures of lung function such as pulmonary 
function tests (PFT).  Patients with cGVHD have PFTs performed at intervals post allogeneic 
HSCT; however, keeping a watchful eye between PFTs and monitoring respiratory status are 
necessary for early intervention.	Strategies to alert providers to a decline in pulmonary function 
earlier than conventional practice could lead to earlier interventions that may result in sustaining 
acceptable pulmonary function (Stadler et al., 2009).  
Sexual dysfunction among individuals with cGVHD is focused on women with vaginal 
cGVHD.  There have been advancements in treatments and strategies to mitigate this symptom; 
however, it still remains an issue.  In a study of 23 women diagnosed with genital cGVHD, 21 
women were unable to remain sexually active due to complications such as pain, scaring and 
strictures (Stratton et al., 2007).  This study demonstrated that sexual dysfunction was not limited 
to only women diagnosed with vaginal cGVHD.  Seven females and four males reported having 
sexual dysfunction.  Two had a diagnosis of vaginal cGVHD, thus this appears to be an issue to 
assess with all individuals with cGVHD (Wong et al., 2013). Sexual dysfunction had significant 
positive correlations with lack of energy, nearing significant positive correlation with 
inflammatory marker CRP, and a significant negative correlation with the SWB QoL subscale.  
Other than fatigue, sexual dysfunction was the only variable to significantly correlate with SWB. 
Pain, depression, and fatigue are established in the literature as being among the most 
common symptoms of patients with cancer.  Significant positive correlations were demonstrated 
among many dimensions of the cluster symptom measures.  Although cGVHD is a complication 
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following treatment, this finding suggests a constellation of symptoms that may form a symptom 
cluster in this population.  Each of the measures used in this study to explore symptoms included 
items for pain, depression and fatigue.  Significant correlations were noted between similar 
items.  Pain, depressive symptoms and fatigue all negatively correlated with QoL.  Exploring 
these relationships over time with a larger sample is necessary for determination.  The positive 
correlations among symptoms and cytokines IL-6, IL-10, and CRP merit examining these 
findings in a larger sample. A significant increase in serum IL-6 levels between patients with and 
without lack of energy was found; however, there was no difference noted in IL-6 levels of 
patients with mild, moderate, or severe cGVHD.  A study conducted by Rohleder, Aringer, and 
Boenter (2012) found increased IL-6 levels in individuals with impaired sleep and fatigue.  This 
finding brings into question the identification of IL-6 as a potential biological correlate of fatigue 
independent of cGVHD severity.  
Cytokines play a major role in influencing and regulating inflammatory responses.  
Dysregulation of cytokines has been associated with auto-immune diseases such as rheumatoid 
arthritis and systemic lupus erythematosus (Kishimoto, 2010; Munroe et al., 2014).  Significant 
correlations were found among cytokines IL-1β, IL-6, IL-10, and IFN-y.  Historically, cytokines 
have been described as pro-inflammatory or anti-inflammatory and instrumental in promoting 
acute responses from T-helper (TH) 1 cells or mediating B-cell proliferation from TH2 cells 
(Mossmann, Cherwinski, Bond, Giedlin, & Coffman, 1986).  TH lymphocytes are demarcated by 
the expression of cell surface molecule CD4 and are identified by the cytokines they produce.  
The discovery of the TH1 and TH2 model was a seminal breakthrough in the field of 
immunology.  Further research into this delicate interplay has led to further delineation of 
inflammatory mediators; however, the use of the TH1 and TH2 archetype continues in use as a 
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way to gain insight about inflammation (Muller, 2002).  The notion of TH1 cells as strictly an 
anti-viral or anti-tumor reponse and TH2 as solely involved with humoral immune response has 
been redefined to examine many disease states.  T cell derived cytokines are being examined in 
disease states such as schizophrenia, depression, and chronic pain and cGVHD (Kim et al., 2004; 
Yoon, Kim, Lee, Kwon, & Kim, 2012).  Typically, IL-10 (produced by TH2 cells) acts to 
suppress secretion of IFN-y by TH1 cells and shifts immune response to cell-mediated immunity 
and dampens the immune response (Plotnikoff, Faith, Murgo, & Good, 2007). IL-6 inhibits TNF 
and IL-1β, thus associations noted in this study are consistent with the cytokine pathways 
(Kishimoto, 2010). Cytokine IL-6 has been identified as a key cytokine in symptoms of 
depression and fatigue and has been noted as a mediator of oral inflammation (Fall-Dickson, et 
al., 2010).  The positive association between lack of energy and IL-6 and the significant increase 
in serum levels, make IL-6 a candidate for a potential biomarker of fatigue in cGVHD.   
The NINR recognizes the negative impact symptoms have on quality of life and supports 
research to improve understanding symptoms and the biological mechanisms underlying 
symptoms (NINR, 2011).  The goal of which is to improve quality of life through better 
symptom management.  In studies of patients who received HSCT, patients without cGVHD one 
to two years following HSCT did not report having impaired QoL whereas patients with cGVHD 
reported QoL scores, at the same time-point following HSCT, below that of both population 
norms and other cancer patients (Baker & Frasier, 2008; Fall-Dickson et al., 2010; Webster, 
Cella, & Yost, 2003).  Some participants of this study had QoL scores that were below both 
general U.S. population and cancer population normative values.  Though this study reports QoL 
mean scores similar to U.S. population normative values, significant negative correlations were 
noted among symptoms and QoL.  Severity of cGVHD and symptoms have demonstrated a 
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negative correlation to QoL (Pidala et al., 2011; Pidala et al., 2012).  Findings of the significant 
negative correlations among symptoms and QoL suggest symptoms may be a predictor of QoL 
outcomes however, need to be examined further. 
There are some limitations of this study.  Genrealizability of these results is limited due 
to the small sample size of this study and lack of control group.  This study was conducted at a 
single site, limiting the number of participants eligible for this study.  The study was conducted 
at a center’s long term follow up clinic.  As such, patients are monitored closely for any 
complications consistently and may receive intervention earlier more frequently than individuals 
seen in other institutions performing bone marrow transplantation without a long term follow up 
clinic.  This may partially explain the low pain scores and/or higher mean QoL scores noted in 
this study.  There was no eligibility criteria set for the length of time since diagnosis although 
this was captured as an individual and disease factor.  This may have skewed important 
information about symptoms.  Time from onset of cGVHD may effect associations and should 
be considered as part of the eligibility criteria in future studies.  This study examined 
inflammatory markers, cytokines and CRP, but did not include the use of controls.  The result is 
a profile of levels of cytokines and CRP for this sample and does provide information useful in 
assessing these levels for future studies.  To compensate for the lack of a control group, 
inflammation was examined by symptom and individuals that did not have the symptom served 
as the control.  A confounder of this method may be the possibility of an inflammatory response 
preceding the behavioral response of the symptom.  This was a cross-sectional study thus a 
limitation is assessment of symptoms and biomarkers at a single time point.  Results may differ 
at another time. 
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The findings of this study provide a profile of the symptoms, inflammation and QoL of 
patients diagnosed with cGVHD and associations among those variables.  Noted were evidence 
of associations among symptoms and inflammation as were significant negative associations 
among symptoms and QoL.  Further examination of these associations should be tested using a 
larger sample with a longitudinal design to better understand the effect of time on these 
relationships and the impact of the symptom trajectory on QoL.  The presence of symptoms 
individuals with cGVHD experience emphasizes the significance for clinical evaluation of 
symptoms in this population and draws attention to existent relationships among symptoms, 
inflammation, and QoL. Further exploration of these relationships is pivotal in understanding the 
interplay among symptoms and inflammation and their impact on QoL and is essential towards 
developing targeted interventions aimed at mitigating symptoms of cGVHD.  
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Table 1 
Individual Factors (N=24) 
Characteristic n %
Sex 
Female 14 58.3
Male 10 41.7
Race 
Caucasian 21 87.5
African American 3 12.5
Ethnicity 
Hispanic 2 8.3
Non-Hispanic 22 91.7
Married 
Yes 19 79.2
No 5 20.8
Employment 
Full Time 10 41.2
Part Time 2 8.3
Not Working 12 50.0
Diagnosis 
AML 7 29.2
CML 3 12.5
MDS 4 16.6
MM 3 12.5
Other 7 29.2
Conditioning 
Total Body Irradiation 11 45.8
Other 13 54.2
Gender Match 
Yes 14 58.8
No 10 41.2
Donor Type 
Related 19 79.2
Unrelated 5 20.8
ECOG 
0 2 8.3
1 17 70.8
2 5 20.8
Note: AML=acute myelogenous leukemia; CML= chronic myelogenous leukemia, MDS= myelodyplasic 
symdrome, MM= multiple myeloma; Diagnosis Other = non-Hodgkin’s lymphoma, B-cell lymphoma, T-
cell lymphoma, multiple myeloma; Conditioning Other = reduced intensity radiation and/or 
chemotherapy; ECOG= European Cooperative Oncology Group. 
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Table 2 
Disease Factors (N=24) 
Variable n %
cGVHD onset 
De Novo 17 70.8
Quiescent 4 16.7
Progressive 3 12.5
NIH cGVHD global rating 
Mild 4 16.7
Moderate 12 50.0
Severe 8 33.3
Number of organs involved 
1 4 16.7
2 8 33.3
>  3 12 50.0
Platelet  
< 100,000 4 16.7
> 100,000 20 83.3
Immunosuppressive Therapy 
Systemic 11 45.8
Topical 5 20.8
Both 6 25.0
None 2 8.4
Note: De Novo= never had acute chronic graft-versus-host disease (aGVHD); Quiescent= 
resolved aGVHD; Progressive= has signs of aGVHD but has progressed to cGVHD; platelet 
count is in microliters of whole blood. 
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Table 3 
 
Frequency of Symptom Bother by Body System and Total Scores from the Lee cGVHD Symptom 
Scale (N=24) 
Symptom n (%) n (%) n (%) n (%) n (%) 
 not at all 
bothered 
slightly 
bothered 
moderately 
bothered 
quite a bit 
bothered 
Extremely 
bothered 
SKIN      
Abnormal skin color 12 (50.0) 3 (12.5) 4 (16.7) 3 (12.5) 2 (8.3) 
Rashes 14 (58.4) 6 (25.0) 2 (8.3) 2 (8.3) 0 
Thickened skin 20 (83.3) 0 1 (4.2) 0 3 (12.5) 
Sores on skin 18 (75.0) 4 (16.7) 2 (8.3) 0 0 
Itchy skin 13 (54.2) 2 (8.3) 5 (20.8) 3 (12.5) 1 (4.2) 
EYES AND MOUTH       
Dry eyes 4 (16.7) 3 (12.5) 5 (20.8) 7 (29.2) 5 (20.8) 
Need to use eye drops               
frequently 
5 (20.8) 1 (4.2) 3 (12.5) 5 (20.8) 10 (41.7) 
Difficulty seeing 
clearly 
7 (29.2) 3 (12.5) 7 (29.2) 3 (12.5) 4 (16.7) 
Need to avoid certain 
foods due to mouth 
pain 
17 (70.8) 4 (16.7) 0 1 (4.2) 2 (8.3) 
Ulcers in mouth 22 (91.7) 0 1 (4.2) 0 1 (4.2) 
Receiving nutrition 
from an intravenous 
line or feeding tube 
24 (100.0) 0 0 0 0 
BREATHING       
Frequent cough  14 (58.3) 1 (4.2) 4 (16.7) 4 (16.7) 1 (4.2) 
Colored sputum 18 (75.0) 3 (12.5) 2 (8.3) 0 1 (4.2) 
Shortness of breath 
with exercise  
6 (25.0) 6 (25.0) 4 (16.7) 5 (20.8) 3 (12.5) 
Shortness of breath at 
rest  
18 (75.0) 3 (12.5) 1 (4.2) 2 (8.3) 0 
Need to use oxygen  22 (91.7) 0 0 0 2 (8.3) 
EATING AND 
DIGESTION  
     
Difficulty swallowing 
solid foods 
16 (16.7) 5 (20.8) 2 (8.3) 0 1 (4.2) 
Difficulty swallowing 
liquids  
23 (95.8) 0 0 1 (4.2) 0 
Vomiting  21 (87.5) 1 (4.2) 2 (8.3) 0 0 
Weight loss 21 (87.5) 0 3 (12.5) 0 0 
MUSCLES AND JOINTS       
Joint and muscle aches 8 (33.3) 7 (29.2) 5 (20.8) 2 (8.3) 2 (8.3) 
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Symptom n (%) n (%) n (%) n (%) n (%)
 not at all 
bothered
slightly 
bothered
moderately 
bothered
quite a bit 
bothered 
Extremely 
bothered
Limited joint 
movement 
13 (54.2) 4 (16.7) 3 (12.5) 3 (12.5) 1 (4.2)
Muscle cramps 12 (50.0) 6 (25.0) 2 (8.3) 1 (4.2) 3 (12.5)
ENERGY  
Loss of energy  5 (20.8) 6 (25.0) 7 (29.2) 4 (16.7) 2 (8.3)
Need to sleep 
more/take naps 
8 (33.3) 5 (20.8) 7 (29.2) 2 (8.3) 2 (8.3)
Fevers 23 (95.8) 1 (4.2) 0 0 0
MENTAL AND 
EMOTIONAL  
 
Depression 17 (70.8) 3 (12.5) 4 (16.7) 0 0
Anxiety 12 (50.0) 8 (33.3) 4 (16.7) 0 0
Difficulty sleeping 10 (41.7) 4 (16.7) 5 (20.8) 1 (4.2) 4 (16.7)
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Table 4 
Total Scores for the Lee cGVHD Symptom Scale and the Memorial Symptom Assessment Scale 
(MSAS) 
Variable Subscale Mean (SD) Median Range 
Lee cGVHD 
Symptom Scale 21.80 (13.00) - 4.1-45.5
Skin - 15.0 0.0-70.0
Eyes and Mouth 31.10 (20.20) - 0.0-83.3
Breathing - 17.5 0.0-65.0
Eating and Digestion - 6.3 0.0-43.8
Muscles and Joints - 21.9 0.0-93.8
Energy 25.70 (18.60) - 0.0-66.7
Mental and Emotional 20.80 (16.50) - 0.0-58.3
   
MSAS  00.65 (.43) - 0.2-1.7
 Global Distress Index 00.91 (.64) - 0.0-2.4
 Physical Symptoms 00.69 (.52) - 0.0-1.8
 Psychological Symptoms 00.74 (.54) - 0.0-2.0
Note: Scoring for the Lee cGVHD Symptoms Scale is 0-100 with higher scores indicating greater 
symptom bother; MSAS scores range from low (0) to high (4). 
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Table 5  
Memorial Symptom Assessment Scale Results (N=24) 
Symptom 
Present 
n 
Frequency 
Mean (SD) 
Severity 
Mean (SD) 
Distress/Bother 
Mean (SD) 
Total 
Mean (SD) 
Difficulty Concentrating 13 2.25 (0.87) 1.42 (0.67) 1.42 (1.31) 1.69 (0.86)
Pain 12 2.92 (1.00) 2.6 (1.00) 2.08 (1.16) 2.70 (0.82)
Lack of Energy 20 2.84 (0.90) 2.16 (0.90) 2.11 (1.41) 2.37 (0.90)
Cough 14 2.29 (0.91) 1.64 (0.63) 1.41 (1.23) 1.69 (0.78)
Feeling Nervous 8 1.88 (0.35) 1.14 (0.38) 0.86 (0.38) 1.29 (0.23)
Dry Mouth 16 3.50 (0.63) 2.31 (0.95) 2.06 (1.24) 2.63 (0.78)
Nausea 4 1.50 (0.58) 1.75 (0.50) 1.50 (1.00) 1.58 (0.57)
Feeling Drowsy 14 2.07 (0.62) 1.64 (0.63) 1.00 (0.88) 1.57 (0.48)
Numbness/Tingling in Hands and 
Feet 13 2.54 (1.05) 1.31 (0.48) 1.08 (0.95) 1.64 (0.66)
Difficulty Sleeping 12 2.76 (0.93) 2.00 (0.91) 1.46 (1.20) 2.06 (0.87)
Feeling Bloated 5 3.40 (0.55) 2.20 (1.10) 2.80 (1.10) 2.80 (0.84)
Problems with Urination 4 2.50 (0.58) 1.25 (0.50) 2.25 (1.50) 2.00 (0.61)
Vomiting 2 2.00 (0.00) 2.00 (1.41) 2.50 (2.12) 2.17 (1.18)
Shortness of Breath 13 2.53 (1.00) 1.92 (0.86) 1.85 (1.34) 2.10 (0.99)
Diarrhea 2 2.50 (0.71) 1.50 (0.71) 1.50 (0.71) 1.83 (0.71)
Feeling Sad 6 1.83 (0.41) 1.33 (0.52) 1.50 (0.55) 1.56 (0.34)
Sweats 6 2.67 (0.52) 1.67 (0.52) 1.83 (1.67) 2.06 (0.71)
Worrying 14 1.79 (0.58) 1.36 (0.50) 1.00 (0.56) 1.38 (0.45)
Sexual Dysfunction 11 2.73 (1.10) 2.55 (1.29) 2.82 (1.25) 2.47 (1.31)
Itching 8 2.38 (0.92) 1.50 (0.76) 1.38 (1.19) 1.75 (0.89)
Lack of Appetite 2 3.50 (0.71) 3.00 (1.41) 3.00 (1.41) 3.17 (1.18)
Dizziness 2 2.00 (0.00) 1.50 (0.71) 1.50 (0.71) 1.67 (0.47)
Difficulty Swallowing 7 2.14 (0.69) 1.86 (0.69) 2.14 (1.57) 2.05 (0.91)
Feeling Irritable 8 1.63 (0.74) 1.25 (0.46) 1.50 (1.41) 1.46 (0.69)
Mouth Sores* 3 N/A 1.33 (0.58) 1.33 (1.53) 1.33 (1.04)
Change in Taste* 3 N/A 1.00 (0.00) 2.00 (0.00) 1.50 (0.00)
Weight Loss* 2 N/A 1.50 (0.71) 1.50 (2.12) 1.50 (1.40)
Hair Loss* 5 N/A 2.40 (1.52) 2.00 (1.58) 2.20 (0.91)
Constipation* 3 N/A 3.00 (1.73) 2.33 (2.08) 2.67 (1.89)
Swelling Arms/Legs* 7 N/A 2.00 (0.58) 2.00 (1.50) 2.00 (0.71)
Don't Look Like Myself* 7 N/A 2.14 (1.07) 2.57 (.98) 2.36 (0.99)
Skin Changes* 8 N/A 2.25 (1.04) 2.34 (1.06) 2.31 (1.00)
Note: *Only severity and distress are measured for these symptoms; SD=standard deviation; scores are 
based on a 4-point Likert-type scale where 4 indicate the highest symptom presentation. 
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Table 6 
Mean Scores of Cluster Symptoms 
Measure Mean (SD) Median Range
Brief Pain Inventory  
Total - 0.3 0-6.4
Interference - 0.0 0-8.3
Severity - 0.8 0-5.8
Hospital Anxiety and Depression Subscale 4.1 (3.5) - 0-11.0
Brief Fatigue Inventory  
Total 3.0 (2.4) - 0-8.0
Interference 2.4 (2.6) - 0-9.5
Severity 4.0 (2.5) - 0-9.3
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Table 7 
Cytokine and C-reactive Protein (CRP) Distributions 
Inflammatory 
Marker 
Mean (SD) Median Range
Cytokines    
IL-1β 4.70(4.31) 0.03-14.93
IL-6 23.70 (20.20) 0.01-85.50
IL-10 - 16.00 0.50-109.08
TNF 27.05(25.17) 1.27-96.16
IFNy 126.56 (124.30) 2.03-508.17
CRP - 6.42 0.53-90.00
Note: Cytokines are reported in picograms/milliliter; CRP=C-reactive protein; CRP is reported 
in milligrams/milliliter. SD= standard deviation; cytokine and CRP raw values. 
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Table 8 
Quality of Life Scores from the FACT-BMT 
Measure Subscale Mean (SD) Range
FACT_BMT (0-148) 113.28 (20.90) 58-136
 FACT_G (0-108) 83.89 (16.15) 41-101
 BMTS (0-40) 29.38 (5.44) 17-38
 TOI (0-96) 69.08 (16.76) 30-88
PWB (0-28) 20.66 (6.59) 6 to 27
SWB (0-28) 23.99 (3.68) 12 to 28
EWB (0-24) 20.21 (3.18) 10 to 24
FWB (0-28) 19.04 (6.16) 5 to 28
Note: FACT= Functional Assessment of Cancer Therapy; G= General; BMT=Bone Marrow 
Transplant; S= subscale; PWB= Physical Well-being; SWB= Social Well-being; EWB= 
Emotional Well-being; FWB= Functional Well-being; TOI= Trial Outcome Index and is the sum 
of the PWB, FWB, and BMTS; SD= standard deviation 
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Table 9 
Correlations among Cluster Symptoms and Quality of Life 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 2 3 4 
1-BPI 1.00 0.36 0.24 -0.51 
2-HADS-D 0.36 1.00 0.82 -0.87 
3-BFI 0.24 0.82 1.00 -0.80 
4-FACT-BMT -0.51 -0.87 -0.80 1.00 
Note: A p value < .05 was considered statistically significant.  Pain significantly correlated 
with quality of life; depression significantly correlated with fatigue and quality of life; fatigue 
significantly correlated with quality of life; BPI= Brief Pain Inventory; HADS-D= Hospital 
Anxiety and Depression subscale; BFI= Brief Fatigue Inventory; FACT-BMT= Functional 
Assessment of Cancer Therapy-Bone Marrow Transplant.
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Figure1. Biobehavioral Conceptual Model to Examine Chronic Graft-Versus-Host-Disease.  
Chronic graft-versus-host disease (cGVHD) is influenced by individual and disease factors and 
influences symptoms. There is an interaction between cGVHD and inflammation. Inflammation 
and symptoms have a reciprocal relationship as do quality of life and symptoms.  
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Figure 3. 
Correlations between Depressive Symptoms and Pain and Fatigue 
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• p= .27
BFI_I
• r=.20
• p= .34
BFI_
S
• r= .21
• p=.32
BFI_T
• r=.34
• p=.11
BFI_I
• r= .30
• p=.16
BFI_S
• r=.30
• p=.15
BFI_T
• r= .15
• p= .47
BFI_I
• r= .14
• p= .51
BFI‐S • r=.15
• p=.47
BPI_T 
BPI_I 
BPI_S 
Figure 2. Correlations found in this study between the Brief Pain Inventory (BPI) total measure (T) and the 
subscales interference (I) and severity (S) and the Brief Fatigue Inventory (BFI) total measure (T) and the subscales 
interference (I) and severity (S). A  value less that .05 is considered significant.  
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BPI_T
• r= .36
• p= .09
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• r= .46
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• r= .82
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Figure 3. Correlations found in this study between the Hospital Anxiety and Depression Scale (HADS) depression 
subscale (D) and the Brief Pain Inventory (BPI) total measure (T) and the subscales interference (I) and severity 
(S). Correlations found in this study between the HADS-D and the Brief Fatigue Inventory (BFI) total measure (T) 
and the subscale interference (I) and severity (S). A p value less than .05 is considered significant. The symbol (*) 
marks significant correlations.   
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Chapter 5 
Summary 
 
 
 
To better understand the symptomology of chronic graft-versus-host disease (cGVHD) 
inclusive of possible biological mechanisms of symptoms and how they may relate to quality of 
life (QoL), this dissertation study focused on elucidating a profile of symptoms, inflammation, 
and QoL in a sample of participants diagnosed with cGVHD.  In addition, it was of interest to 
determine if there were relationships between and among these variables.  As a certified 
oncology nurse working with bone marrow transplant recipients, this researcher witnessed the 
distress caused by cGVDH.  Symptoms were particularly distressing for patients and were often 
difficult to manage, yet there was not much known about typical symptoms or if certain 
symptoms co-occurred.  Secondly, as cGVHD is a complication individuals are living with, at 
times for many years, survivorship issues, such as QoL, are of interest in cGVHD research and 
have been suggested to be included in clinical trials as possible endpoints to determine 
intervention efficacy (Filipovich et al., 2005; Schulman, 2006). 
 Cytokines, a surrogate marker of inflammation, have been found to be associated with 
symptoms of cancer such as pain, depression and fatigue (Meyers, 2008; Seruga, 2008). 
Cytokines have also been examined in cGVHD and have been found to be associated with some 
auto-immune diseases that present similarly to cGVHD (Baird & Montaine, 2008; Klimiuk, 
Sierakowski, Domyslawska, & Chwiecko, 2011). Therefore, it was a logical for this researcher to 
explore cytokines previously examined in cGVHD, in symptoms individuals with cGVHD may 
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be experiencing.  Of specific interest to this researcher was knowing which symptoms present 
with cGVHD and to what extent, through a biobehavioral lens, and how QoL is affected by 
cGVHD.  The first step in this research inquiry was a review of the literature to determine what 
was already known and where there were gaps that needed to be addressed.  Findings from this 
empirical review prompted the specific aims for this initial research into the symptomology of 
cGVHD.  
 Using the knowledge about the gaps in literature into the symptomology of cGVHD, a 
study was proposed to describe the symptoms, inflammation, and QoL in individuals diagnosed 
with cGVHD and examine the associations between and among symptoms (cGVHD specific, 
general [prevalent in other cancer populations], and cluster [pain, depression, and fatigue]), 
inflammatory markers (IL-1β, IL-6, IL-10, TNF and IFN-γ) and CRP, and QoL.  To this 
researcher’s knowledge, this is the first study using the general symptom measure (MSAS) and 
cluster symptom measures (BPI, HADS, and BFI) in this population.  
 There were several prominent symptoms noted across all symptom measures. 
Comparisons of pro-inflammatory cytokines and CRP levels were noted to show an observed 
pattern of elevation in individuals reporting the presence of specific general symptoms as 
opposed to individuals who did not report having the same symptom. Cytokine IL-6 had a 
significant increase between individuals reporting lack of energy and individuals without lack of 
energy.  Pain, depressive symptoms, and fatigue were noted in many participants. There did not 
seem to be any decrease in QoL means for the FACT-BMT total; however, the PWB and the 
FWB subscales demonstrated the lowest scores. Several individuals had lower than average QoL 
scores.  There were significant correlations between and among symptoms, inflammatory 
markers, and QoL. Significant correlations among domains of pain, depression and fatigue, 
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indicate the possibility of a symptom cluster.  Inflammatory markers were consistent with 
cytokine pathways and appear to be over-expressed in this sample of individuals. There were 
many negative associations among symptoms and QoL indicating a possibility of symptom 
influence on QoL. This study provides preliminary information into the interplay between 
inflammation and symptom presentation and need to be examined further to make any 
conclusion.  The initial plans for this program of research will be to replicate this study with the 
following: 1) a larger sample size, 2) use of a control group for cytokine comparison, and 3) use 
of in-depth measures of noted general symptoms such as sleeping difficulty.   
One of the most significant findings in this study was the presence of symptoms that may 
be only suspect of a particular site of cGVHD such as dry mouth or sexual dysfunction.  
Thorough assessment of symptoms is necessary to most effectively manage symptoms. Evidence 
about how symptoms present and the frequency and severity of symptoms, provides information 
for use when assessing patients’ symptoms. 
Another key finding of this study was the potential influence inflammation may have on 
symptom presentation.  Knowledge about symptoms and mechanisms affecting the frequency 
and severity of symptoms may enable practitioners to implement strategies for anticipatory 
guidance of cGVHD complications during pre and post transplant counseling. 
Significant differences in cytokine levels Il-1β, Il-6, and IL-10 make these cytokines 
candidate markers for future investigation.  The complication of cGVHD is complex and the 
etiology is poorly understood.  Current research is focused on identification of target biomarkers 
for identification of possible disease initiation, progression, remission, and recurrence. It is of 
interest to know how cGVHD manifests.  Knowing if symptoms and cytokines cluster by body 
system and if cGVHD clusters by body system is of interest.  There may be different biological 
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and behavioral profiles depending on the affected site.  Knowledge about how symptoms present 
and biological mechanisms, such as inflammation, is fundamental to the development and testing 
of novel interventions to mitigate symptoms and improve QoL for individuals with cGVHD. 
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Appendix A 
Search Terms for State of the Science Manuscript 
 
 
The PubMed search terms to capture literature about symptoms and cGVHD were 
(("Signs and Symptoms"[Mesh] OR Symptom*[Title/Abstract])) AND (("Graft vs Host 
Disease"[Majr] OR Chronic Graft-vs-Host Disease* OR Chronic Graft versus Host 
Disease*[Title/Abstract] OR cGVHD[Title/Abstract] NOT Acute Graft-vs-Host 
Disease*[Title/Abstract] OR Acute Graft versus Host Disease*[Title/Abstract] OR 
aGVHD[Title/Abstract] AND (English[lang])) AND ("last 10 years"[PDat] AND 
Humans[Mesh] AND English[lang] AND adult[MeSH])).  The PubMed search terms to capture 
literature about cytokines and cGVHD were (("Cytokines"[Mesh] OR cytokines[Title/Abstract] 
AND ("last 10 years"[PDat] AND Humans[Mesh] AND English[lang] AND adult[MeSH]))) 
AND (("Graft vs Host Disease"[Majr] OR Chronic Graft-vs-Host Disease* OR Chronic Graft 
versus Host Disease*[Title/Abstract] OR cGVHD[Title/Abstract] NOT Acute Graft-vs-Host 
Disease*[Title/Abstract] OR Acute Graft versus Host Disease*[Title/Abstract] OR 
aGVHD[Title/Abstract] AND (English[lang])) AND ("last 10 years"[PDat] AND 
Humans[Mesh] AND English[lang] AND adult[MeSH])) AND ("last 10 years"[PDat] AND 
Humans[Mesh] AND English[lang] AND adult[MeSH]).  The PubMed search terms to capture 
literature about quality of life and cGVHD were (("Cytokines"[Mesh] OR 
cytokines[Title/Abstract] AND ("last 10 years"[PDat] AND Humans[Mesh] AND English[lang] 
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AND adult[MeSH]))) AND (("Graft vs Host Disease"[Majr] OR Chronic Graft-vs-Host Disease* 
OR Chronic Graft versus Host Disease*[Title/Abstract] OR cGVHD[Title/Abstract] NOT Acute 
Graft-vs-Host Disease*[Title/Abstract] OR Acute Graft versus Host Disease*[Title/Abstract] OR 
aGVHD[Title/Abstract] AND (English[lang])) AND ("last 10 years"[PDat] AND 
Humans[Mesh] AND English[lang] AND adult[MeSH])) AND ("last 10 years"[PDat] AND 
Humans[Mesh] AND English[lang] AND adult[MeSH]).  The CINAHL search terms to capture 
literature about symptoms and cGVHD were ((MH "Graft Versus Host Disease") OR Chronic 
Graft-vs-Host Disease* OR Chronic Graft versus Host Disease* OR cGVHD) NOT (Acute 
Graft-vs-Host Disease* OR Acute Graft versus Host Disease* OR aGVH) AND ( (MH "Signs 
and Symptoms (Non-Cinahl)") OR (MH "Symptoms") OR symptom* ).   
The CINAHL search terms to capture literature about cytokines and cGVHD were ((MH 
"Graft Versus Host Disease") OR Chronic Graft-vs-Host Disease* OR Chronic Graft versus Host 
Disease* OR cGVHD) NOT (Acute Graft-vs-Host Disease* OR Acute Graft versus Host 
Disease* OR aGVH ) AND ((MH "Cytokines OR Chemokines (Non-Cinahl)") OR (MH 
"Cytokines OR Chemokines") OR cytokine OR chemokine* ).  The CINAHL search terms to 
capture literature about quality of life and cGVHD were ((MH "Graft Versus Host Disease") OR 
Chronic Graft-vs-Host Disease* OR Chronic Graft versus Host Disease* OR cGVHD) NOT 
(Acute Graft-vs-Host Disease* OR Acute Graft versus Host Disease* OR aGVH ) AND ( (MH 
"Quality of life (Non-Cinahl)") OR (MH "Quality of life") OR quality of life* ) 
 



 Chronic Graft Versus Host Disease 
Enrollment Documentation 
Study ID: ___ ___ ___ ___ 
Date of Enrollment: ____________________________ 
Please check all that apply: 
_____The patient is at least 21 years of age 
_____The patient has a diagnosis of cGVHD 
_____The patient is able to understand and speak English  
_____The patient does not have dementia 
_____The patient does not have active psychosis 
_____The patient has not started any anti-depressant medication within 30 days 
_____The patient is not pregnant 
_____The patient is not incarcerated  
If any of the above is not verified, the patient should NOT be enrolled in the study. 
The following has been discussed with the patient: 
_____The informed consent in its entirety 
_____The voluntary nature of the study 
_____Alternatives to participation 
_____Questions about the study 
The following actions have been completed: 
_____The patient has willingly agreed to participate in the study 
_____The patient has verbalized understanding of the study and has signed the consent form 
_____The patient has received a copy of the signed consent form 
The patient is scheduled for a visit on 
Date: 
Location: 
Time: 
A trained staff member will meet the patient at scheduled visit to complete study session. 
Other pertinent data: ________________________________________________________________ 
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________ 
Study Nurse: ______________________________________ Date: ___________________________ 
cGVHD Symptom Study                                                                                                              
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Study ID ______________________________ 
Date  ______________________________ 
Data Collected by (Please Print): _______________________________________ 
Location: _______________________________________________  
 
 
 
 
 
 
_______ Specimen delivered (1 small purple tube) 
____________________________________________________________________________
____________________________________________________________________________
____ 
 
 
 
 
 
 
 
 
_______ PSS-10 
_______Lifestyle Profile 
 
 
 
_______ BPI 
_______HADS  
Score = _________ 
 
_______ BFI 
 
 
_______ Demographic with 
Disease Profile 
________ MSAS 
________ Lee Symptom Bother 
Data Collected 
_______ Patient received Gift Card    ___________________________ Gift Card Number 
Gift Card Information 
Blood Samples 
Other Information 
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
__________________________________________________________ 
 
Data Collected by (Please Sign):  _________________________________ Date: ________ 
________ FACT-BMT 
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